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20% of patients diagnosed with ovarian cancer (OC) cannot receive treatment at all due to the 
severity of the disease when discovered. The 80% of patients that receive treatment, as much as, 
90% relapse in less than six months and, by the end of two years fail to respond to treatment as a 
result of multi-drug resistance. As genetic studies fail to provide a complete picture in the biology 
of disease, epigenetics including spatial and radial organisation of the genome has become a well-
established that provides a greater understanding beyond the sequence. Chromosomes are non-
randomly organised within interphase nuclei, which can vary slightly from cell type to cell type, their 
proliferation and disease status. The functional organisation within interphase nuclei is kept in place 
and regulated by a plethora of structural and mechanical proteins such as lamins and nuclear 
myosins (NMs), and along with many other proteins are known together as the nucleoskeleton. 
Irregularities in these proteins have been implicated in many diseases, including metastatic cancers 
and their chemoresistant counterparts. NM1 role in spatial chromosome organisation has been 
established, and with the emergence of NM6 role in nuclear organisation, both their overexpression 
in OC and involvement transcription presents them as an attractive co-study.     
This research investigates the disease-related chromosome territory (CT) positionings of OC through 
four key chromosomes in a panel of OC cells; SKOV-3 PEO-1 PEO-4 MDAH-2774, in addition to a 




and a peripheral localisation was observed chromosome X. Chromosomes were subsequently 
assessed for location post-NM1/6 knockdown revealing that chromosome territories relocalised 
closer to the localisations of the control cell line, and following the acquisition of platinum-resistance 
of MDAH-2774, all four chromosomes predominated centrally in nuclei. The analysis also revealed 
that chromosome X might play a more fundamental role in ovarian tissue and cancer that than 
previously thought and the initial aim of its use as a control was challenged. Distribution 
discrepancies in the OC cells were found in the nuclear lamins and myosins with further 
investigations revealing significant elevations of NM1 and NM6. The elevations also displayed a 
different stoichiometry ratio in the platinum-resistant cell line PEO-4 which led to the creation of a 
novel lab-grade platinum-resistant cell line MDAH-2774CR from the naïve line MDAH-2774 to 
investigate further resistant-specific NM1/NM6 stoichiometry and spatial CT organisation in OC. 
Moreover, combination assays with MDAH-2774CR and NM1 knockdown resulted in cell death that 
surpassed its sensitive counterpart, that has future clinical potential to treat chemoresistant OC. 
In this research, we aim to broaden the comprehension of the many mechanisms involved in the 
development and progression of an aggressive cancer. The analysis of the CT positioning of 4 out 
of 23 chromosomes was able to reveal characteristics within OC nuclei at key milestones of the 
disease, making this level of investigation, and information, important in understanding OC and its 
successful treatment.   
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CHAPTER 1  
GENERAL INTRODUCTION 
1.1 OVARIAN CANCER (OC) 
1.1.1 Reasons for Concern  
Globally, when compared to other female gynaecological cancers (breast, endometrial and cervical), 
ovarian cancer (OC) has the lowest five-year survival rate due to its high metastatic potential, late 
diagnosis and multi-drug resistance (figure 1.1). In women, it is the fourth most common cancer, 
the second most common gynaecological cancer and is the number one cause of death for female 
cancers, claiming 140,000 lives globally in 2012, that was due to late diagnosis at an advanced 
stage (III and IV), with a sizeable metastatic tumour present in the abdomen (Dakubo, 2017). In 
the UK (2002-06), the five-year survival for stage I, II, III and IV were 90%, 43%, 19% and 4% 
respectively signifying that even though 10% of women diagnosed at stage I, they still do not 
survive beyond five-years (Cancer Research, UK). A significant number of women respond well to 
initial treatment, however, those with advance stages relapse within 18 months, and those who 
retained sensitivity are re-treated until restricted by chemoresistance. Even more alarming is that 
20% of women diagnosed with OC cannot receive any treatment at all due to the severity of the 
disease when it is discovered (Target Ovarian Cancer, UK). 




- adapted from Public Health England, 2018. 
Figure 1. 1 Average Five-Year Survival Rate Amongst Male and Female Reproductive Cancers:  
Age: 15 to 99 years. Diagnosed between 2013 and 2017 then followed up to 2018 in England. OC has the 
lowest survival rate.  
Despite the late-stage diagnosis; improved cytoreductive surgery and chemotherapy have been 
able to increase the five-year survival rate from 37% in the 1970s to 46% in 1999-2005 (Dakubo, 
2017). Expertise in imaging, histopathology, surgery, chemotherapy, and palliation are all required 
for optimum outcomes. Histopathology, however, determines the specifics of the latter procedures 
as it distinguishes between different sub-types that harbour genetic mutations with the potential to 
predict the efficacy of tailored treatments. In 2012, the worldwide incidence rate of OC was 239,000 
and mortality rate at 152,000 with a projected increase by 2035 of 55% and 67% respectively (The 
World Ovarian Cancer Coalition, 2018). OC is ranked fifth in the UK and US, and seventh worldwide 
of all lethal female cancers and though the incidence rates vary among geographic region and 
ethnicities, the goal of earlier detection and novel drug targets remains the same across all borders, 
and the continued progress of developing new treatments can improve the outlook (National Cancer 
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1.1.2 The Disease  
Often termed the ‘silent killer’ or ‘the whispering disease,’ as its lethality surfaces at the advanced 
stage when diagnosed due to the lack of recognisable and absolute symptoms in earlier stages 
(figure 1.1 and 1.2). In the UK the lifetime risk is 1 in 60, with the median age of 58 years 
(randomised trials), the median age of diagnosis is 63 years in the overall population and for those 
genetically predisposed a median age of 53 years (Mavaddat et al., 2013). For these reasons, it is 
one of the deadliest cancers to affect women.  
Table 1. 1 Signs and Symptoms of OC:  
According to the 2015 National Institute for Health and Care Excellence (NICE) guidelines for suspected 
recognition and referral.  
Abdominal distension/bloating 
Loss of appetite +/- early satiety 
Pelvic/abdominal pain 
Increased urinary urgency/frequency 
Unexplained weight loss/fatigue 
Unexplained changes in bowel habits 
New IBS symptoms in over 50s 












- adapted from the International Federation of Gynecology and Obstetrics (FIGO) staging system and National Ovarian 
Cancer Coalition (NOCC) 
Figure 1. 2 FIGO and NOCC Stages of OC 
 
Depending on their originator cell, there are three types of OC: Epithelial (85-90%), Stromal 
(~10%) and germ (1-2%). The research for this PhD focuses on epithelial OC than the rare germ 





•IA - confined to the 
1 ovary
•IB - found on both 
ovaries 
•IC - spilling out of 
the ovaries 
Stage 1 - confined to 
the ovaries 
•IIA - extension to 
fallopian tubes or 
uterus 
•IIB - extension to 
other pelvic regoins 
Stage II - pelvic 
extension 
•IIIA - microscopic 
presence in upper 
abdomen or lymph 
nodes
•IIIB - visible in upper 
abdomen <2cm size
•IIIC - visible in upper 
abdomen >2cm size 
with liver or spleen 
presence
Stage III - beyond 
the pelvis 
•IVA - present in 
fluid around the 
lungs 
•IVB - inside lungs, 
liver or spleen 
Stage IV - through 
out the body





Figure 1. 3 Three Categories of OC Origin:  
Surface epithelium, germ cell and stromal, which closely resembles epithelial in terms 
of morphology, symptoms, spread and treatment (reviewed in Jayson et al., 2014).  
 
The insidious nature of OC as compared to tumours of other organs, stems from its location, as it 
directly extends to major neighbouring organs which are aided by the peritoneal cavity that 
facilitates the transport of exfoliated tumour cells (figure 1.4). This intricate and diffused 
environment makes chemotherapy more feasible than surgery unless it is of a low grade and organ-
confined nature (reviewed in Naora and Montell, 2005). Dissemination also takes a route through 
the lymphatic system (pelvic and para-aortic lymph node) than the more common vascular system 
(reviewed in Naora and Montell, 2005). 




-Naora and Montell, 2005 
Figure 1. 4 The Compromising Anatomical Location of the Ovaries:  
In the peritoneal cavity, the ovarian tumour is compressing against multiple organs; 
tumour cells detach, overcome anoikis and settle onto the other organs (Naora and 
Montell, 2005).  
During ovulation, the rupture and release of egg produces a local inflammatory microenvironment 
and explains why increased ovulation is associated with increased OC risk (Yang-Hartwich et al., 
2015). Epidemiological findings stated that the risk of OC is reduced by states of anovulation such 
as pregnancy, oral contraceptives, and tubal ligation (reviewed in Jayson et al., 2014). In contrast, 
states of supraphysiological ovarian stimulation such as fertility treatments and hormone 
replacement therapy (HRT) during menopause have been implicated in increasing its risk in both 
breast and OCs (reviewed in Jayson et al., 2014). Endometriosis, polycystic ovary syndrome 
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(PCOS), human papillomavirus (HPV), perineal talc and smoking have all been found associated 
with the disease (reviewed in Jayson et al., 2014).  
1.1.3 OC Oncogenes and Tumour Suppressor Genes 
Cell division and differentiation are regulated by a family of growth factors (cytokines) and are 
carefully balanced by another family of apoptotic regulators. When the balance is disturbed, the 
result is cancer where cells start dividing uncontrollably or damaged cells circumventing apoptosis. 
The disturbance of this balance begins at the genetic level, and the accumulation of molecular 
genetic alterations gives critical roles to several oncogenes and tumour suppressor genes (TSG).  
Oncogenes first start as a proto-oncogene, and alteration of a single allele is sufficient to activate 
its oncogenic form; whereas TSGs requires the activation of both alleles to remove its negative 
control on cell growth. Oncogenes are activated predominantly through mutations, translocations, 
and amplification, whereas TSGs can be activated by mutation, deletion, or chromosome loss. 
Oncogene mutations produce a faulty form of the regulatory protein, enhancing its role in the cell 
cycle whereby TSG mutations rid the regulatory protein restraints on cell division.  
In OC, the primary oncogenes comprise of HER2/ERRB2/neu, c-myc, K-ras/Braf and PIK3CA 
(Aunoble et al., 2000 and Shayesteh et al., 1999) and the primary TSGs include p53, BRCA1/2, 
PTEN and ARID1A (Aunoble et al., 2000; Takeda et al., 2016; Tamwar, 2013). OC description and 
diagnosis are extensive and everchanging as Shih and Kurman, 2004 proposed a classification of 
epithelial OC (eOC) tumours in type I: low grade with BRAF, KRAS, and PTEN mutations and type 
II: high-grade with p53, BRCA1, and BRCA2 mutations, however, together with this, figure 1.5 
highlights the mainstream model.  
 




- adapted from Banerjee and Kaye, 2013 and Lheureux, Braunstein and Oza, 2019. 
Figure 1. 5 eOC Subtypes Summary (FIGO classification):  
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1.1.4 Genes  
My PhD research examined the location of chromosomes that contain genes p53 and BRCA 1/2 
found in high-grade tumours, HER2 in low-grade and mucinous and the particularly interesting 
ARID1A for its additional role in spatially partitioning chromosomes (Wu et al., 2019). There is much 
cross-talk between these genes and their pathways, that is often a result of mutations leading to 
carcinogenesis; however, cases, where carcinogenesis takes place without an evident mutation, 
cause and effect is not as clear cut which requires investigations beyond the sequence.  
 ARID1A 
ARID1A protein is a multi-kinase inhibitor encoded by the ARID1A gene on chromosome 1 (Takeda 
et al., 2016). It is a member of the BAF sub-complex of the SWI/SNF chromatin remodelling complex 
that has critical roles in the cell cycle, apoptosis, differentiation, gene stability and DNA repair where 
its knockdown reveals increased cellular proliferation (Hoffman and Liebermann, 2008; Takeda et 
al., 2016; Reyes-Gonzales et al., 2015). There is a high frequency of ARID1A mutations in OC; 30-
61% depending on the severity, type, and origin, whereas 86-100% of OC cases have ARID1A 
protein deficiency (Hoffman and Liebermann, 2008; Takeda et al., 2016).  
 BRCA1 and BRCA2 
The five times increased prevalence of BRCA mutations in the Ashkenazi Jewish population has 
greatly increased their risk for breast and OC compared to the general population (Simchoni et al., 
2006). BRCA proteins are localised in nuclei and produced abundantly in the thymus and testis with 
lower levels in the breast and ovaries. They are associated with breast and OC that is known to 
affect women through hereditary means. 5-10% of OC stems from the hereditary disposition of 
BRCA1 and BRCA2 genes located on chromosomes 17 and 13, respectively (Aunoble et al., 2000). 
Though less affected, men can also inherit the mutation as illustrated by CRUK, where for every 
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143rd female, one male is diagnosed with breast cancer. The risk of OC associated with BRCA2 is 
considerably lower at 30% than BRCA1 with 50% and women with either germline mutation have 
a 40-60% lifetime risk; however, the BRCA gene test can make patients aware of their pre-
disposition and following options such as routine check-ups, hysterectomy, and mastectomy (Prat 
et al.,2005; Aunoble et al., 2000; Jayson et al., 2014). BRCA1 is a 220 kDa protein, and BRCA2 is 
a 400kDa protein that works in genome protection, each at different stages (Roy, Chun and Powell, 
2012).  
 p53 
p53 mutation is the most common genetic alteration in OC found on chromosome 17. Almost 
universal, a mutation is found in over 79% of OCs, 75% of all cancers and many chemoresistant 
tumours are also positive for p53 alteration (Aunoble et al., 2000; Jayson et al., 2014; Carrillo et 
al., 2015). The gene encodes for a 53kDa protein performing roles in arresting cell cycle and 
inducing programmed cell death (Aunoble et al., 2000; Lakin and Jackson, 1999).  
 HER2-(neu, ErbB2, and p185)  
First identified by a group of scientists in the 1980s, HER2 is located on chromosome 17 and in 
OC, its overexpression reduces the survival of the patient as compared to one with a regular 
expression (Iqbal and Iqbal, 2014). Although generally essential in cell growth, a mutated HER2 
protein plays a crucial role in approximately 30% of OCs also extending to breast and cervical cancer 
(reviewed in Aunoble et al., 2000). The transmembrane protein has a tyrosine kinase activity 
belonging to a family of epidermal growth factor receptors (Aunoble et al., 2000). In cancer, both 
oncogenic mutation and overexpression lead to independent and constant cell cycle activation.  
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1.1.5 Current Surveillance    
OC usually presents itself with 3-4 months of abdominal pain or enlargement often mistaken for 
irritable bowel syndrome such that NICE has recommended women experiencing these symptoms 
get serum cancer antigen 125 (CA-125) as a supplementary screen (reviewed in Jayson et al., 
2014). If CA-125 shows no elevation, screening then proceeds to a pelvic exam, 
transvaginal/abdominal ultrasonography, and laparoscopy (Coticchia, Yang and Moses, 2008; 
reviewed in Jayson et al., 2014). There are no single reliable early screening or predictive markers 
for OC; however, there are screening algorithms that combine biomarkers on premenopausal and 
postmenopausal women over 40 years for OC risk (WOCC, 2018). The two main clinical biomarkers 
are CA-125 which has a relatively higher sensitivity and HE-4 that has a relatively higher specificity 
(WOCC, 2018). 
 1981 - Serum CA-125 
CA-125 is the most routine non-invasive biomarker preoperatively used to predict malignancy 
potential in diagnostic, prognostic and monitoring purposes. This mucin-like transmembrane 
glycoprotein shows a strong correlation connecting its rise and fall with disease progression and 
regression, respectively (reviewed in Boivin et al., 2009). Approximately 80% of women diagnosed 
at late-stage OC show elevated CA-125 serum levels, which highlights that roughly 20% of people 
with late-stage cancer do not express CA-125 (Coticchia, Yang and Moses, 2008; WOCC, 2018). 
Furthermore, only 50% of early-stage OC show elevated CA-125 expression. CA-125 also lacks 
specificity and sensitivity since it is also expressed amid benign non-gynaecologic circumstances. 
Additionally, women can have elevated CA-125 levels and be considered low risk if it remains 
unchanged for years (WOCC, 2018). Interestingly, CA-125 over-expression has been recently found 
to protect cells against the effects of genotoxic drugs, thus reducing cancer cells sensitivity to 
chemotherapy (Boivin et al., 2009). 
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 1991 - Serum HE4 
Human epididymal secretory protein E4 (HE-4) was first identified in 1991 then later in 1999 in OC 
cells, this glycoprotein is involved in tumour progression extending to the breast, lungs, kidneys, 
bladder, GI tract and endometrium (WOCC, 2018). However, the highest HE-4 levels are expressed 
in ovarian and endometrial cancers. HE-4 is also expressed in healthy tissues that include the breast, 
colon, respiratory tract, distal renal tubules, genital tract, epididymis, vas deferens, salivary glands 
and fallopian tubes with the highest in the trachea and salivary glands (WOCC, 2018). It is important 
to note that 32% of the cells that do not express CA-125 express HE-4, and 50% of the patients 
that do not express serum CA-125 have elevated HE-4 (WOCC, 2018).  
 The Newcomers  
Both CA-125 and HE-4 have the potential as screening, diagnostic, prognostic, monitoring and 
predictive markers, especially when combined in algorithms that can also determine risk and 
discriminate between benign and malignant tumours (WOCC, 2018). Currently, more than thirty 
potential biomarkers in serum are being evaluated with, and without CA-125, since by itself, CA-
125 is insufficient as a screening biomarker (Coticchia, Yang and Moses, 2008). Other biomarking 
methods include screening circulating tumour cells, stem cells and circulating tumour DNA in 
addition to genome, transcriptome, microRNA, and proteasome profiling. The OncoOVARIAN Dx test 
by Bioprognos combines six serum tumour markers for early statistical probability (non-definitive) 
that exceeds all current tests including individual biomarkers, algorithms, and its predecessor OVA1 
by Vermillion that is based on five serum biomarkers (Bioprognos, 2020).  
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1.1.6 Current Treatment  
Largely unchanged for the last 40 years, the standard first-line care involves a combination of de-
bulking surgery, platinum-based drugs and/or Taxol-based drugs (depends on the patient’s 
tolerance). Chemotherapy is administered before surgery, shrinking the tumour for effective 
cytoreduction or after to remove remnants post-surgery.  
 Surgery  
Surgery entails preoperative imaging and discussion followed by removal of the entire womb, 
ovaries, fallopian tube, omentum (the thin fold of abdominal fatty tissue containing lymph and 
vasculature tissue) and tumour de-bulking to remove as much tumour tissue as possible, provide a 
histopathological diagnosis and stage the disease (Jayson et al., 2014). Conservative surgery 
options are considered for fertile women in early stages wanting to maintain their fertility. The field 
of surgery has had its improvements with multidisciplinary surgical teams and improved imaging 
however in cases where disease spread is extensive, beyond the abdominal cavity patients are 
switched to chemotherapy only or offered preoperative chemotherapy before de-bulking (Jayson et 
al., 2014). 
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 Chemotherapy  
 
- adapted from Roche, 2017 
Figure 1. 6 Historical View of Chemotherapy Usage for OC 
 
Chemotherapeutics can be used in mono-, combination or as adjuvant therapy which is often 
preferred for its synergistic effects; mono-therapy is favoured in cases where side effects of the 
combination are too severe, maintenance therapy is used in remission to prevent relapse, especially 
in cases of hereditary predispositions (table 1.2) (Palmer and Sorger, 2017). Targeted therapies 
have become highly successful as they are incredibly selective for characteristics specific to cancer 
cells, thus reducing/eliminating effects on the healthy cells (Palmer and Sorger, 2017). 
Radiotherapy, on the other hand, is no longer accepted as standard practice since other contents of 
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Table 1. 2 Brief Background of the Notable Chemotherapeutic Drugs Approved Use in OC Therapy:  
An overview of the mechanisms, drawbacks and how they are circumvented in the management of OC.  
Drug 
Description  Mechanism  Drawbacks  Alternatives  Reference 
TARGET: Nucleic Acids 
1844  
Platins / 




discovered in the 1970s 
and its safer analogue 
carboplatin in the 1980s 
have been successful 
anticancer drugs for 
decades. 
Its alkylating property damages mitotic 
DNA via aquation that then crosslinks 
preferably with the guanine base, 
rendering the DNA beyond repair, 
committing the cell to apoptosis. 
 
Chemoresistance  Alternative mono- or 





It is ranked one of the 
most effective mono-
therapy chemotherapeutic 
agents ever developed. 
Derived from the bacteria 
Streptomyces, anthracycline localises in 
the nucleus, intercalates with DNA and 
RNA to stop transcription and 
replication. 
Cardiotoxic side effects Cardio-protectant drugs, 
longer infusion rates or 
most commonly formulated 
with a polyethylene glycol 
conjugated (PEGylated) 
liposome that enhances its 
circulation increase tumour 
cell specificity and lowers 
its toxicity profile. 
Minotti et 
al., 2004 
TARGET: Cell Cycle 
1978  





Originating from the well-
publicised pacific yew 
plant, approved for use in 
OC in 1992 
Tubular-targeting drug that inhibits 
microtubule segregation, promoting its 
polymerisation, thus preventing cell 
cycle events such as spindle assembly 
and chromosome segregation. The cell 
averts cell division or undergoes 
apoptosis.  
 
Dose-limiting toxicity Due to its toxicity, it is 
usually used post-
platinum-resistance as a 
second-line of treatment or 





Gemcitabine is commonly 
used for platinum-
sensitive recurrent OC, 
and less so in platinum-
resistant disease. 
It primarily blocks G1/S progression at 
the S-phase as cell growth is also 
inhibited through minor mechanisms as 
the gemcitabine metabolites affect 
other regulatory processes. 
Mono-therapy has the 
lowest response rate 
when compared to 





Its rare property of ‘self-
potentiation’ makes 
gemcitabine attractive, 





al., 2013  
Plunkett et 
al., 1995 
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TARGET: Survival Pathways 
1997 
Bevacizumab 
Bevacizumab is a 
humanised monoclonal 
antibody with mouse 
origin 
Inhibits Vascular endothelial growth 
factor (VEGF) that promotes the growth 
of blood vessels in response to hypoxia, 
thus reducing tumour activity by 
altering its vascular nature. 
 
Adverse effects such as 
hypertension and 
gastrointestinal 
perforation were noticed  
Side effects need to be 
considered when treating 








inhibitors capitalise on the 
difference between 
healthy and cancer cells. 
Healthy cells have many compensatory 
pathways to deal with DNA damage; 
however, as tumours become 
increasingly mutagenic their pathways 
streamline leaving them with fewer 
repair pathways than the healthy cells, 
sometimes only one compensatory 
pathway is left. Many times, this 
compensatory pathway involves PARP, 
a DNA damage sensor for both DSB and 
SSB repair pathways, and a PARP 
inhibitor can completely cut the tumour 
of its survival. 
 PARP mono-therapy is used 
in BRCA deficient cells, 
where it was found 90% 
more effective than in wild-
type cells in addition to 
being 3X more potent than 
cisplatin.  
In combination therapy, 
PARP inhibitors render the 
cell unable to repair 
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1.1.7 Drug Resistance 
While chemotherapy is highly effective, especially in earlier stages, OC can be oftentimes diagnosed 
too late. In less than six months, 80 - 90% of patients relapse and by the end of two years, they 
fail to respond to any available chemotherapy, where this resultant chemoresistance can be due to 
a plethora of factors (figure 1.7) (Norouzi-Barough et al., 2017). Recurrence typically diagnosed via 
a CA-125 test or computed tomography (CT-) scan receives second-line chemotherapy and are also 
considered for surgery if beneficial (Jayson et al., 2014).  
The interest in ‘platins’ has slowed down; however, it has resurged amid the increase of drug 
resistance. The platinum-resistant disease has the potential of 15% response within six months of 
platinum treatment, partial sensitivity after 6-12 months of being platinum-free with increasing 
sensitivity in reoccurrence after 12 months (Jayson et al., 2014). Following further rounds of 
alternative drugs, surgical de-bulking and relapses, the patient is left with an inoperable metastatic 
disease with multi-drug resistance (MDR). Post-acquisition of MDR, the patient is switched from 
curative to palliative care where a series of non-specific/sub-standard chemotherapeutics, hormone 
therapy and pain relievers are used to ensure comfort over cure (Palaia et al., 2019). 
 




Figure 1. 7 Causes and Characteristics of Drug resistance:  
The plethora of factors or a combination of adaptive dysregulations continues to be a challenge in combating drug-resistance.  


























overexpression of drug metabolising enzymes (DMEs) that are often overexpressed in 
resistance cells 
the shift in influx (downregulation) and efflux (upregulation) membrane transporters 
equilibrium
chemoresistant dysregulation has been evidenced in glucose metabolism, lipid metabolism 
and glutamine metabolism
genetic alterations (rearrangements, translocations, mutations and amplifications); 
overexpression of class III tubulin against taxanes, y-actin against both taxanes and vinka-
alkaloids and topoisomerases in malignant and chemoresistant ovarian cancer 
downregulation or mutation of pro-apoptotic factors and overexpression of anti-apoptotic 
factors have been associated with platinum and taxanes resistance 
a higher level of intrinsic DNA damage was found in sensitive cells versus platinum-resistant 
ones
DNA methylation alterations on candidate genes (<1%) have been reported to be involved 
in platinum-resistance, histone acetylation alterations found in chemoresistant ovarian 
cancer cells and dysregulation of  microRNAs in ovarian cancer chemoresistance induction 
have been correlated 
its role in metastasis is well characterised, and its contribution to drug resistance is 
emerging. Associations have been made between over-expression, accumulation of its 
transcription factors and drug resistance in ovarian cancer cells 
antioxidant defence components are seen upregulated and ROS producers downregulated in 
cisplatin-resistant ovarian cancer cells
over 25 oncogenes have been known to contribute to drug resistance in ovarian cancer, 
including Ras, HER2 and PIK3CA 
Is there a characteristic change in nuclear spatial organisation in chemoresistant OC cells? 
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5.1.1.1 Resistance principle  
Under the ‘resistance principle’, the tumour cells undergo selective pressure through chemo-drugs 
and adapt through the acquisition of new traits that resembles that of the healthy cell, thus evading 
treatment like non-tumorigenic cells (Rosa et al., 2014; Bell & Gilan, 2020). The new traits can be 
auto-acquired or from healthy cells that they used as a template (Rosa et al., 2014). This includes 
reverse mutations such as in BRCA1/2 mutations, the reappearance of healthy copies of 
chromosomes as seen in the PEO1/PEO4 eOC cell lines and an increase genomic stability since 
proliferation rate is slowed due to the re-activation of pathways such as DDR, MAPK and mTOR, 
both previously interrupted in the sensitive cancer versions (Swisher et al., 2008; Cooke et al., 
2010; Kozar et al., 2019). Chemotherapy relies on rapidly dividing cells; therefore, our thinking of 
tackling chemoresistant cells needs to change as they may not be as rapidly dividing in the same 
way. 
1.1.8 Summary 
OC is a daunting reality, and the timespan between diagnosis to a chemoresistant disease is short, 
thus equal attention is needed on both earlier diagnosis and chemoresistance. There is still a long 
way to go for reliable early-stage / predictive biomarker and curative adjuvant options in 
chemoresistance, but information on the molecular mechanisms is growing rapidly; however, 








-image source: Lheureux, Braunstein and Oza, 2019 
 Figure 1. 8 Summary of the Treatment Guidelines in OC (advanced):  
A. Diagnosis, B. frontline management, and C. treatment upon recurrence.  
+/‐ indicates with/without; chemo -chemotherapy; doxo -doxorubicin; IP -intraperitoneal; IV -intravenous; PARPi -PARP-
inhibitor; PFI -platinum‐free interval; plat -platinum; R0 -reduction of tumour bulk with 0 residual disease. 
  




1.2 THE NUCLEUS   
Cells and tissues are routinely used as diagnostic tools, however in the 1930s-40s, as technology 
improved studies started looking towards the nucleus. During these decades, George 
Papanicolaou, developed a stain, known as the ‘Pap test’ that studied the structure of the 
cytoplasm and the nucleus, differentiating and diagnosing pre-malignant stages cervical cancer 
which led to its decrease from the leading cause to the eighth cause of cancer-related death amongst 
women (Zink et al., 2004). Nuclear morphological features such as shape, size and nucleus-
cytoplasmic ratio has potent disease diagnostic and prognostic potential that also translates to OC 
cells as they can be distinguished by their large nucleus; and it was not until recently that nuclear 
architecture could be studied on a molecular level (Sengupta et al., 2020). The first and largest 
organelle discovered within the cell was the nucleus in the 17th century, a recognised site of 
numerous functions; preservation, storage, processing, and duplication of information encoded on 
DNA made possible by a tightly controlled high-level spatial architecture (Crosetto and Bienko, 
2020).  
There is a growing wealth of information that supports the non-random three-dimensional (3D) 
arrangement of the genome as a determining factor in transcription which has not been limited to 
mammalian cells as a similar organisation was found in yeast (Zink et al., 2004; Lanctôt et al., 
2007; Zaidi et al., 2007; Akhtar and Gasser, 2007; Gorkin, Leung and Ren, 2014). Transcription 
and transcription factors, determine if, when and what extent a gene is expressed or not, thus, any 
perturbations (genetic or epigenetic) set off a chain reaction to the disease. Most carcinogenic 
pathways are not fully understood; as cancer was thought to be driven primarily by sequence 
mutations; nevertheless, it is now widely acknowledged that the contribution to carcinogenesis goes 
beyond the sequence (Crosetto and Bienko, 2020). 
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1.2.1 Genome Organisation – The Right Place at the Right Time   
Within recent years, the high degree of nuclear organisation research directed the recognition of 
chromatin and sub-nuclear components such as the nuclear envelope (NE), nuclear matrix, nuclear 
bodies, and the nucleoli that ensures the efficient functioning and cross-talk of processes; where 
disruptions to the components led to nucleopathies and cancer (van Driel, Humbel and de Jong, 
1991, Strouboulis and Wolffe, 1996, Foster and Bridger, 2005). This also revealed chromosome 
territories (CTs) where chromosomes are packaged into a spatially limited volume and, at the sub-
chromosomal level, organisation comprises of the metaphase chromosomes, A/B compartments (as 
identified by high-throughput chromosome conformation capture (Hi-C)), small domains such as 
lamin-associated domains (LADs),  larger domains such as topologically associating domains (TADs) 
and long-range chromatin looping (Lieberman-Aiden et al., 2009; Dixon et al., 2012; Rao et al., 
2014). The organisation of membrane-less bodies and domains spontaneously arise as outlined by 
the recent emergence of the phase separation principle (figure 1.9) (Banani et al., 2017; Shin and 
Brangwynne, 2017). This would explain why bodies such as the nucleoli and nuclear speckles remain 
distinct from nucleoplasm without a membraned divider (Dundr, 2012). These bodies collectively 
recognised as ‘biomolecular condensates’ contain macroscopic properties that govern specific 
molecular interactions resulting in behaviour similar to that of liquid droplets and by extension may 
play a role in compartmentalising chromosomes into territories or sub-compartments in the nucleus 








- image Source: Banani et al., 2017   
Figure 1. 9 Phase Separation in the Eukaryotic Cell:  
Schematic of the numerous biomolecular condensates in the membranes, cytoplasm and nucleus of eukaryotic 
cells. Some compartments are cell-type specific, such as Balbiani bodies and germ granules in germ cells, and 
RNA transport granules and synaptic densities in neuronal cell types.  
 
Phase separation does not account for the location or relocation of a body or domain, and while it 
is a relatively new, more multidisciplinary high-throughput work on its dynamics is required. Aside 
from the genome being organised in an energetically stable emulsion of concentrated condensates, 
phase separation still poses many questions such as what determines the sites of the condensates, 
time of assembly or disassembly, how does it affect the genome, and its contribution to disease 
progression and cancer?  
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 Chromosome Territory History 
Up until the 19th century, it was believed that chromosomes where temporary structures that 
formed at the start of mitosis and subsequently dissolved in the daughter nuclei like soup. Turning 
into the 20th century, Carl Rabl, 1885 hypothesised that chromosomes are organised into territories 
while still maintaining their genetic and structural integrity throughout the cell cycle and Theodor 
Boveri, 1909 coined the term ‘chromosome territories’ (figure 1.10) (Cremer et al., 1993). They 
further stated that the territories also do not mix; however, the idea was abandoned up until five 
decades ago when Cremer et al., 1976 applied laser-UV-micro-irradiation (257nm) on the 
interphase nuclei Chinese hamster cells, qualitatively confirming territorial organisation postulated 
by Rabl and Boveri. Thomas and Christoph Cremer used radiography to track radioactively labelled 
nucleotides incorporating into the location of DNA, damaged by the laser beam, which showed very 
few adjacent chromosomes affected following the next metaphase cycle. Finally, in 1999, Croft et 
al. demonstrated the radial organisation of human chromosomes 18 and 19 in the nucleus relative 
to the periphery and centre.  
 
- image source: Fraser et al., 2015. 
Figure 1. 10 Human Genome Organisation within the 3D Nucleus:  
A. CTs during interphase; nuclear pore complexes perforate the NE, and the nuclear lamina shown as a 
filamentous mesh inside the NE and the nucleolus in white. B. Female karyotype in mitotic cells.  
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 Radial Position  
From 1985 onwards, quantitative progress was made with fluorescence in-situ hybridisation (FISH), 
and three-dimensional microscopy, which further found that CTs are not randomly positioned but 
are situated in preferred radial positions relative to the nuclear periphery emphasising the 
significance of functional compartmentalisation (figure 1.11) (Bridger and Bickmore, 1998; Croft et 
al., 1999; Cremer et al., 1993).   
 
- image source: Orsztynowicz et al., 2017. 
Figure 1. 11 A Schematic Representation of Radial Positioning within the Nucleus: 
FISH probe signal is positioned radially from nuclear border to the nuclear centre divided three 
locations C - central, I - intermediate and P - peripheral as evaluated distance.  
In the mammalian cell, compartmentalisation begins with chromatin of two types; tightly packed 
heterochromatin, that is intensely stained with a predominance at the nuclear lamina (NL) and 
euchromatin which is 1.4x less condensed in the nuclear interior (Fedorova and Zink, 2008). This 
has led to the notion that the nuclear periphery is transcriptionally repressive and the nuclear 
interior is transcriptionally permissive, however more recent findings suggest that this 
compartmentalisation is not exclusive and that there are other determinants of radial chromatin 
positioning (Kupper et al., 2007; Kumaran and Spector, 2008; Finlan et al., 2008). 
There are many studies of the altered radial organisation of chromosomes in cancer, for example, 
Cremer et al., 2003 reported that while cancer cell lines showed positioning according to gene 
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density, up to 31% had inverted positions for chromosome 18 and 19 and Murata et al., 2007 
reported a similar inversion in a third of papillary thyroid carcinoma cells. Furthermore, activated 
oncogenes were observed to be preferentially located in the nuclear interior in some cancers, while 
others appeared at the periphery (Harnicarova et al., 2006; Bartova et al., 2000/2005; Wiech et 
al., 2009; Meaburn and Misteli., 2008). In Meaburn and Misteli, 2008 extensive study in breast 
cancer, identified genes with altered positions that repositioned during early tumorigenesis, 
however, many of which showed no correlation with the change in transcription. Aberrant radial 
positioning of the genome remains unclear.  
 Karyotype and translocations  
Radial positioning is evolutionarily conserved for over 300million years irrespective of highly 
divergent karyotypes (Tanabe et al., 2002). In humans, chromosome positioning appears stable 
with aneuploidy, as the regulating, positioning mechanism stays the same even though the 
chromosome numbers change (Bridger, 2000; Boyle et al., 2001; Tanabe et al., 2002). This can be 
observed when chromosome 18 and 19 maintained their positions as diploids and triploids (including 
cancer) in addition to chromosome X being maintained at the periphery despite increased ploidy 
(Croft et al., 1999; Boyle et al., 2001; Cremer et al., 2003. For these reasons, the karyotype of 
these cell lines (figure 2.1) would not be considered a primary factor.  
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Differences in chromosomes position for translocated derivatives are specific to the chromosomes 
involved, but in several human tumours, no shift in chromosome territory has been observed 
(Cremer et al., 2003). In the lymphocyte nuclei, chromosome 18 (periphery) and 19 (interior) are 
located separately, where the derivative t(18;19) did not significantly relocate however the 
translocated material of chromosome 19 oriented towards the centre where it typically locates (Croft 
et al., 1999). On the other hand, chromosome organisation in terms of proximity can, in turn, 
influence the frequency of translocations resulting in novel fusion transcripts inducing 
carcinogenesis (figure 1.12) (Lever and Sheer, 2010).  
 
- image source: Misteli, 2007. 
Figure 1. 12 Chromosomal Translocations:  
Physical chromosome proximity contributes to the probability of translocations. Following the 
malfunctioning of DSB repair and apoptosis evasion, parallel double-strand breaks illegitimately 
join possibly creating rearrangements with a selective growth advantage (reviewed in Lever and 
Sheer, 2010).  
Chromosomal rearrangements can lead to aberrant gene expressions that are essential in 
carcinogenesis, as the resultant gene fusions can produce oncogenic activity (duplications and 
amplifications) or remove tumour suppressing activity (deletions) (Mitelman et al., 2007).  In 
cancer, the formation of translocations can be explained by two models; the ‘breakage-first’ model 
DSBs move then recombine or the ‘contact-first’ model DSBs recombination arise from already 
proximally positioned chromosomes (Soutoglou and Misteli., 2007; Misteli and Soutoglou., 2009). 
Translocation recombination events of proximally close chromosomes are proposed to take place at 
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the boundary of the chromosome territory (CT) since transcriptionally active loci are located at the 
boundary it increases the tendency for translocation also supporting correlations of transcriptional 
activity and recurrent translocations (reviewed in Lever and Sheer, 2010). 
 Gene Density vs Chromosome Size  
CT organisation builds that gene-rich regions of the genome are positioned at the interior and gene-
poor chromosomes peripherally (Croft et al., 1999 and Bridger et al., 2000).  In the rod cells of 
nocturnal mammals, this is observed where the active gene-rich chromosomes hold a perinuclear 
location and the inactive genes towards the nuclear centre, possibly accounting for an evolutionary 
adaptation to low-intensity light vision (Solovei et al., 2009). Pigs also showed gene-rich regions; 
murine fibroblasts have gene-rich and -poor regions internally and peripherally respectively; the 
primate homologues of chromosome 18 (gene-poor) and 19 (gene-rich) in chickens showed 
periphery and central locations respectively; however, there was also a tendency for larger 
chromosomes to occupy peripheral locations highlighting that gene density is not the sole 
determinant of chromosome positioning (Habermann et al., 2001; Federico et al., 2004; Mayer et 
al., 2005; Tanabe et al., 2005).   
Gene-density organisation correlated with round nuclei as in lymphocytes, and, when the nucleus 
shape was oval or ellipsoid as in fibroblasts, a size-dependent organisation predominates; however, 
this was primarily under quiescence or early S-phase in fibroblast as gene-density was observed 
outside these phases (Bridger et al., 2000; Cremer and Cremer, 2001; Croft et al., 1999; Sun, Shen 
and Yokota, 2000; Boyle et al. 2001; Bolzer et al., 2005; Meaburn et al., 2007). In lymphocytes 
and fibroblasts, chromosome 18 is at the periphery, and chromosome 19 is at the nuclear interior; 
furthermore, it was also observed in fibroblasts when chromosome 18 and 19 were both centrically 
located; chromosome 19 would locate more internally due to having double the number of genes 
than chromosome 18 (Croft et al., 1999; Bolzer et al., 2005; Sun, Shen and Yokota, 2000). In 
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addition, Sun, Shen and Yokota, 2000 outlined that smaller chromosomes like 19 and 21 are 
centrally located in fibroblasts cells while Bickmore, 2013 showed gene-rich chromosome 22 as the 
most centrically located chromosome, supporting both the size and gene density factor. The 
influence of gene density or chromosome size is not absolute, but one can take precedence over 
the other.   
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 Activity  
Location is also determined by activity and expression where chromosomes are functionally 
compartmentalised for two main regulatory processes; activation (compartment A) and silencing 
(compartment B), and for the same reasons, they are re-organised within the nucleus (Lieberman-
Aiden et al., 2009; Simonis et al., 2006). The distinct location and relocation of chromosomes are 
influenced by transcriptional activity within the nuclei (Finlan et al., 2008; Fritz et al., 2016). 
The nuclear interior is correlated with activity, and the nuclear periphery is often implicated as the 
silencing regions; however, being positioned at the nuclear periphery does not render a gene 
inactive nor inaccessible, as some expression does take place at the periphery in mammalian cells 
and yeast while some active genes are found at the nuclear pores, in other words, peripheral location 
does not mean peripheral repression (Brickner and Walter et al., 2004; Casolari et al., 2004; Cabal 
et al., 2006; Taddei et al., 2006; Takizawa et al., 2008). Whole chromosome re-positioning has 
been observed in erythroid differentiation, adipogenesis, T-cell differentiation, porcine 
spermatogenesis, post hormonal stimulus, and serum stimulation that was further shown to take 
place within 15 minutes (reviewed in Bartova and Kozubek, 2006; Mehta et al., 2010). Though the 
mechanisms are not clear, genes have also been evidenced in the same manner; the non-random 
spatial positioning of active genes in the interior and inactive genes towards the periphery has been 
observed for IGH and CD4, vice versa for CD8 and, RB1 that does not move regardless of activity 
(Skok et al., 2001; Bartova et al., 2002; Mahy, Perry and Bickmore, 2002; Kosak et al., 2002; Roix 
et al., 2003; Kim et al., 2004; Scheuermann et al., 2004; Takizawa et al., 2008).  
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 Out-looping  
Within CTs, genes cluster for transcription efficiency, where gene-rich clusters orient towards the 
interior and gene-poor clusters orient towards the periphery (Shopland et al., 2006). Within the X 
CT, the rim is lined with gene-rich regions, and the non-coding regions are internalised, regardless 
of activity (Clemson et al., 2006). Some genes such as c-MYC, PAX6 and TTN do not significantly 
alter their location within their chromosomal territory and on the other extreme are genes or gene 
clusters that extend out (generally towards the interior) and intermingle with the territory of another 
(Volpi et al., 2000; Mahy, Perry and Bickmore, 2002; Williams et al., 2002; Bartova et al., 2002; 
Ragoczy et al., 2003; Galiová, Bártová and Kozubek, 2004; Scheuermann et al., 2004; Chambeyron 
et al., 2005; Branco and Pombo, 2006).  
The ‘neighbourhood effect’ highlights that nearby changes in expression sometimes drive re-
positioning events where genes are simply a passenger of adjacent genes (preferentially clusters). 
The extreme case of loop expulsion over several micrometres encompassing active multigene 
clusters from their CT is prominently exemplified in murine and human cells; when actively 
transcribing, the human major histocompatibility complex II (MHC class II) locus extends out of 
chromosome 6, however, does so preferentially towards chromosome 1, 2, and 9 but not 
chromosome 8 territory (figure 1.13) (Volpi et al., 2000; Branco and Pombo, 2006). Later 
observations include clusters containing FLNA on chromosome X, genes on chromosome 11, 
epidermal differentiation complex genes, β-globin-like genes, mouse Hox cluster, genes inducing 
porcine stem cell differentiation into adipocytes (Mahy, Perry and Bickmore, 2002; Williams et al., 
2002; Ragoczy et al., 2003; Scheuermann et al., 2004; Galiová, Bártová and Kozubek, 2004; 
Chambeyron and Bickmore, 2004; Chambeyron et al., 2005; Szczerbal, Foster and Bridger, 2009). 
  




- image source: Misteli, 2007 
Figure 1. 13 Chromosome Out-Looping:  
Gene cluster extending out of its CT via the formation of a large chromatin loop.  
Loci out-looping (thought to be facilitated via the inter-chromosome domain (ICD) but, challenged 
by Branco and Pombo, 2006) are usually directed towards active RNA Pol II, Cajal bodies and 
splicing speckles/SC35 domains, that is affected when RNA polymerase II transcription is inhibited 
suggesting purpose in expression (Boyle et al., 2001; Fedorova and Zink, 2008; Heard and Bickmore 
2007; Bickmore, 2013). Looping has led to the reconsideration of CTs to include the ‘territory core’ 
visualised with standard chromosome ‘paints’ and the ‘territory corona’ the surrounding territory 
visualised by FISH using locus-specific probes or gene-dense chromatin probes (Bickmore and van 
Steensel, 2013). In this framework, looping starts from the core into the one own’s corona into the 
corona of a neighbouring territory (Bickmore and van Steensel, 2013). A base for tethering is also 
required as findings have shown this type of associations with the nuclear periphery, nuclear pore 
complex, nucleolus and the abundant transcription/replication factories that they loop towards (Ishii 
et al., 2002; Cook, 2002; Byrd and Corces, 2003; Yusufzai et al., 2004; Chakalova et al., 2005; 
Noma et al., 2006; Misteli, 2007). Extensive chromatin looping is more prevalent than thought, as 
it is an energetically and functionally favourable arrangement (Branco and Pombo, 2006; 
Marenduzzo, Micheletti and Cook, 2006).  
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 Topologically Associated Domains (TADs)  
Chromatin are also organised into TADs categorised with the A/B compartmentalisation (figure 1.14) 
(Gonzalez-Sandoval and Gasser, 2016). Each TAD is evolutionary conserved and enriched for certain 
proteins to express a subset of genes specific to the identity of the cell (Gonzalez-Sandoval and 
Gasser, 2016; Valton and Dekker, 2016). There are also regions insulated against TADs to limit 3D 
interactions of distant regulatory regions (reviewed in Azagra et al., 2020). Dynamic long-range 
interactions are detected in TADs among promotors and enhancers to regulate the activation or 
repression of transcription (Gonzalez-Sandoval and Gasser, 2016). The disruption of TAD 
boundaries reveals genes to unsuitable regulatory elements resulting in abnormal gene expression 
(Valton and Dekker, 2016; Campbell, 2019). Carcinogenesis as a result of TAD disruption can take 
place via two mechanisms; one where the boundaries are deleted or mutated leading to the fusion 
of two adjacent TADs and the other that includes genomic rearrangements that breaks up the TADs, 
creating new ones while the boundary remains unaltered (reviewed in Valton and Dekker, 2016).  
This highlights the vital role in understanding the mechanisms and long-range chromatin control of 
TADs and how mutations, deletions and rearrangements can lead to the dysregulation of TSGs and 
oncogenes.  
  




- image source: Gonzalez-Sandoval and Gasser, 2016. 
Figure 1. 14 Topologically Associated Domains (TADs):  
TADs classified into two compartments: A-type (active) or B-type (inactive) (orange, red, yellow). Within a 
given TAD is an enrichment of specific proteins for tailored gene expression. * - TADs encompass long-range 
chromatin interactions that are detected between promoters and enhancers, leading to the activation or 
repression of genes. NPC - nuclear pore complex and NE - nuclear envelope.  
 
TADs with NL association have also been defined as LADs; therefore, a LAD can encompass a few 
TADs, and a TAD can encompass a one or more LADs (Gonzalez-Sandoval and Gasser, 2016). LADs 
overlap to a more significant extent with B compartments (Gonzalez-Sandoval and Gasser, 2016). 
  




LADs are genomic regions that interact with the NL exhibiting roles in anchoring, organisation and 
gene repression. LADs form a condensed dynamic layer of chromatin lining at the NL moving to and 
from the periphery and partially randomised after each mitosis (van Steensel and Belmont, 2017). 
In mammalian cells, there are ~1,000 – 1,500 LADs covering more than one-third of the genome, 
and in murine embryonic stem cells they were found to lower expression by 1000-fold compared to 
genes located elsewhere; rendering them noteworthy (reviewed in Irianto et al., 2016; van Steensel 
and Belmont, 2017). Their features are typical of heterochromatin as they are less transcriptionally 
active with a low gene-density and found to overlap to a larger extent with B compartments (figure 
1.15) (Guelen et al., 2008).  
Both LADs and the NL are polymeric entities that result in multivalent interactions that stably 
secures chromosomes to the periphery via non-overlapping regions, NE transmembrane proteins 
(NETs) and barrier‐to‐autointegration factor (BAF) (reviewed in van Steensel and Belmont, 2017).  
However, whether and how lamins play a role is still an open question as they were found to play 
zero roles in facilitating genome-wide LAD organisation in murine ES cells further suggesting that 
lamins are not a significant determinant of LADs, instead roles of other non-lamin NE components 
such as lamin-associated proteins (LAPs) and NETs (Amendola and van Steensel, 2015; reviewed 









- image info: reviewed in van Steensel and Belmont, 2017. 
Figure 1. 15 Summary of Sub-LADs Hierarchy:  
NADs and PADs have substantial overlap with LADs, not identical; however, may have the same preserved 
outcome; hence complete silencing is not dependant on peripheral location (van Steensel and Belmont, 2017). 
iLADs can be actively recruited to the nuclear interior while still attached by neighbouring LADs to the NL; this 
results in a ‘tug of war’ mechanism or ‘chromatin stretching’ through a possible force-generating mechanism 
(Khanna et al., 2014).  
  
constitutive LADs (cLADs)
•more gene-poor and are 
collectively speculated to 
form a structural backbone 
with a higher tethering 
power to the NL and the 
folding of the interphase 
chromosomes
facultative LADs (fLADs)
•relatively more gene-dense and 
are more flexible as they are 
frequently detached from the 
nuclear lamina followed by gene 
activation
NADs
•a subset of LADs 
associated with the 
nucleoli 
PADs





•opposite to LADs are internal LADs (inter-
LADs/iLADS) that are LAD regions positioned 
away from the NL corresponding to 
compartment A. 
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1.2.2 Lamins    
Since 40% of the genome associates with lamin proteins, genome organisation cannot be 
investigated without exploring related roles of lamins (Guelen et al., 2008). The lamin family consist 
of A-type (Lamin-A, -C, -C2, and -A∆10) and B-type (lamin-B1, -B2 and -B3) lamins encoded by genes 
three genes LMNA, LMNB1, and LMNB2 (figure 1.16) (Stuurman, Heins and Aebi, 1998). Lamin-C2 
and -B3 are testis-specific and Lamin-A∆10 although it is somatic, its expression profile is uncertain.  
 
- image source: Irianto et al., 2016. 
Figure 1. 16 The Major Forms of Lamins (in somatic cells of human, mice and most other 
vertebrates):  
LMNA gene produces lamins A and C via alternative splicing whereas LMNB1 and LMNB2 separately 
encode Lamin B1 and B2 respectively. Lamins share common regions or amino acids but differ in 
their post-translational modifications. 
A-type lamins are not expressed in early neuronal, embryonic or stem cells, whereas all nucleated 
cells express B-type lamins, indicative of both their essential roles in the lamina (reviewed in Burke 
and Stewart, 2013; Chen et al., 2019). When Lamin B1 and B2 were knocked down in HeLa cells, it 
resulted in arrested growth and apoptosis and though lamin A/C is suggested to be non-essential 
at the cellular level, has been linked to at least 12 different diseases in addition to cancer (Burke 
and Stewart, 2013). Additionally, in murine keratinocyte or hepatocyte cells, lamin A/C role was 
fortified when lamin B1 and B2 was knocked down, the cells did not exhibit severe pathology as they 
expressed high levels of lamin A/C (Yang et al., 2011a; Yang et al., 2011b). Furthermore, in 
neuronal cells that exhibit little to no lamin A/C, a knockdown of lamin B1 or B2 rendered the cell 
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more susceptible to nuclear membrane rupture (Yang et al., 2011a; Yang et al., 2011b; Chen et 
al., 2019). It is possible that A-type lamins step in when deficient in B-type lamins; however, while 
the role is not found reciprocated, there is still more research required.  
The NE is dotted with nuclear pore complexes (NPCs) that are responsible for the transport of 
molecules between the nucleus and cytoplasm (Rout et al., 2000). Within the envelope is the 
perinuclear space that houses the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex. The 
LINC complex spans the entire membrane and directly connects the cytoskeleton with the NL 
possibly conveying mechanical signals to alter chromosomes (figure 1.17) (Rout et al., 2000; de 
Lanorelle, 2012; Osmanagic-Myers et al., 2015).  
 
 
- image source: Irianto et al., 2016. 
Figure 1. 17 Continuity from the Cytoskeleton to the Nucleoskeleton:  
The cytoskeletal network interacts with the lamins (juxtaposed networks on the inner NE) that 
may act as a mechanotransduction bridge between the chromosomes and the extracellular 
environment.  
The architecture and regulation within the nucleus begin at the filamentous network of lamins 
primarily through tethering at the periphery via LADs relaying the signal to other nuclear proteins 
within the nucleoplasm. The mechanism of chromosomal regions attaching to the lamins via 
tethering constrains them in the nuclear peripheral region, through which approximately 500 loci 
are regulatorily silenced, a mechanism that remains unclear (figure 1.18) (Heun et al., 2001; Chubb 
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et al., 2002; Finlan, 2008; Fedorova and Zink, 2008; Shevelyov and Ulianov, 2019). 
 
- image source: Shevelyov and Ulianov, 2019. 
Figure 1. 18 A Schematic Representation of the Three Assumed Lamina-Chromatin Tethering 
Mechanisms:  
The lamina components may bind with either specific DNA motifs, modified nucleosomes or unmodified 
nucleosomes present in LADs of the genome (Shevelyov and Ulianov, 2019). 
Chromatin anchoring may be more intricate than originally thought since NE proteins and LADs 
show tissue-specific expression and cell-type variability, tethering could differ amongst cell types 
(van Steensel and Belmont, 2017; Burke and Stewart, 2013). Not all lamin-tethered genes are 
repressed, and the involvement other proteins have been suggested peripheral activation (Fedorova 
and Zink., 2008; Ibarra and Hetzer, 2015; Randise-Hinchliff and Brickner, 2016). Aberrant tethering 
or the lack of becomes a concern when carcinogenic pathways are set off due to abnormal 
transcriptional silencing of oncogenes and TSGs (Kazanets et al., 2016; Burke and Stewart, 2013). 
 Lamin and Cancer  
Lamins provide structural support for the nuclear membrane in addition to influencing the nuclear 
shape and when over or under-expressed profound disease implications are presented (Zink et al., 
2004; Bridger et al., 2007; Burke and Stewart, 2013). Most notably the premature ageing disease 
Hutchinson-Gilford progeria syndrome (HGPS), attributed to a mutant lamin A (progerin), resulting 
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in radial organisation disruption, which is attractive as ageing is amongst the highest risk factors 
for cancer (Bridger et al., 2007; Bickmore, 2013; reviewed in Irianto et al., 2016). Normal nuclei 
have a regular ellipsoid shape but, in many cancers, an irregular sometimes tissue type-specific 
contour is observed and correlations are beginning to emerge between the dysmorphic nuclei 
(nuclear atypia) in cancers and lamins (table 1.3) (Zink et al., 2004; reviewed in Irianto et al., 
2016).  
Table 1. 3 Changes in the Levels of A-type and B-type Lamins in Cancer:  
 
Type of cancer  
A-type lamins B-type lamins 
Ovarian serous  ↑ 
 
Ovarian  ↓ ↑ 
Lung ↓ 
 
Breast  ↓ ↓ 
Colon  ↓ ↓ 
Colorectal  ↑ ↑ 
Colonic and gastric  ↓ 
 
Primary gastric ↓ 
 
Basal cell skin  ↓ 
 











- adapted from Irianto et al., 2016 
Lamins fluctuations may indirectly affect cancer progression through chromosome conformation and 
tethering via LADs as well as fluctuating gene expression through transcriptional regulators 
(reviewed in Irianto et al., 2016). Luxton et al., 2010; Folker et al., 2011 showed that cells absent 
of A-type lamins was incapable of nuclear re-positioning and centrosome polarisation. Lamins also 
serve to protect the genome by preventing chromosomal aneuploidies and regulate their spatial 
excursions within the nucleus as seen in the colorectal cancer cell line (DLD1) upon Lamin A/C and 
B2 depletion (Ranade et al., 2017). In the same cell line, Camps et al., 2014 showed CT 
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decompaction and increased abnormal nuclear shapes in the absence of lamin B1 and Sengupta and 
Sengupta, 2017 also revealed alterations in nucleolar morphology and nucleoplasmic dynamics upon 
lamin B2 depletion.  
Previous studies have demonstrated the vital role of microenvironment mechanics in cancer 
progression which makes lamins particularly interesting since they were shown to be 
mechanosensitive and implicated in the hypothetical nuclear motor complex that includes nuclear 
myosin (Mehta et al., 2008; reviewed in Irianto et al., 2016). In 3D, lamins have shown roles in 
modulating cancer cell migration with impact on tumour growth. In Xenograft models, perturbed 
lamin A showed increased migration and overexpressed lamin A reflected a pro-survival function 
(Harada et al., 2014). Lamins mirror tissue stiffness (a ‘mechanostat’) where the nucleus of stiffer 
tissues with also be stiffer due to a higher lamin content, as demonstrated in-vitro when lung cancer 
and primary mesenchymal stem cells were grown in a stiffer matrix, their lamin A/C levels were 
higher (reviewed in Irianto et al., 2016). A-type lamins affect the morphology and visco-elastic 
properties of the nucleus in a way that over-expression increases nuclear stiffness (Osmanagic-
Mayers et al., 2016). While studies have shown that this might increase its nuclear integrity, it may 
also reduce invasive migration as the transient knockdown of lamin A/C led to the initial rapid growth 
of tumours and softer nuclei, with greater efficiency of migrating through small micro-pores 
(Osmanagic-Mayers et al., 2016).  
Currently, the cancer-related findings on lamins are limited, and further investigation is required for 
its mechanistic link, therapeutic, diagnostic and even its prognostic value as higher lamin A in breast 
cancer has been associated with better clinical outcomes and low lamin A with the recurrence of 
colon cancer (Wang et al., 2009; Belt et al., 2011; Capo-chichi et al., 2011; de las Heras, Batrakou 
and Schirmer, 2013). Numerous lamin-cancer connections raise many possibilities in its role from 
epigenetic modifications that lead to oncogene activation, or migration inhibition of tumour 
suppressors or by even protecting the genome from damage.  




To organise the structure of the nucleus and chromatin, the lamina must complex with other proteins 
to relay signals. Emerin interacts with the inner nuclear membrane, as it can bind to chromatin both 
directly and indirectly, (possibly with a role in chromatin tethering due to its binding and co-
localisation with both A-type and B-type lamin) and interact with NET proteins, BAF and chromatin 
(Holaska and Wilson, 2006; Berk, Tifft and Wilson, 2013). Emerin also binds to nuclear actin and in 
the disease Emery-Dreifuss Muscular Dystrophy (EDMD), emerin suffers a missense mutation, and 
its binding to F-actin is disrupted (Holaska and Wilson, 2006).  
Emerin, together with lamin and LADs, has been implicated in maintaining the structural integrity 
of the nucleus and progression of the cell cycle and its mutation is associated with many 
degenerative diseases including cancer (Reis-Sobreiro et al., 2018; Urciuoli et al., 2020). 
Abnormalities in emerin are associated with mechanical weakness as its loss may disrupt the actin-
based, lamin-reinforcing system required for nuclear integrity which may be responsible for the 
‘amoeboid’ tumour phenotype in cancers (Reis-Sobreiro et al., 2018) (figure 1.19). In breast and 
prostate cancer cells (in-vitro), human prostate cancer tissue and circulating tumour cells (in-vivo), 
the depletion lamin A/C leads to nuclear shape instability with a correlated gain in malignancy 
characterised the reduction and/or mis-localisation of emerin (Reis-Sobreiro et al., 2018). 
Differential expression of lamins and emerin were also correlated to tumour aggressiveness in the 








- adapted from Reis-Sobreiro et al., 2018 
Figure 1. 19 Emerin Nucleus in Cancer:  
Reduction and/or mis-localisation of emerin corresponds to a gain in malignancy. Emerin contributes to nuclear 
shape stability where aberrations can lead to ‘amoeboid’ tumour phenotype of the nucleus and the cell that 
aids in migration.  
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1.2.4 Nuclear Myosins  
The two significant aspects of genome organisation are location and relocation. Aside from being 
functionally compartmentalised, chromosomes are functionally moved in response to proliferation 
and differentiation and some cases as a result of disease, as spatial positioning regulates gene 
expression at some level (Finlan et al., 2008; Meaburn and Misteli, 2008). In the interphase nuclei 
of various organisms’ genomes are non-randomly organised that can rapidly relocate upon a 
stimulus as shown by Mehta et al., 2010 and Bridger, 2011, where within 15 minutes, chromosomes 
relocated after serum removal. Chuang et al., 2006 showed that chromosomes move in a 
unidirectional, curvilinear path perpendicular to the NE at velocities of approximately 0.1-0.9µm/min 
covering distances over 1-5µm. The nucleus is a highly organised organelle, and while its contents 
are dynamic, phase organisation does not account for the energy-requiring process of CTs or 
‘biomolecular condensates’ functionally moving. The motor protein family of myosins that exist in 
the cytoplasm are also found in the nucleoplasm, with roles in transportation, anchorage and tension 
sensing depending on structural and mechano-enzymatic characteristics (figure 1.20) (Fili and 










- image source: Fili and Toseland, 2019.  
Figure 1. 18 Schematic Representation of Unconventional Myosins Fulfilling Multiple Roles in Vital 
Cellular Processes:  
The myosins partake in a wide range of intracellular roles and thus require spatial and temporal regulation.   
Myosin structure consists of one or two motor heads (conserved 80kDa) where ATP hydrolysis, 
nucleotide-binding and actin-binding occurs; a neck region (of variable lengths; depending on the 
number isoleucine–glutamine (IQ) motifs) that amplifies conformational changes during the ATPase 
cycle creating the ‘power-stroke’, and a tail domain (coiled-coil, helical lever or single α-helix) that 
determines the myosin conformation, dimerization and mediates interaction with cargo and lipids 
(McGurk et al., 2006; reviewed in Fili and Toseland, 2019). The head domain can bind to actin and 
contains a specialised ATPase that hydrolyses ATP to ADP slowly in the absence of actin and 4-5x 
faster in its presence (Lodish et al., 2000). Facilitating the conformational changes required for the 
power-stroke is an IQ domain on the neck region that binds calmodulin (CaM) (Fili and Toseland, 
2019). The tail domain is positively charged and binds specific negatively charged cargo which 
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includes lipids and DNA with models proposing that the strength of this binding allows DNA to remain 
attached during the actomyosin power-stroke (Lodish et al., 2000; de Lanerolle, 2012). Variation 
in the head and neck domain reveal that myosins could potentially play critical motor roles not only 
on cargo but also localisation (Cook, Gough and Toseland, 2020). Myosins use the energy produced 
from ATP hydrolysis for mechanical work along the actin within the cell to move proteins and aid in 
holding the cell together through anchorage and contractile tension (Vreugde et al., 2006; Kapoor 
et al., 2017). The proper functioning of myosin requires it to be activated at the right time, 
appropriate conformation, suitable binding partner, cargo, and lastly at the correct location. 
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 Functional Diversity of Nuclear Myosins: 
Conventional myosins encompass cardiac muscle myosin, smooth muscle myosin and non-muscle 
myosin II. Unconventional myosins account for 2/3 of myosin genes perform roles in endo-/exo-
cytosis, intracellular trafficking and morphology, cell adhesion and motility and transcription (Cook, 
Gough and Toseland, 2020). Non-muscle myosin was discovered after observing ATP-dependent 
contractile events in non-muscle cells leading to the discovery of 18 ‘unconventional’ subtypes of 
the conventional muscle myosin (Vreugde et al., 2006). After being under scepticism for three 
decades, it is now clear that nuclear myosin (NM) exists in addition to its popular counterpart actin 
carrying out distinctly essential functions in the nucleus.  
Table 1. 4 Summary of Nuclear Myosins and their Genes  
Name 
Gene 
Nuclear Myosin I MYOIC – Isoform B 
Myosin I MYO1C – Isoform A and C 
Non-muscle myosin IIA MYH9 
Non-muscle myosin IIB MYH10 
Myosin Va MYO5A 
Myosin Vb MYO5B 
Myosin VI MYO6 
Myosin X MYO10 
Myosin XVI MYO16 
Myosin XVIIIβ MYO18β 
-reviewed in Cook, Gough and Toseland, 2020 
In the early 1990s, the roman nomenclature for myosin was proposed as the family began to grow 
unexpectedly (Mooseker & Foth, 2007). To date, there are more than seven classes of the 
superfamily that have been discovered in the nucleus most notably I, II, V, VI, X, XVI and XVIII 
(table 1.4) (de Lanerolle, 2012). This research focuses on two NMs: NMI (NM1) and NMVI (NM6) 
recognised for their roles in the spatial organisation within the nucleus and briefly highlights NMVa 
and NMVb (NM5a and 5b), NMXVI (NM16) and NMVXIIIβ (NM18β) due to roles in the genome and 
OC. 
 




NM1 was the first NM discovered and have been relatively well-studied and is the most prominently 
expressed NM in vertebrates (reviewed in Mooseker and Foth, 2008). NM1 plays conventional roles 
in the directed movement of interphase chromosome regions in addition to its ability to attach to 
chromatin remodelling complex and participate in transcription through direct interaction with RNA 
Pol I and II, mediating the phosphodiester bond formation during transcription initiation (reviewed 
in Mooseker and Foth, 2008). Philimonenko et al., 2010 highlights an additional transcription role 
of NM1 involving rRNA, where the nucleolar positioning of actin and NMI is responsible for rRNA 
maturation and maintenance of the nucleolar structure where it is was further stated that the 
distribution of NM1 in the nucleolus, closely relates to the transcription process. The ATPase activity 
of NM1 is required for the initiation of transcription and the formation of the first phosphodiester 
bond validating its role as a transcription factor (Philimonenko et al., 2010; Hofmann et al., 2006.)  
Studies have found that NMI and actin are tightly connected by separate but supporting roles, yet 
its mechanism remains unclear. Chuang et al., 2006 also showed the inhibition of rapid long-range 
chromosome movements when mutant NM and actin was expressed, which emphasised significant 
roles in the motor arm of regulation. Mutational studies of nuclear actin and myosin rendered them 
necessary for efficient rRNA transcription and powering the active process of chromosome re-
positioning (reviewed in de Lanerolle, 2012). Actin and NM1 were also necessary for activating 
genes on multiple chromosomes by estradiol, re-positioning of the gene locus, and chromosome re-
positioning after serum starvation (Hu et al., 2008; Mehta et al., 2010). Mehta et al., 2010 showed 
that chromosome relocation takes place upon the removal and addition of serum facilitated by NM1. 
This was demonstrated by direct inhibition of NM1, via RNAi of NM1 and through the inhibition of 
ATP and GTP.  
 




- image source: Toseland Lab: http://toselandlab.mechanicsanddynamics.com.  
Figure 1. 19 Simplified Structure of NM1 and NM6:   
A. NM1 the Nuclear localisation sequence (NLS) in the IQ motif that contains CaM binding sites. PH domain for 
lipid binding in the tail. B. there is a short coiled-coil in the tail of NM6 and PIP2 domain for lipid binding.  
 
NM6 
In the mammalian cell, NM6 is found in nuclear extracts, and in several cancer cell lines, it was 
immunolocalised in discrete foci in interphase nuclei (Mooseker and Foth, 2008). NM6 is the only 
member of the superfamily that moves backwards as it moves toward the minus end on the actin 
track (Dunn et al., 2006). NM6 co-localises and co-immunoprecipitates with mRNA, promotors of 
the target genes and RNA Pol II in the nucleus during active transcription, implicating its role as a 
direct transcription factor (Vreugde et al., 2006; Mooseker and Foth, 2008). Additionally, NM6 
depletion led to a decrease in the target mRNA steady-state, and its inhibition halted transcription 
(Vreugde et al., 2006; Mooseker and Foth, 2008). The complex formed by NM6 and RNA Pol II also 
includes NM1; however, NM6 differs in its ability to dimerise, its large and extensively variable step 
size in addition to being able to act as an anchor for immense mechanical loads; therefore, the 
mechanism could be totally different to NM1 (reviewed in de Lanerolle and Serebryannyy, 2011; Fili 
and Toseland., 2019). While NM1 has been implicated in the spatial organisation of chromosomes, 
NM6 has been hypothesised to be a spatial organiser of transcription (Mehta et al., 2010; Fili and 
Toseland., 2019). The shared interaction of NM1 and NM6 with RNA Pol II raises many questions to 
whether they are working alone, together, or against when bound to RNA Pol II (Figure 1.22). 




- image Source: Cook, Gough and Toseland, 2020 
Figure 1. 20 Anchoring/transport of RNA polymerase II by Nuclear myosin:  
NM1 and NM6 can bind to DNA directly via their C-terminal tail domain and indirectly to RNA Pol II through 
actin, by their motor domain (Cook, Gough and Toseland, 2020). This model suggests that myosin could either 
anchor RNA Pol II or transport it along the DNA. However, the question remains to whether NM1 and NM6 are 
working alone, together, or against when bound to RNA Pol II.  
 
NM5a and NM5b 
The splice variant isoform NM5a has been observed in the nucleus of spermatocytes, where both 
NM5a and NM5b in the nucleus of ovarian mouse cells (Sun et al., 2010; McGurk et al. 2006). Li 
and Yang, 2016 hypothesised that NM5a interacts with chromosomes as other NMs have been found 
too. Pranchevicius et al., 2008 presented roles for NM5a in transcription, nuclear 
compartmentalisation and localises at RNA processing sites (nuclear speckles) raising possible roles 
in splicing. NM5a also has a valuable role in viral replication transporting viral particles by interacting 
with its capsid proteins, and some viruses go further into promoting the formation of the required 
actin filaments (reviewed in de Lanerolle, 2012). NM5b, often less studied but is attracting attention 
in the transcription process as it was found present in the nucleolus interacting with RNA Pol I, β-
actin and newly transcribed rRNA (Lindsay and McCaffrey, 2009). Its association with RNA Pol I was 
altered when an RNA Pol I blocker was used (Lindsay and McCaffrey, 2009). 




NM16 is unique as it is exclusively expressed in the nucleus and localises primarily in the nucleolus 
(Reck-Peterson, Novick and Mooseker, 1999). NM16 is seen in the cytoplasm after being exported 
as a result of DNA replication stress, resulting in a reduction in the nucleus whereas an over-
expression following either DNA damage, nucleotide insufficiency or DNA pol suppression, delays 
cell cycle progression into the S-phase (Cameron, Liu and Pihkala, 2013; Li and Yang, 2016). The 
C-terminal tail is responsible for localisation, and the N-terminal head interacts with stress-induced 
nuclear actin rods; however, the function of NM16 in interphase is not known (reviewed in Mooseker 
and Foth, 2008).  
NM18 
NM18 was immunolocalised in the cytoplasm of undifferentiated myoblast, and upon differentiation, 
part of the NM18 enters the nuclei (Salamon et al., 2003). A similar observation was found in 
primary skeletal muscles cells and cardiomyocytes (Salamon et al., 2003). NM18 is required for 
microfibrillar development and a candidate TSG after being associated with lung and OC (Yanaihara 
et al., 2004; de Lanerolle and Serebryannyy, 2015). NM18 gene is found on chromosome arm 22q 
that contains three other TSGs linked with several other mammalian cancers, which were found 
either reduced, mutated or hypermethylated in lung and OC cell lines (Yanaihara et al., 2004). 
Yanaihara et al., 2004 showed the isoform NM18b had reduced expression in all four ovarian cell 
lines used and in 71% of the 17 primary cell line used. Though its nuclear role is undefined, when 
NM18 was restored using 5-aza-2-deoxycytidine and/or trichostatin A, anchorage-dependent 
growth of several tumour cell lines was suppressed, thus reinforcing is TSG role in human 
carcinogenesis (Ajima et al., 2007). 
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1.2.5 Nuclear Actin 
A unique feature of NM is that it does not interact with microfilaments like conventional myosins 
thus impacting the traditional concept of just being an actin-based motor using actin filaments for 
translocation (Li and Yang, 2016). As microfilaments do not constitutively exist in the nucleus, but 
only appear adaptively, myosins must, therefore, interact with the established nuclear actin 
(Baarlink et al., 2013). The entire myosin superfamily contains actin-activated ATPase that tethers 
and move organelles along actin filaments through cycles of attachment and detachment to actin 
(reviewed in Cook, Gough and Toseland, 2020). Its interaction with RNA Pol II increases its activity 
8-fold and thus considered a transcription factor (Hofmann et al., 2004; Grummt, 2006). Upon the 
binding of actin and myosin, the tail is directed towards a nuclear cargo to bind; this co-binding 
produces a strain on myosin where it is then conveyed along actin (Hofmann et al., 2006, de 
Lanerolle, 2012; reviewed in Cook, Gough and Toseland, 2020). Whether actin is present in the 
nucleus in monomeric, polymeric or filamentous forms; the exact state that actin interacts with NMs 
is still uncertain (reviewed in Cook, Gough and Toseland, 2020).  
Actin tracks can now be observed in the nucleus, interact with several classes of NM, form 
actomyosin for contractility during translocation through narrow spaces, and regulatory roles in 
transcription and cell cycle (de Lanerolle, 2012; Serebryannyy et al., 2016; Davidson et al., 2020). 
Nuclear myosin has also been observed driving the movement of heterochromatin breaks towards 
the periphery while long-range actin filaments are also observed extending from the 
heterochromatin DNA damage sites to the nuclear periphery (Caridi et al., 2018). An independent 
nuclear role proposed for actin is that it relaxes chromatin structure giving way for out-looping and 
possibly transcription, but not necessarily moving the chromosome (Fedorova and Zink, 2008). 
Furthermore, the perturbation of actin polymerisation through a G13R mutation or latrunculin A 
drug results in loss of movement in CTs, rearrangements and transcriptional stimulation (Chuang 
et al., 2006; Dundr et al., 2007; Mehta et al., 2010). These data show that multiple actin subunits 
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are required for the movement of nuclear entities by NMs.   
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1.2.6 Hypothetical Motor Complex: 
A study by Mehta et al., 2008 proposed a hypothetical complex of nuclear proteins that are presently 
considered part of the NE and nucleoskeleton that could also be functionally present in roles 
involving transcriptional regulation (figure 1.23). Rapid repositioning of the CTs during interphase 
appears to be facilitated by NM and actin that falls within a nuclear motor complex. The Bridger lab 
has also found that required or expected chromosome re-positioning is altered or absent in cells 
that possess mutant lamin A or emerin deficiency and upon inhibition of myosin and actin (Mehta 
et al., 2008 and Bridger et al., 2014).  
 
- image source: Simon and Wilson, 2011. 
Figure 1. 21 Possible Arrangement of the Hypothetical Motor Complex:  
Showing interactions of NM1 (nuclear MYO1C) with emerin and actin as well as A-type lamins with 
emerin and actin. This complex and its protein may be important for maintaining the 
nucleoskeleton dynamics and anchorage. Nuclear MYO1C binds emerin and actin to produce 
tension in a similar way to cytoplasmic MYO1C in ear hair cell stereocilia. INM -inner nuclear 
membrane and ONM-outer nuclear membrane.  
For the hypothetical nuclear motor complex to hold, these four proteins must be connected, though 
are not limited to them. Although not currently visualised, de Lanerolle, 2012 pointed out that NMI 
then interacts with chromosomes to facilitate its movement with the mechanical aid of actin.  




The information on the molecular cancer mechanisms is growing rapidly; however, the discovery of 
novel and effective drug targets to improve the therapeutic outcomes is lacking. In OC, there is 
currently no standard practice, and the biomarkers in current clinical use still present a substantial 
number of false negatives and false positives, while the field is rapidly progressing for better 
treatment predictions and preventing unnecessary surgeries. The challenge increases as the disease 
experience MDR (multidrug resistance), resulting in the need to include it in all fields of research 
equally. The plethora of nuclear roles and disease association have been studied for decades, but 
full genetic knowledge will also require investigating the 3D arrangement of the chromosomes. 
Research Objective:  
This research started by investigating the disease-related altered positioning of CTs (of 
chromosomes 1, 13, 17 and X) in four OC cell lines (SKOV-3, PEO-1, PEO4 and MDAH-2774) while 
also addressing their nuclear distribution and levels of NM1 and NM6, and a brief highlight on A-
type and B-type lamin discrepancies within the disease. Since NM are responsible for the most 
significant input into movement within the hypothetical nuclear motor complex, the altered CTs 
were compared to the post knockdown CTs following NM1 and NM6 RNAi. Then finally, to address 
the gap in research of chemoresistant-related alterations, CTs were mapped on a lab-created 




CHAPTER 2  
CHROMOSOME SPATIAL ORGANISATION AND 
NUCLEAR MOTORS IN OC 
2.1 INTRODUCTION 
OC is the deadliest amongst gynaecological cancers, and in this field of study to date, breast and 
prostate cancers have taken the forefront. While well-funded breast and prostate, amongst other 
non-gynaecological cancers, are over-diagnosed and over-treated, the opposite is taking place for 
under-funded OC (Welch and Black, 2010). Challenging the shortage of additional prognostic 
markers to identify aggressive to indolent cancers can benefit both sets of patients by reducing the 
healthcare costs of treating over-diagnosed and over-treated cancers so that under-diagnosed and 
under-treated cancers can benefit.  
Advances in gene regulation in cancer research are sometimes unsuccessful and not well understood 
because part of the picture is missing since functional chromosome positioning is over-looked. The 
unique oncogene MECP2 exemplifies this, found on the inactive female chromosome X, MECP2 that 
is unmutated, yet overexpressed in 18% of cancers through an unknown mechanism (Neupane et 
al., 2016). As the acceptance and relevance of spatial chromosome positioning are emerging in 
diseases, it is crucial to re-evaluate diseases with gene regulation and expression discrepancies. 
The aggressive nature of OC provides a good starting point to understand the disease further with 
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the potential to understand other cancers in addition to nucleopathies.  
2.1.1 Spatial Chromosomal Organisation in Cancer 
Chromosomes non-randomly occupy spatial territories in interphase nuclei and re-position in 
response to changes in the functional requirements of the nucleus. For instance, in the absence of 
serum, chromosomes 18 and 13 relocated from the nuclear periphery to the nuclear interior, 
chromosome 10 from the intermediate nuclear region to the periphery and chromosome X remained 
at the nuclear periphery in primary human dermal fibroblasts when serum was removed (Mehta et 
al., 2010; Bridger et al., 2014). The spatial organisation can both reflect and contribute expression, 
and changes within the nuclei as in the case of chromosome 7 in leukemic cells (Brickner, 2017; 
Federico et al., 2019). Chromosome 7 changed its spatial location in response to breakage on its q-
arm caused by abnormalities that may have contributed to its altered transcriptional activity due to 
accompanied re-positioned genes (Federico et al., 2019). Aside from influence by transcription 
factors and chromatin changes on spatial organisation, proximity to the nuclear periphery can also 
affect expression as exemplified by Finlan et al., 2008 who showed tethering chromosomes to a 
protein of the inner nuclear membrane reversibly induced suppressed some (but not all) genes as 
they also depended on histone deacetylases (that removes the acetyl from histone allowing the DNA 
to wrap more tightly and thus rendering it inactive).  
When compared to their healthy counterparts, cancer-specific re-positioning of gene loci is 
observed in both reproductive cancers breast and prostate (Zeitz et al., 2013; Meaburn et al.,2016; 
Leshner et al.,2016). Although 94% and 57% of the genes mapped in prostate and breast cancer 
have non-altered positions, it is essential to recognise the ones that do (Meaburn et al., 2009; 
Leshner et al., 2016). Interestingly, in thyroid, colon and cervical cancers, chromosome 18 re-
positions internally, and chromosome 19 re-positions away from the nuclear interior (Cremer et al., 
2003; Murata et al., 2007; Wiech et al., 2009). However, one must keep in mind, where genes such 
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as FLI1 re-positions in 100% and 92.9% of breast and prostate cancers respectively, it is difficult 
to stratify aggressive and indolent cancers with this gene, so it becomes a matter of finding the 
right chromosomes and genes to exploit clinically (Meaburn et al., 2016; Leshner et al., 2016).  
2.1.2 NM cancer-specificity 
The nucleus is the largest organelle in the cell, and movements of components within this highly 
organised space requires the use of motor proteins such as myosins. Nuclear myosins also change 
their distribution in response to functional requirements; in proliferating cells, NM1 is seen 
throughout the nucleoplasm, concentrated around the nucleoli, and regulating long-range 
chromosome dynamics during interphase that changes into aggregates when the serum is removed 
(induced quiescence) (Pestic-Dragovich et al., 2000; Chuang et al., 2006; Hofmann et al., 2006; 
Mehta et al., 2010; Kulashreshtha et al., 2016). Building on the rapid re-location of chromosomes 
within 15 minutes of serum-removal and restoration of NM1, Mehta et al., 2010 observed the 
relocation resumed only after 24-36 hrs as the proliferating distribution of NM1 was restored.  
NM6 has not been directly linked to spatial chromosome organisation but has been shown to 
organise RNA Pol II spatially and is overexpressed in all the reproductive cancers; prostate, ovarian 
and breast (Dunn et al., 2006; Yoshida et al., 2004; Wang et al., 2015; Hari-Gupta et al., 2020). 
NM6 is the only myosin in the superfamily of myosins that moves towards the minus end of actin, 
and the unique property to move backwards enables its involvement in migration, endo-/exocytosis 
and RNA Pol II-dependent transcription (Wells et al., 1999; Roberts et al., 2004; Vreugde et al. 
2006). When NM6 is inhibited or knocked down, it perturbs the spatial organisation of RNA Pol II, 
affecting the anchorage of their chromatin clusters and gene/promoter associations which can be 
useful drug targets in cancer and understanding its biochemistry (Hari-Gupta et al., 2020).  




Nuclear myosins alone cannot explain the complex biomechanical roles of spatial chromosome 
organisation. Nuclear myosins are known to bind DNA and are involved in transcription; however, 
they also complex with other nuclear proteins, such as emerin and actin (reviewed in Mehta et al., 
2008; Cook, Gough and Toseland, 2020). These two proteins bind to each other but, also together 
they bind to lamin on their other end, forming a hypothetical nuclear motor complex (Mehta et 
al., 2008). Through this complex, a series of mechano-transduction events, including histone 
modifications; the cell cycle status can influence functional genome repositioning events (reviewed 
in Mehta et al., 2008). Lamins in concert with other structural nuclear proteins such as actin 
maintain the nuclei's structural and genome integrity, where dysregulation in these proteins leads 
to dysmorphic nuclei and genome instability (reviewed in Irianto et al., 2016). DNA interactions 
with the NL have been mapped in human, Drosophila and murine cells in large domains (LADs) 
instead of foci, and through a tethering mechanism to transcriptionally inactive sites of the NL, 
these LADs assume a repressive role (Guelen et al., 2008; Pickersgill et al., 2006; Peric-Hupkes et 
al., 2008; van Steensel and Dekker, 2010). With more than 1,000 of these domains, their disputed 
influence under lamins, and the characteristic dysmorphic nuclei in cancer, it is vital to address 
lamins in OC (Guelen et al., 2008).  
2.1.4 Why these chromosomes?  
Chromosome 1 contains the TSG gene ARID1A that is mutated in 62% of OC cases and found 
deficient in 86-100% of OC cases are in ARID1A protein (Aunoble et al., 2000). What also makes 
ARID1A interesting is its role in spatially partitioning chromosomes through its role in B-
compartment formation and weakening of the border strength in topologically associated domains 
(TADs) in accordance with gene expression (Wu et al., 2019). Furthermore, ARID1A knockouts 
increased the volume of the nucleus and chromosomes in addition to the intermixing of small 
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chromosomes 19 and 22 (Wu et al., 2019). This would possibly mean intermixing of 
chromosomes/CTs in OC, by and large, downstream effects in transcription.  
Chromosome 13 contains the TSG BRCA2 while chromosome 17 contains TSG BRCA1 and p53 
in addition to the oncogene HER2. 5-10% OC cases are due to BRCA1/2 mutations, while 79% of 
all cases have p53 mutations and 30% have HER2 amplification (Aunoble et al., 2000). These genes 
are also implicated in breast, cervical and prostate cancers and could provide translational value to 
other cancers. Chromosome X was used as a spatial reference chromosome as it occupies a 
peripheral region in the nuclei of cells such as HeLa, lymphocytes, primary human dermal fibroblasts 
and mouse embryonic fibroblasts (Kurz et al., 1996; Cremer and Cremer, 2001; Mehta et al., 2010; 
Deng et al., 2015). However, in OC, it shows a preferential trend towards monosomy, and recently 
the paternal X-chromosome was linked to OC, making it an intriguing inclusion to this study (Eng 
et al., 2018).  
  




Spatial genome repositioning events are orchestrated by a plethora of complexes and proteins, one 
of these; is the hypothetical nuclear motor complex that holds both motor and anchoring roles 
(Mehta et al., 2010). Disruption in the anchoring and motor activities can, in turn, interrupt the cell 
cycle influence on the organisation, leading to chromosomes with unstimulated repositioning (high 
NM), unresponsive to functional repositioning (low NM), high repressory anchorage (high lamins) 
or lack of repressory anchorage (low lamins), all eventually leading to disease-related effects on 
gene regulation. Spatial chromosomal and gene positions are conserved throughout the cell cycle, 
and any alterations could allow the diagnosis of specific diseases and then possibly avenues to 
treatment (Tanabe et al., 2002; Meaburn, 2016).  
Even though there is growing evidence of oncogenic genomic spatial organisation, there is still a 
deficit in information to produce a reliable biomarker panel. The infrastructure for FISH in clinics 
already exists and can be used by integrating tissue samples already removed from patients (no 
additional invasiveness required) could be extended to diagnostics and prognostics. There are many 
probes sets available for a cancer diagnosis; for instance, Abbot Molecular currently manufactures 
FISH kits for bladder and lung cancer diagnosis based on translocation rearrangements. However, 
if this design can implement proximity positioning of silent culprits (healthy genes such as MECP2), 
new ways of diagnosing, prognosing and treating the OC can be personalised in addition to rectifying 
ineffective treatment and toxic dosing.  
This chapter sets out to test the hypothesis of cancer-associated spatial chromosomal repositioning 
events in OC by positioning of 3 significant chromosomes (1, 13 and 17) containing prevalent TSGs 
and oncogenes related to OC and challenging chromosome X as a proximity control, at least in OC. 
The spatial territories of these four chromosomes were positioned in 4 cancer cell lines SKOV-3, 
PEO-4, MDAH-2774, PEO-1. Since epithelial OC accounts for approximately 80-90% of cases, a non-
CHAPTER 2: Chromosome Spatial Organisation and Nuclear Motors in OC 
 
81 
immortalised control epithelial cell (HOSEpi) was used. This chapter also aimed to validate the 
hypothesis that irregularities in NM and lamins correlate with cancer-associated chromosomal 
repositioning events by examining the nuclear distribution of 6 proteins: NM1, NM6, lamin A, lamin 
C, lamin B1 and lamin B2.  
With FISH, the potential for a CT biomarker panel for OC construction was investigated, and with 
just four whole chromosomal OC-specific repositioning events it was possible to extract trends 
between each cell line, clonally related lines and those that possessed chemoresistance. The 
inclusion of indirect immunofluorescence (indirect-IF) and western blots (WB) showed 
inconsistencies in nuclear proteins, providing explanations to the dysfunctional spatial organisation 
in OC.  
 
  
CHAPTER 2: Chromosome Spatial Organisation and Nuclear Motors in OC 
 
82 
2.2 METHODS  
2.2.1 Cell Culture  
Human epithelial OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774 were gifted from the Karteris 
group, Brunel University London (attained from ATCC). Cells were cultured in supplemented Roswell 
Park Memorial Institute (RPMI) 1640 medium (Gibco) containing 10% FBS, 2mM L-glutamine 
(Sigma) and 50U/mL penicillin / 50 µg/mL streptomycin (Gibco) in a humidified 5% CO2 incubator 
at 37°C. They were frozen in 5% DMSO, new batches were removed from liquid nitrogen every 8-
12 weeks, and after two weeks stocks were made. 
Healthy human ovarian surface epithelial (HOSEpi) cell line (SC-7310) was purchased from ScienCell 
research laboratories and cultured onto glass coverslips for use in 2.2.3 (IF). These are non-
adherent cells; therefore, the flasks/ wells were treated before seeding with poly-L-lysine (2µg/cm2) 
that is 15µL of poly-L-lysine stock (10mg/mL) in 10mL sterile water at 37°C overnight (or minimum 
1hr) in the incubator, then rinsed twice with sterile water. Cells were initially grown in Ovarian 
Epithelial Cell Medium (OEpiCM) (ScienCell), however, for bulking up they were grown in complete 
RPMI 1640 in suspension.  
From another purchased pellet of 5x106 cells, 2x106 was fixed for FISH, and 2x106 was used to 
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Table 2. 1 Ovarian Cell Lines Summary:  
Images were taken using an iPhone on a light microscope of control cell line HOSEpi, and OC cell lines SKOV-
3, PEO-1, PEO-4 and MDAH-2774. Highlights the history of tumour cells that were all adenocarcinomas 
derived from ascites fluid, doubling time (t) and genetic variations (Beaufort et al., 2014 and Hernandez et al., 
2016). These cell lines were a kind gift from the Karteris Group (Brunel University London). 
HOSEpi 
(ScienCell) 
Healthy epithelial control 




























Doubling t: 27 hrs 
Endometrioid 
100X 100X 100X 100X 
Derived from a 64yr old 
Caucasian woman from 
ascites fluid in 1973.   
 
TP53, NF1, PIK3CA, 
HRAS, ARID1A, ERBB2 
(Amplification) 
PEO-1, PEO-4 and PEO6 
were extracted from one 
patient by Dr Simon 
Langdon in February 1982, 
November 1982, and 
February 1983, 
respectively. PEO-1 was 
extracted after one 
chemotherapy treatment 
while still showing 
sensitivity.  
 
TP53, BRCA2  
 
PEO-4 was extracted when 
the disease had become 
resistant against cisplatin, 
chlorambucil and 5-
fluorouracil treatments 
(Langdon et al., 1988 and 
Wolf et al., 1987). Contains 
a secondary mutation 
restoring BRCA function 
that was lost in its 
predecessor cell line PEO-1 
(Cooke et al., 2010). 
 
TP53, BRCA2 (Silent)  
Taken from a female 
patient in January 1972 it 
showed tumorigenicity in 
inoculated nude mice.   
 
TP53, BRCA1 (Silent), 
BRCA2 (Silent), PIK3CA, 
KRAS, ARID1A 
 







-continued on next page  
SKOV-3 - hypodiploid 
cell line with a modal 
chromosome number 
of 43 (63.3%) in a 
range between 42 to 
45. Higher ploidies had 
a rate of 32%. 
Monosomy or diploid: 
X (ATCC).  
PEO-1 - Monosomy: 6, 
13, 17, 21, 22, X and all 
others were diploid 
(Cooke et al., 2010).  
PEO-4 - Monosomy: 6, 10, 17, 
22, X and all others were 
diploid, and chromosome 13 
appeared absent (Cooke et al., 
2010). Showed re-appearance 
of chromosome 8 and 17 that 
was missing from PEO-1 (Wolf 
et al., 1987).  









Figure 2. 1 Karyotype Background  
A. SKOV-3: 10 Metaphases (Image source: Roschke et al., 2002). B. PEO-1: 19 Metaphases (Image source: 
Cooke et al., 2010). C. PEO-4: 23 Metaphases (Image source: Cooke et al., 2010). There was a reappearance 
of healthy copies of chromosome 1, 9, 11 and 17 in PEO-4 that was previously absent in PEO-1. D. MDAH-
2774: 7 Metaphases (Image source: Freedman et al., 1978). 
  
This research uses 4 ovarian cancer cell lines that displayed a unique karyotype from each other. When compared to a normal 
karyotype, they showed high chromosomal instability (structural and numerical); however, the karyotype remains relatively 
stable when established in cell culture as highest instability takes place during carcinogenesis and does not persist in continued 
growth (Roschke et al., 2002). Roschke et al., 2002 showed this in colorectal and ovarian cell lines, including SKOV-3 for 25 
passages.  PEO-6, the platinum-resistant successor of PEO-4, was taken from the patient 3 months after and showed high 
similarity where only 4% of their genome differed (Cooke et al. 2010). MDAH-2774 Karyotype remained constant after 50 
metaphases (Freedman et al., 1978).  
MDAH-2774 - Triploidy: 
1,2,3,6, 1 1, 12, 16, X; 
monosomy: 17 and 21; 6 of 7 
cells were triploid in 
Chromosome 5, and the other 
chromosomes had a non-
specific variation with a 
tendency toward triploidy 
(Freedman et al., 1978). 
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2.2.2 Fluorescence in-situ Hybridisation (FISH) 
 Probe Preparation:  
Biotin-labelled chromosome probes were made by degenerate-oligonucleotide-primed PCR (DOP-
PCR) using sequence pools (micro-dissected whole chromosome arm templates, a kind gift from Dr 
Michael Bittner) of chromosomes 1, 13, 17 and X (Telenius et al., 1992). Two rounds of amplification 
were performed first without labelling and second with biotin-16-UTP (1mM, Roche) labelling.  
Table 2. 2 The DOP-PCR Reagents: 
Run 1 (without biotin-16-UTP labelling) and run 2 (with biotin-16-UTP labelling). Master mixes were scaled up 
proportionally.  
REAGENTS 
RUN 1: without biotin-16-UTP RUN 2: with biotin-16-UTP 
5X DOP-PCR Buffer 10 10 
dACGTP (2mM) 5 5 
dTTP (2mM) 5 2 
DOP primer (20μM) 5 5 
Taq (20U/μL) 1 1 
Water 23 12 
Template 1 5 
biotin-16-UTP - 10 
TOTAL 50 50 
 
Table 2. 3 DOP-PCR Cycle Conditions: 
Run 1 (with 30 cycles) and run 2 (with 34 cycles).  
PHASE 
CYCLE TEMPERATURE (°C) TIME 
Initial Denaturation 1 95 3 mins 
Denaturation Run 1: 30 
 
Run 2: 34 
98 20 secs 
Primer Annealing 62 1 min 
Extension 72 30 secs 
Final Extension 1 72 5 mins 
Cooling / Collection  4 ∞ 
The amplified products were confirmed by performing a 1% agarose gel electrophoresis. 1g Agarose 
was dissolved in 100mL 1X Tris-acetate-EDTA (TAE, w/v) and then 5μL of SYBR® Safe (Invitrogen 
10,000X) was added to the warmed mixture. It was poured into a gel tray fixed with a 12-well comb 
and left to solidify. 1X TAE was poured into the electrophoresis tray with the solid gel till fully 
submerged. The samples were prepared by combining 5μL of PCR product and 1μL of loading dye. 
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3μL of the 1 kb DNA ladder (50µg/ml, BioLabs) was added into the first well, followed by the other 
samples. The gels were run for 40 mins at 80V. Visualisation of the products was performed with 
the Bio-Rad Molecular Imager Gel Doc XRS (Image Lab Software). The secondary template was 
stored at -20ºC until required and labelled probes were precipitated with ethanol or also stored until 
required.  
 Ethanol Precipitation: 
To the biotin-labelled probe mixture for every 200-400µg (per slide) of labelled chromosome 7µg 
of Cot-1 DNA (1µg/1µl, Roche), 3µg of Herring Sperm (Invitrogen), (1/10 v/v) of 3M Sodium Acetate 
(pH5.2), 200% ethanol and incubated at -80°C for at least 30 mins followed by 30 mins 
centrifugation at 4°C at (14,000rpm). The supernatant was removed, and the pellet was washed 
with 70% ethanol, followed by 15 mins centrifugation at 4°C (14,000rpm). The supernatant was 
removed, and the pellet was allowed to dry on a 50°C hot block. 12uL of hybridisation mix (50% 
Formamide, 10% 20X SSC and 1% Tween 20) per slide was added to resuspend the dried pellet 
(overnight at room temperature).  
 Cells for Sample Preparation: 
Trypsinised cells in solution were pelleted by centrifugation at 300-400g for 5 mins, incubated for 
15 mins in a hypotonic solution (0.56% w/v) KCl solution, re-pelleted and fixed using ice-cold (3:1 
v/v) Methanol:Acetic Acid solution on ice or -20°C for at least an hour. The fixation steps were 
repeated until minimal cytoplasm was observed under a light microscope.  
Cells were dropped onto dampened glass microscope slides, baked at 70°C for 60 mins followed by 
5 min serial dehydration in 70%, 90% and 100% ethanol solutions. They were heated at 70°C for 
5 mins in a dry oven and then transferred to 70% formamide (pH 7.0 v/v) solution at 70°C for 
exactly 2 mins. Ice-cold 70% ethanol was used to fix the open DNA in place. Then the slides were 
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placed on a 37°C warming plate ready for hybridisation.  
 Hybridisation:  
To the denatured cells upon slides, 12µL (per slide) of probe labelled with Biotin was denatured at 
72°C for 10 min and allowed to re-anneal for 10 mins (min) to 120 mins (max) at 37°C. 12µL was 
dropped onto a slide, sealed with a coverslip and rubber cement, then incubated in a humidified 
chamber at 37°C for minimum 18 hrs.  
 Washes:  
After 48 hrs, post-hybridisation washes were initiated thrice in 50% formamide (pH 7.0) at 45°C 
for 5 mins each followed by 0.1X Sodium Saline Citrate (SSC, Na3C6H5O7) (pH 7.0) washes at 60°C 
for 5 mins each and finally cooled in 4X SSC at room temperature. Cooled slides were blocked with 
4% BSA in 4xSSC for 10 mins then incubated with streptavidin-conjugated-cyanine3 (Cy3) 
(ThermoFisher) in 1% BSA (1:200) for 1 hr in a dark humidified chamber at room temperature. A 
final wash was performed with 0.05% Tween20 in 4X SSC for 5 mins at 42°C. The edge of the slides 
was blotted on a tissue to remove excess liquid and mounted in Vectashield containing 4,6-
diamidino-2-phenylindole (DAPI) (Vector Labs) and stored at 4°C until use.  
 Image and Analysis:  
Using the LEICA DM4000 microscope, epifluorescence microscopy was performed on each slide 
using 40X and 100X (in immersion oil (Immersol™)). For each chromosome of each cell line, 50-
100 images were captured using “LAS AF” Leica Software.  
From each data set at least 50 images were randomly selected in IPLab Spectrum Software on a 
Macintosh Apple Computer (MAC) to analyse the whole chromosome positions using erosion script 
analysis (Croft et al., 1999; Boyle et al., 2001).  DAPI signal area (total nucleus) was divided into 
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five equal concentric shells from the periphery to the nuclear centre (1 to 5) as depicted in figure 
2.2. Cy3 conjugated streptavidin was used to reveal the annealed chromosome painting probes, 






Figure 2. 2 Erosion Analysis Representation:  
The erosion software divides the nucleus into five equal concentric rings called ‘shells’. The chromosome signal 
for each shell (in green) is the divided by the area of that shell (in blue) that then represents the estimated 
occupancy of the chromosome relative to the periphery or centre. 
The script determined the pixel intensity of DAPI and the Cy3 (chromosome signal) which was 
normalised by division: % Cy3 pixel intensity / % DAPI Pixel Intensity for the five shells in Microsoft 
Excel. The output of the analysis was tabulated, graphed with ± error bars (SEM), and two-tailed 
student’s t-test (p0.5) was performed on excel (Croft et al., 1999).  
It is also noteworthy that the occupancy is not absolute and most often partial in nearby shells 
(figure 2.3) (Meaburn and Misteli, 2007). Signal concentration in shells 1 and 2 represented a 
preferred peripheral occupancy of that chromosome, shell 3 an intermediate preference and shells 
4 and 5 a central preference. 
 
 











Figure 2. 3 Erosion Analysis Sample Output:  
Depicting the output post-analysis of the tabulated numbers representing a chromosome that is preferentially 
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2.2.3 Indirect Immunofluorescence  
Cells were grown for 48 hrs on glass coverslips, washed 3 times with 1X phosphate-buffered saline 
(PBS) (Sigma:1 tablet in 200mL), fixed with methanol: acetone (1:1 v/v) for 10 minutes on ice, 
and then washed again with 3 times PBS 1X. 20µL of primary antibody diluted in 1% FCS in PBS 
(v/v) was placed on the coverslips overnight at 4ºC, 1hr at room temperature or 30 mins at 37ºC. 
After incubation, the coverslips were washed 27 times in 1X PBS and returned to the humidified 
chamber. The coverslip was then covered with 20μL of the secondary antibody and incubated in the 
dark for 1hr at room temperature. The coverslips were washed in 27 times PBS 1X followed by 3 
times in ddH2O, blotted on a tissue to remove excess liquid and mounted with DAPI.  
Table 2. 4 Antibody List: 
Primary and secondary antibodies and their dilutions used for indirect immunofluorescence.  
Primary Ab 
Dilution Secondary Ab Dilution  
Rabbit anti-Myo IB (Thermofisher) 1:100 Donkey anti-rabbit-Cy3 (Merck MiliPore, UK) 1:500 
Rabbit anti-Myo VI (Thermofisher) 1:100 Donkey anti-rabbit-Cy3 (Merck MiliPore, UK) 1:500 
Mouse anti-Ki67 (Thermofisher) 1:100 Goat anti-mouse-FitC (Jackson Laboratories, USA) 1:1000 
Rabbit anti-Lamin B1 1:500 Donkey anti-rabbit-Cy3 (Merck MiliPore, UK) 1:500 
Mouse anti-Lamin B2 1:400 Goat anti-mouse-FitC (Jackson Laboratories, USA) 1:1000 
Mouse anti-Lamin A (Abcam, UK) 1:100 Goat anti-mouse-FitC (Jackson Laboratories, USA) 1:1000 
Rabbit anti-Lamin C (ThermoFisher, UK) 1:200 Donkey anti-rabbit-Cy3 (Merck MiliPore, UK) 1:500 
 
The HOSEpi cells are non-adherent cells, so they were fixed in solution with 1mL methanol: acetone 
(1:1, v/v) for 10 minutes on ice, centrifuged and washed once 1mL PBS 1X, incubated with 1mL 
primary antibody overnight at 4ºC, 1hr at room temperature or 30 mins at 37ºC, washed once again 
1mL PBS 1X, then incubated 1mL secondary antibody for 1hr in the dark at room temperature. The 
cells were washed once again with PBS 1X and attached to slides using Shandon Cytospin 2 
(Marshall Scientific) (400g).  
Coverslips were mounted onto slides with DAPI for epifluorescence microscopy using the Leica 
DM4000 microscope. All slides were analysed for specific patterns of NM distribution in 200 nuclei. 
CHAPTER 2: Chromosome Spatial Organisation and Nuclear Motors in OC 
 
92 
Images of representative patterns were captured of the patterns scored, which were: dispersed foci, 
aggregate foci, dispersed and aggregate foci and negative. 
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2.2.4 Western Blot Assay  
Trypsinised cells were fractionated for nuclei; a pellet of approximately 2x106 cells was resuspended 
in 100uL hypotonic buffer for 15 mins at 37°C to swell the cytoplasm of the cell to aid douncing. 
The mixture was transferred to a microcentrifuge tube, spun at 800rpm for 6 mins and the 
supernatant was removed as the cytoplasmic extract. The pellet washed in another 100uL of the 
hypotonic buffer and checked under a light microscope for cytoplasm residue (in the case of excess 
cytoplasm, the wash was repeated). 100µL of 2X Laemmli buffer (Sigma-Aldrich; 20% glycerol, 
10% 2-mercaptoethanol, 4% SDS, 0.004% bromophenol blue and 0.125M Tris HCl, pH6.8) was 
then added to both the final pellet (nuclear extract) and the first supernatant (cytoplasmic extract) 
and stored in -80°C until use.  
Before loading, the samples were heated to 90°C for 10 mins. Two 10-well 10% SDS-PAGE Bio-Rad 
pre-cast gels were placed into the tank and filled with running buffer (3.02% TRIS, 14.4% Glycine 
and 1% SDS). To each well, on one gel, 10µL of the cytoplasmic sample and on another gel, 5 µL 
of the nuclear extract was loaded and ran at a current of 80mA (40mA for one gel) and 300V for 
approximately 40 mins.  
In a tray, 800mL ice-cold transfer buffer (3.01% TRIS and 14.06% Glycine) and 200mL of methanol 
were mixed. The gel was removed from the plates and mounted into the blot ‘sandwich’ (Black side, 
sponge, 2x filter paper, gel, nitrocellulose membrane, 2x filter paper, sponge, transparent side). 
The sandwich was fitted into the tank and kept cool with an ice block in the tank and surrounded 
by ice tray. Current was applied at 400mA and 300V for 1hr and 30 mins, respectively.  
The membranes with the transferred proteins were placed into blocking buffer (1g milk powder in 
20mL TBS 1X 0.1% Tween20) in a sealed dark chamber on an orbital shaker overnight at 4ºC. The 
membranes were then washed with TBS 1X 0.1% T20 and incubated with 5mL of the primary 
antibody (diluted in 5% BSA in TBS 1X with 0.1% T20) in a sealed dark chamber on an orbital shaker 
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overnight at 4ºC. On the control membrane, GAPDH antibodies where added and on the second gel 
antibodies for NM1 and NM6 was added.  
Table 2. 5 Li-Cor Antibody List: 
Used for the WB of NM1 (Myo1B) and NM6 (MyoVI) and their dilutions. 
Primary Ab 
Dilution Secondary Ab Dilution  
Rabbit anti-Myo Ib (Thermofisher) 1:1,000 Donkey anti-rabbit IRDye 800CW/680RD (Li-Cor, UK) 1:15,000 
Rabbit anti-Myo VI (Thermofisher) 1:1,000 Donkey anti-rabbit IRDye 800CW/680RD (Li-Cor, UK) 1:15,000 
Rabbit anti-GAPDH (Thermofisher) 1:2,000  Donkey anti-rabbit IRDye 800CW/680RD (Li-Cor, UK) 1:15,000 
 
The membranes were washed 3 X in TBS 1X 0.1% T20 (15 mins each) and incubated with 5mL of 
the secondary antibody (Li-Cor 800cw/680RD DkyxRb diluted 1:15,000 in 1% BSA in TBS 1X with 
0.1% T20) for 1hr at room temperature in a dark chamber. The membranes were washed 3 times 
for 5 mins with PBS, then visualized with the Li-Cor Odyssey Imaging System (Li-Cor, UK) at 
wavelengths 800 nm (green) and 700 nm (red). The images from the membranes were uploaded 
to ImageJ software (Version 1.53a) to calculate the band intensities.   




2.3.1 Spatial Chromosomal Organisation in OC: 
To characterise the disease-related spatial chromosome organisation in OC, four key chromosomes 
were chosen (based on the oncogenes and TSGs found mutated in OC) to be mapped using FISH 
and erosion analysis software: chromosome 1, chromosome 13, chromosome 17 and chromosome 
X. This was performed on four tumour cells (SKOV-3, PEO-1, PEO-4 and MDAH-2774) and compared 
to one control cell line (HOSEpi) (figure 2.3 and 2.4).  
  





HOSEpi SKOV-3 PEO-1 PEO-4 MDAH-2774 
1 
     
13 
     
17 
     
X 
     
Figure 2. 4 Chromosome Spatial Positioning:  
Images for the nuclear localisations of chromosomes 1, 13, 17 and X in OC cell lines SKOV-3, PEO-1, PEO-4 
and MDAH-2774 and the control cell line HOSEpi (non-cancer) delineated using 2D-FISH. Nuclear DNA is blue-
stained with DAPI, and whole chromosome signals were visualised via Cy3 and converted to green for software 
recognition. Magnification x400 / x1000. Scale bars represent 25µm. 
To quantify these changes, 50-100 images were analysed using an IPLab erosion software method 
as described in section 2.2.2.6 (Croft et al., 1999; Boyle et al., 2001; Clements et al., 2016) that 
creates a mask around the nuclear DAPI signal and then divides the nuclei into five concentric shells 
and then calculates the % of chromosome (green) signal in each shell. Shell 1 signifies the 
outermost periphery and shell 5 signifies the centre, as shown in figure 2.2. Cy3 dye was used, and 
the greyscale image for it converted to green for software detection. The output of the analysis was 
tabulated, plotted with ± error bars (standard error of the mean, SEM), and a 2-tailed student’s t-
test (unpaired, unequal variances) was performed on excel (table 2.6). Signal concentration in shells 
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1 and 2 represented a preferred peripheral occupancy of that chromosome, shell 3 an intermediate 
preference and shells 4 and 5 a central preference. A graphical panel comparing the control cell 
HOSEpi against the four tumour cells was constructed using the output graphs from MS excel (figure 
2.4).  





HOSEpi SKOV-3 PEO-1 PEO-4 MDAH-2774 
1 
     
 Intermediate Intermediate  Central Central Central 
13 
     
 Intermediate Central Intermediate Intermediate Central 
17 
     
 Periphery Central Intermediate Central Central 
X 
     
 Periphery Periphery Periphery Periphery Periphery 
Avg. p-value  0.278 0.224 0.133 0.170 
Figure 2. 5 Image Analysis: Chromosome Spatial Positioning:   
These histograms demonstrate the nuclear localisation of chromosomes 1, 13, 17 and X in OC cell lines SKOV-
3, PEO-1, PEO-4 and MDAH-2774 and the control cell line HOSEpi (non-cancer), visualised using 2D-FISH and 
positioned by erosion analysis software [section 2.2.5] (Croft et al., 1999, Boyle et al., 2001 and Clements et 
al., 2016). The bars and error bars signify means and standard error of the mean of 50-100 nuclei, respectively. 
Y-Axis represents % Cy3 whole chromosome probe signal / % DAPI nuclear signal, and the X-axis represents 
the nuclear periphery to the nuclear interior location (1 to 5). Student’s t-test of all cancer cells performed 
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 SKOV-3 PEO-1 PEO-4 MDAH-2774 
Chromosome 1 
Shell 1 0.887 0.133 0.065 0.098 
Shell 2 0.704 0.050 0.019 0.005 
Shell 3 0.972 0.360 0.047 0.083 
Shell 4 0.954 0.031 0.316 0.289 
Shell 5 0.691 0.091 0.005 0.038 
AVG ➔ 0.842 0.133 0.091 0.103 
Chromosome 13 
Shell 1 0.079 0.010 0.021 0.097 
Shell 2 0.002 0.132 0.409 0.022 
Shell 3 0.000 0.052 0.003 0.001 
Shell 4 0.608 0.101 0.081 0.917 
Shell 5 0.000 0.362 0.083 0.000 
AVG ➔ 0.138 0.132 0.119 0.207 
Chromosome 17 
Shell 1 0.048 0.166 0.178 0.531 
Shell 2 0.001 0.104 0.303 0.008 
Shell 3 0.004 0.250 0.371 0.339 
Shell 4 0.421 0.070 0.009 0.012 
Shell 5 0.001 0.941 0.732 0.447 
AVG ➔ 0.095 0.306 0.318 0.268 
Chromosome X 
Shell 1 0.149 0.105 0.000 0.035 
Shell 2 0.017 0.311 0.005 0.149 
Shell 3 0.012 0.060 0.002 0.006 
Shell 4 0.008 0.975 0.004 0.253 
Shell 5 0.000 0.178 0.000 0.062 
AVG ➔ 0.037 0.326 0.002 0.101 
Table 2. 6 p-values against HOSEpi: 
Shells that showed no significant differences with p0.5 are highlighted in red, the shells that showed statistical 
differences with p0.5 are unhighlighted, and the shells that showed statistical differences with p0.05 are 
highlighted in green. The average values listed below; the red value represents no significant differences 
[p0.5]; the black values are significantly different [p0.5] and the green values significantly different [p0.05]. 
15/16 tumour chromosomes were significantly different from the position of comparable 
chromosomes within the control cell line (p0.5) where chromosome 1 of tumour cell line SKOV-3 
showed a high p-value of 0.842. Chromosome X of all cell lines was preferentially located at the 
periphery, which complies with previous literature of the preferred occupancy (Belmont et al., 1986; 
Kurz et al., 1996; Boyle et al., 2001; Cremer and Cremer, 2001; Mehta et al., 2010; Deng et al., 
2015). 
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2.3.2 Nuclear Myosin Presence and Distribution in OC:  
To investigate the drivers behind this tumorigenic change in CT, the distribution network of nuclear 
motors was investigated through indirect-IF. This can elucidate dysfunctional roles as NM1 that 
have shown a motor role in chromosomal movement and is known to associate with proteins of the 
nucleoli and nucleoplasmic speckles, and NM6 has also been found elevated in OC cells that also 
associates with nucleoplasmic speckles and proteins therein (Percipalle et al., 2006; Vreugde et al., 
2006).  
A scoring system of specific patterns was devised of dispersed foci (nucleoplasmic speckles 
patterns), aggregate foci (nucleoli pattern), dispersed and aggregate foci and negative (Figure 2.4, 
2.5 and 2.6). The distribution score of the tumour cells was compared to that of the control cell line 












    
NM6 
    
Figure 2. 6 NM1 and NM6 Distribution Patterns Images:   
Representative images of the nuclear distribution pattern (dispersed foci, aggregate foci, dispersed and 
aggregate foci and negative) were captured in 4 OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774 and a 
control cell line (non-cancer). DNA was stained using DAPI (blue), and the NM1 protein was revealed by indirect 
IF with a Cy3 conjugated secondary antibody. Magnification x400 / x1000. Scale bars represent 25µm. 
  




Figure 2. 7 NM1 Distribution Patterns Score:  
Bar graph shows the score of 4 NM1 patterns (dispersed foci, aggregate foci, dispersed and aggregate foci and 
negative) in 4 OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774 and a control cell line (non-cancer). The 
bars and error bars for each cell line (X-axis) represents means of 3 replicate slides and SEM for a total of 200 
nuclei as a percentage (% / Y-axis). Student’s t-test of the cancer cells patterns was performed against the 
wild-type (healthy HOSEpi).  
* - denotes statistically different by one confidence interval (0.5) and ** - denotes statistically different by two confidence 













HOSEPI SKOV-3 PEO-1 PEO-4 MDAH-2774
dispersed foci 0 34 0 0 30
large aggregate foci 23 0 27 0 0
dispersed and large aggregate foci 47 64 67 89 69

















Figure 2. 8 NM6 Distribution Patterns Score:  
Bar graph shows the score of 4 NM6 patterns (dispersed foci, aggregate foci, dispersed and aggregate foci and 
negative) in 4 OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774 and a control cell line (non-cancer). The 
bars and error bars for each cell line (X-axis) represents means and SEM for a total of 200 nuclei as a 
percentage (% / Y-axis). Student’s t-test of the cancer cells patterns was performed against the wild-type 
(healthy HOSEpi).  
* - denotes statistically different by one confidence interval (0.5) and ** - denotes statistically different by two confidence 













HOSEPI SKOV-3 PEO-1 PEO-4 MDAH-2774
dispersed foci 56 60 0 0 86
large aggregate foci 29 31 0 95 0
dispersed and large aggregate foci 0 0 90 0 10
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NM1 is directly involved with complexes of RNA Pol I (nucleoli) and RNA Pol II (nucleoplasmic 
speckles) transcription, post-initiation steps and chromatin remodelling (Percipalle et al., 2006). 
Vreugde et al., 2006 found high levels of NM6 in the nucleus of OC cells with RNA Pol II complex 
association. Therefore, we expected to see predominantly aggregate and dispersed foci for NM1 and 
dispersed foci for NM6. NM1 aggregates and dispersed foci had the highest frequency in all the cell 
lines; however, NM6 dispersed foci was observed in all cell lines except PEO-4.  
Hudson, 2007 demonstrated that lamins A/C showed normal distribution using indirect IF; however, 
it was found over-expressed in OC tissues using protein microarrays. Therefore, it was imperative 
to quantify the protein levels of NM1 and NM6. NM1 and NM6 have recently been found in substantial 
amounts in the cytoplasm; thus for the WBs, nuclear extracts were made thus reflecting the nuclear 
protein content only (Venit et al., 2016; Vreugde et al., 2006) (figure 2.8 and 2.9). Corresponding 
cytoplasmic extracts for the nuclear extracts were also used so the nuclear proteins can be 
normalised against GAPDH as lamins have been found abnormally expressed in cancer cells, 
including ovarian, prostate and breast cancers, thus unreliable (as reviewed by Guinde et al., 2018).  
  




















Figure 2. 9 NM1 and NM6 Levels (Li-Cor Images):  
Cytoplasmic and Nuclear extracts of 4 OC cell lines SKOV-3 (lane 1), PEO-1 (lane 2), PEO-4 (lane 3) and MDAH-
2774 (lane 4) and a control cell line (lane 5) were quantified by WB on the Li-Cor Odyssey for NM1 and NM6 
using ImageJ software (Version 1.53a), the band intensities were calculated. The quantities were normalised 
against GAPDH levels (first band) in the corresponding cytoplasmic extracts. 
 
Figure 2. 10 NM1 and NM6 Band Intensities:  
The fluorescence Li-Cor image of the membrane was uploaded to ImageJ software (Version 1.53a) to calculate 
the band intensities. The bars represent protein signal intensity / corresponding GAPDH signal intensity = X-
axis. Above each cancer cell bar is the % increase; SKOV-3 (174%,114%), PEO-1 (286%,158%), PEO-4 





















HOSEpi SKOV-3 PEO-1 PEO-4 MDAH-2774
NM1 3.04 8.31 11.71 10.59 9.08
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The distribution pattern scores of all cancer cells were statistically different (p0.5) from the control 
cell except for NM6 patterns of SKOV-3. When the confidence interval was reduced to p0.05, PEO-
4 was found not significantly different despite the largely incoherent patterns to the control cell. On 
the other hand, the fast-growing MDAH-2774 showed the highest statistical difference (with the 
lower confidence p0.05) in both NM1 and NM6 distribution but exhibited low protein elevations when 
compared to the other cell lines.  
Despite the lack of 0.05 confidence statically significant differences in PEO-4 patterns, the protein 
levels revealed an interesting observation: while SKOV-3, PEO-1 and MDAH-2774 showed a higher 
increase in NM1, the slow-growing platinum-resistant cell line PEO-4 had higher levels of NM6 
instead, reflecting the levels by the ratio in that of the control cell.  
Aside from the NM6 level of MDAH-2774, both nuclear proteins showed an elevation of >100% for 
all cell lines, highlighting a probable role in the tumorigenic chromosomal arrangement of the cancer 
cells, by and large, the disease. If this is the case, it would be valuable to investigate the effects of 
reducing these proteins on the spatial chromosomal arrangement in OC cells (chapter 3).  
  




OC lethality lies heavily within its late diagnosis and chemoresistance. Signs and symptoms of the 
disease are not clear; therefore, the disease needs to be understood much more deeply and earlier. 
There are many known OC-associated TSGs and oncogenes, some with pathways yet to be 
understood, and by investigating the spatial organisation of some critical chromosomes associated 
with its disease progression broadens our understanding. This chapter investigated the spatial 
organisation of chromosomes 1, 13, 17 and X in 4 OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-
2774. The distribution and levels of NM1 and NM6 were also investigated due to their evident roles 
in cancer and genome organisation (Mehta et al., 2010; Große-Berkenbusch et al. 2020).   
2.2.5 Chromosomes  
To study the diagnostic value and functional change of whole chromosome spatial organisation in 
OC cells, using FISH probes, their nuclear distribution was mapped and assessed against a control 
cell. The cell lines had a total average p-value of 0.201, establishing a significant difference (with 
p0.5) between cancer and non-cancer spatial organisation in OC.  
2.4.1.1 Chromosome X as a Proximity Control  
In Mehta’s study, chromosome X showed no change in position regardless of the presence of serum 
or not (Mehta et al., 2010). Inactive chromosome X is known to occupy the nuclear periphery in 
female cells, and active chromosome X of both male and female fibroblasts also have a peripheral 
occupancy; however, its use as a control is challenged as the paternal X it has recently been linked 
to OC (Belmont et al., 1986; Boyle et al., 2001; Eng et al., 2018). Figure 2.4 showed the control 
cell line, chromosome X was appeared peripheral with a predominance in shell 2 followed by shell 
3, hinting towards an intermediate occupancy similar to tumour lines PEO-1 and MDAH-2774. In 
SKOV-3 and PEO-4, chromosome X showed a substantial peripheral occupancy (shell 1). In 
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mammals, chromosome organisation is not absolute as it represents the most probable ‘preferred’ 
location within a variable population as this increase with genes due to their higher dynamics (Croft 
et al., 1999; Boyle et al., 2001). While none of the cell lines showed chromosome X favouring 
interior localisation, the cancer cell lines showed stronger peripheral preferences than the control 
cell and, based on this and emerging studies; chromosome X remains disputed as an absolute 
control. 
2.4.1.2 Chromosome 1 (Key gene: ARID1A) 
There are two chromosome spatial positioning theories; size-based and gene-density-based, where 
size predominates in non-proliferating cells and gene-density in proliferating primary cells 
(Habermann et al., 2001; Federico et al., 2004; Mayer et al., 2005; Tanabe et al., 2005; Bridger et 
al., 2000; Cremer et al., 2001; Croft et al., 1999; Sun, Shen and Yokota, 2000; Boyle et al. 2001; 
Bolzer et al., 2005; Meaburn et al., 2007; Bridger et al., 2014). Chromosome positioning correlation 
to size was also observed in human dermal fibroblasts, where chromosome 1 was at the edge in 
non-proliferating state and moved to the intermediate location during proliferation (Mehta et al., 
2010). The control cell had the largest chromosome in the genome, chromosome 1, at an 
intermediate position with a skew to the periphery. Aside from SKOV-3 that showed no significant 
difference to chromosome 1 of the control cell, chromosome 1 of the other OC cell lines occupied 
the interior.  
2.4.1.3 Chromosome 13 (Key gene: BRCA2) 
A whole chromosome is not confined to its territory as it may stay at its silenced region but have 
an essential gene looped out to an active region (Volpi et al., 2000; Branco and Pombo, 2006). 
Mehta et al., 2010 showed while with serum, chromosome 13 occupied the periphery but part of its 
CT extended towards the interior, presumably linked to nucleoli via NADs. In this study, 
chromosome 13 of HOSEpi, PEO-1 and PEO-4 predominated the intermediate position; however, in 
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the fluorescent 2D FISH images CT extension is observed (Figure 2.3 and 2.11). This was also 
observed in part of the population of SKOV-3 and MDAH-2774, but much of the population shifted 
towards the interior, possibly placing the chromosome in an unwarranted active location, perhaps 
favourable to cancer progression (refer to figure 2.16).  
2.4.1.4 Chromosome 17 (Key genes: BRCA1, p53, HER2) 
Chromosome 17 was found at the nuclear periphery in the control line, an area which is often 
associated with gene repression and transcriptional inactivity; however, this does not render a 
chromosome or gene totally inactive nor remote (Andrulis et al., 1998; Brickner and Walter, 2004; 
Casolari et al., 2004; Cabal et al., 2006; Taddei et al., 2006). Chromosome 17 in all cell lines 
showed a shift away from the periphery possibly accompanied by higher transcriptional activity. 
Remarkably, for MDAH-2774, chromosome 17 showed bi-modal occupancy; however, the images 
showed this was due to part of the population having interior occupancy and part having peripheral 
occupancy.  
2.4.1.5 Cancer Cell Characterisation by Chromosome 
The spatial organisation of chromosome 1, 13, 17 and X of platinum-resistant PEO-4 has the highest 
significant difference against the control cell line, followed by the fast-growing MDAH-2774. Then 
compared against each other; PEO-4 and MDAH-2774 show no significant differences (table 2.7). 
Table 2.7 also displays stronger statistical relationships between MDAH-2774 and PEO-1/PEO-4 and 
weaker statistical relationships with SKOV-3. However, this weak statistical relationship amongst 
the cancer cells was balanced as SKOV-3 has the most robust statistical relationship with the control 
cell line (table 2.6).  
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Table 2. 7 Inter-cell comparisons among the OC lines: SKOV-3, PEO-1, PEO-4 And MDAH-2774 
Means of 50-100 nuclei. Red bold – denotes higher p-value than three others (including wild-type), Green 





SKOV-3 vs  
PEO-1 




PEO-1 vs  
PEO-4 




1 0.172 0.081 0.103 0.261 0.337 0.703 
13 0.021 0.066 0.437 0.403 0.029 0.178 
17 0.058 0.093 0.078 0.546 0.269 0.654 
Avg. p-value  0.084 0.080 0.206 0.403 0.212 0.511 
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2.4.6 Nuclear Lamins 
In primary lymphoblasts, chromosome 1 and 17 have been found in a central nuclear position, while 
chromosome 13 was enriched at the periphery (Boyle et al., 2001). Chromosome 17 was also found 
in the central position of healthy breast cells, MCF-10A (immortalised) and 3/4 breast cancer cells 
(Hassan-Ahmed, 2013). To investigate chromosomes’ 1 and 17 peripheral positionings in ovarian 
tissue that opposes internal positionings in non-ovarian tissue required a closer look, which revealed 
a stretching or extension into the interior accompanied by a peripheral localisation (possibly 
tethered to the NE) in chromosome 13 and 17 (figure 2.6).  
  
 
Chromosome 1 Chromosome 13 Chromosome 17 
 
   
Figure 2. 11 ‘Chromosome Stretching’ in HOSEpi:  
Images of nuclear localisations of chromosomes 1, 13 and 17 in control cell line HOSEpi delineated using 2D-
FISH.  No tethering or stretching patterns were seen in chromosome 1; they were either central or peripheral. 
Nuclear DNA is blue stained with DAPI, and whole chromosome signals were visualised via Cy3 and converted 
to green for software recognition. Magnification x1000 on Leica DM4000.  
‘Chromatin stretching’ occurs when a region is tethered peripherally through LADs (gene-poor and 
repressory) but also associates internally with Inter-LADs (gene-rich and transcriptionally active) 
(Pickersgill et al., 2006; van Steensel and Belmont, 2017). The cancer cells (SKOV-3, PEO-1, PEO-
4 and MDAH-2774) may have lacked this chromosome tethering and stretching mechanism most 
likely due to their aberrant lamin distributions highlighted in figure 2.11 and 2.12 causing them to 
occupy only internal positions. A review by Shevelyov and Ulianov, 2019 highlight studies in 
Drosophila and mammals where the loss of tethering resulted in chromatin occupying a more interior 
position further mentioning that NE attachment during interphase stretches the chromosomes. They 
further proposed that interactions within TADs and macromolecular crowding result in chromosome 
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contraction upon NL tethering loss (Shevelyov and Ulianov, 2019). Systemic chromosome stretching 
was recently described in Caenorhabditis elegans where the organisation of the A/B compartments 
relied on the tethering of lamins to stretch the chromosome and detachment resulted in 
chromosome compaction and A/B compartment intermingling (Sawh et al., 2020). 
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Figure 2. 12 B-type Lamin Distribution Patterns: 
Images of the nuclear distribution pattern of Lamin B1 (red Cy3) and Lamin B2 (green FitC) was captured in 4 
OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774. DNA was blue-stained using DAPI. Magnification x1000 
on Leica DM4000. 
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Figure 2. 13 A-type Lamin Distribution Patterns:   
Images of the nuclear distribution pattern of Lamin A (green FitC) and Lamin C (red Cy3) was captured in 4 
OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774. DNA was blue-stained using DAPI. Magnification x100 
on Leica DM4000.  






Figure 2. 14 Lamin A/C and B1 levels:  
In control cell line (HOSE) and OC cell lines OVCAR5 and A2780 by Capo-Chichi et al., 2011. A. Northern blot 
of lamin A/C, B1 and emerin in healthy and cancer cell lines showing a general increase of lamin B1 and emerin 
mRNA while there was a variation in lamin A/C mRNA B. WB of Lamin A/C in 6 OC cell lines showing a general 
decrease in lamin A/C. C. IF of Lamin A/C (red) and DAPI (blue) in control cell line HOSE and OC cell line 









Figure 2. 15 Lamin Distribution in Breast Cancer:  
In healthy breast cell lines (MCF-10A) and breast cancer cell lines T-47D, GI-101 BT-474 and Sk-Br-3 by 
Hassan-Ahmed, 2013. Indirect IF of lamin A, B1, B2, A/C, and C (green) and DNA/DAPI (blue) in healthy and 
cancer cell lines. 
 
Capo-Chichi et al., 2011 revealed discrepancies in lamin expression and quantity where lamin B1 
was higher in the cancer cells (OVCAR5 and A2780), and lamin A/C showed a reduction when 
compared to the control cell (HOSE) (figure 2.14). Lamin B1 in the 4 OC cells has strong rim stains 
consistent with the over-expression. 
Using epithelial breast cell MCF-10A lamins stains from Hassan-Ahmed, 2013 to depict healthy 
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distribution (figure 2.15), lamin B2, appeared highly compromised in the OC cells, deficient in SKOV-
3 and PEO-1, and as solid aberrated stains inside the nucleus in MDAH-2774 (figure 2.12). Lamin 
B2 depletion can lead to chromosomal instability and aneuploidies in colorectal cancer cells while its 
knockdown showed specific transcriptionally deregulated chromosomes and repositioning of a 
candidate gene (ZNF570) away from the NL that resulted in increased gene expression (RNA-FISH 
and qRT-PCR) (Kuga et al., 2014; Ranade et al., 2017). Lamin A and C show strong rim-stains in 
the healthy distribution, however in MDAH-2774, there were irregularities in lamin A, and with all 
the cell lines, lamin C showed rim-deficiency with internal foci.  
Swift et al. 2013 mentioned the ratio of A-type and B-type lamins determining the mechanical 
properties of nuclei where the relative stoichiometry of A/B-type lamins is cell-type specific in most 
cases. In addition to the breakdown of “chromosome stretching”, the disruption of healthy ratio 
may have also led to downstream effects with associated proteins in addition to those within the 
hypothetical nuclear motor complex resulting in compensatory elevation levels of emerin found by 
Capo-Chichi et al., 2011 and then possibly the increase of NM1 and NM6 observed here and by 
others (Ranade et al., 2019). 
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2.4.7 Nuclear Myosins 
To study the diagnostic value and functional change of NM1 and NM6 in OC cells and set the basis 
for subsequent manipulation of whole chromosome spatial organisation, using Indirect IF and WB 
the nuclear distribution and levels were determined and assessed against control ovarian cells.  
Each cell line except PEO-4 showed a significant difference (p0.05) to at least one protein; however, 
with the appearance of a different distribution in PEO-4 when significant difference considered at 
p0.5 confidence level, PEO-4 was significantly different (table 2.8). After the warranted protein 
quantification, PEO-4 had significant NM1 and NM6 elevations, but unlike the other cell lines, it was 
proportional to the control cell line, i.e., more NM6 than NM1 (table 2.9). This observation is 
particularly interesting as it is a slow-growing platinum-resistant cell line. Chemoresistant tissues 
are known to morphologically adapt to resemble the control cell allowing them to evade therapy 
(Rosa et al., 2014; Bell & Gilan, 2020). 
Table 2. 8 Control Cell vs Cancer Cell:  
Cell Lines SKOV-3, PEO-1, PEO-4 and MDAH-2774 Compared Against the Control HOSEpi (IF): NM1 and NM6 
distribution patterns for 200 nuclei. The red value represents no significant differences (p0.5); the black 
values are significantly different (p0.5), and the green values significantly different (p0.05).  
 
MDAH-2774, on the other hand, showed highest statistical differences in both protein distributions 
despite having relatively lower NM1 and NM6 elevations. This event increases the equal importance 
of protein distribution when investigating fast replicating cancer cell lines. Quite often, the levels of 
the protein take precedence, and its localisations are over-looked.  
 
Cell Line   SKOV-3   PEO-1 PEO-4 MDAH-2774 AVG Protein p-value 
NMI 0.005 0.424 0.336 0.026 0.198 
NM6 0.511 0.009 0.335 0.010 0.216 
AVG Cell Line p-value 0.258 0.217 0.336 0.018 - 
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Table 2. 9 NM1 and NM6 % Elevation: 
Cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774 compared against HOSEpi: [Extracted from figure 2.9]. 
 
 
These results not only indicate that NM distribution and levels are contributory factors to cancer but 
also their stoichiometry. This is supported by possibly shared roles of NM1 and NM6 with RNA Pol 
II (as they have been anticipated to not work together in different complementary capacities but 
rather in two separate pools of RNA Pol II) (figure 1.22) and compensatory isoforms of NM1 even 
within cytoplasmic and nuclear NM1 (Venit et al., 2013; Cook, Gough and Toseland, 2020). 
Toseland’s lab even proposed a compensation mechanism between NM1 and NM6 in the 
perturbation of either protein as NM6-associated RNA Pol II clusters were still present after NM6 
was perturbed (Fili et al., 2019; Hari-Gupta et al., 2020; Große-Berkenbusch et al. 2020). 
Additionally, NM1 was found higher in the faster-growing OC cell lines while nuclear NM6 was higher 
in the slower-growing and platinum-resistant cell line which perhaps may be hinting towards an 
NM1/NM6 stoichiometry related growth rate and chemoresistance (see doubling times in table 2.1). 
Taken together, protein stoichiometry and compensation may explain the cases of SKOV-3 and PEO-
1 (figure 2.6 and 2.7), as one protein is abnormally distributed (NM1 in SKOV-3 and NM6 in PEO-
1), the other is relatively distributed normally (NM6 in SKOV-3 and NM1 in PEO-1), probably in a 
compensatory capacity.   
  
Cell Line   
SKOV-3   PEO-1 PEO-4 MDAH-2774 AVG % 
NMI 174 286 249 199 227 
NM6 114 158 264 57 148 
AVG 144 222 257 128 - 
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2.4.7.1 A Failed Compensation/Feedback Mechanism: a TSG Solution Becomes an 
Oncogene Problem  
Overall, in healthy ovarian cells, chromosomes 1, 17 and X predominate at the nuclear periphery 
and chromosome 13 at the intermediate location while the tumour cell lines showed relocalisations 
toward the interior (active) for all chromosomes. Table 2.1 shows all these cell lines have varied 
TSG mutations (p53, BRCA1/2 and ARID1A), which are usually active in cancer cells. However, 
mutated TSGs producing incorrect proteins, is as if it had not been produced (or 50% product in 
monoallelic mutations). Aiding this is maybe dysregulated lamin repressory tethering and possible 
hypermotility by elevated NM levels. They are altogether pulling or releasing the entire chromosome 
also accompanied by its oncogenes into the active site, which may have been the case for SKOV-3 
chromosome 17 that contains TSG mutations and experience oncogene HER2 amplification. 
  
Figure 2. 16 Hypothetical Schematic: Failed Compensation/Feedback Mechanism:  
Heavy green represents predominant CT occupancy; light green represents temporary CT upon p53 
transcriptional activation that will return to its repressed territory and grey entity represents CT void of the 
previous chromosome which will now house another chromosome in its place.  
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2.4.8 Conclusion  
This research offers another layer of information when understanding the progression of OC through 
the analysis of well-studied nuclear proteins. Not only has this lead to a deeper understanding of 
OC, but it has potentially also introduced chromosome spatial positioning as a biomarker panel with 
diagnostic and prognostic implications, such as has been done for breast cancer - see Meaburn et 
al., 2009 and 2016. Cancer cells are highly proliferative, which may explain why their levels of NMs 
(1 and 6) were higher and distribution altered compared to healthy cells, possibly causing 
unstimulated or hyperactive chromosomal spatial re-organisations. However, aberrations in nuclear 
lamin presence and distribution also highlight a lack of control, possibly causing disrupted tethering 
to repressive sites. There is currently no way of predicting what repositioning occurs, but from this 
study, NMs in addition to lamins highlight a more significant role of the hypothetical nuclear motor 
complex and superfamily stoichiometry.  
The OC cell lines showed higher similarities amongst each other and different when compared to 
the control line, not only concluding that spatial organisation is altered non-randomly in OC, but 
subtypes may share drivers to this disorganisation that can be clinically relevant in diagnostics, 
targeted therapy, prognostics and predicting resistance. In the clinics, chemoresistant cancers are 
treated with therapies for sensitive cancers; however, different cancers require different treatments. 
This study contributes towards tailoring therapies, for fast-growing cancers by reducing NM1 while 
reducing NM6 in chemoresistant cancer may be more useful.  
The study of genomic spatial positioning in OC is at its beginning, and even though a fraction of the 
genome was investigated, we have started to see patterns emerge to drive a plethora of 
investigations encompassing more cell/tissues types, chromosomes, and genes. The work by Mehta 
and Bridger, 2010 showed that concomitant with NM1 restoration post-inhibition or knockdown, 
chromosomes were repositioned back to a proliferative distribution. Moreover, while NM6 has not 
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been linked directly to spatial organisation, it exhibits anchorage properties as a response to force 
and is proposed to share compensatory roles with NM1 through their RNA Pol II associations (Fili et 
al., 2020 and Hari-Gupta et al., 2020). The next chapter, however, investigates further into the role 





CHAPTER 3  
RESTORING CHROMOSOME SPATIAL 
POSITIONING IN OC CELLS VIA RNAI OF 
NUCLEAR MYOSINS 1 AND 6 
3.1 INTRODUCTION 
Chromosomes and genes organise and reorganise depending on the requirements of the cell, by 
employing the nuclear motor complex to move towards the transcriptionally active interior upon 
activation or towards the periphery where it is transcriptionally less active (Brown et al., 1997; 
Shaklai et al., 2007; Szczerbal, Foster and Bridger, 2009; Van de Vosse et al., 2011). Myosins motor 
ability in transporting biomolecules is well known in the cytoplasm; NM1 functions in concert with 
RNA Pol I and II and influences spatial genome organisation, while NM6 have so far been associated 
with RNA Pol II complexes and its role in spatial genome organisation is just emerging (Vreugde et 
al., 2006; Mehta et al., 2010; Venit et al., 2016; Fili et al., 2019; Cook, Gough and Toseland, 2020). 
These associations can influence their distribution and functions, however when their levels are 
perturbed it gets relayed to their distribution and function that alters to suit the perturbation 
(Vreugde et al., 2006; Mehta et al., 2010; Venit et al., 2016; Fili et al., 2019). These and other NM 
isoforms myosins (NM2, NM5, NM9 and NM10) have been implicated via over-expression in many 
cancers (breast, colorectal, prostate and ovarian) in areas of cell migration and invasion (Ouderkirk 
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and Krendel, 2014).  
3.1.1 RNA interference (RNAi) of NM1 and NM6 in Cancer 
RNAi is an indispensable tool in cancer genomics which is being used to identify treatment targets. 
The method transiently suppresses the expression of proteins by introducing constructs of the target 
RNA into the cell, that then recruits the RNA induced silencing complex (RISC), and together these 
two entities cleave the mRNA of the target (in this case NM1 and NM6), thus suppressing the protein 
expression without affecting the DNA (Iorns et al., 2007). This is especially important when the 
protein to be suppressed is essential under normal circumstances (Iorns et al., 2007).  
Ranade et al., 2019 found that lamin A/C and emerin co-knockdown in colorectal cancer cells 
increased cytoplasmic actin while decreasing nuclear actin which may have potentially affected NM1 
activity to enhance chromobility. They further reinforced the intricate crosstalk within the 
hypothetical nuclear motor complex through NM1 inhibition and actin depolymerisation (in addition 
to the lamin A/C and emerin co-knockdown) which led to a restoration of the enhanced chromobility 
(caused by lamin A/C and emerin depletion). Interestingly the knockdown of lamin A/C or emerin 
individually was not enough to alter spatial territory of chromosome 19 (interior) and chromosome 
18 (peripheral), however, a co-knockdown repositioned chromosome 19 away from the nuclear 
interior while chromosome 18 remained unaltered (Ranade et al., 2017/2019). This raises the 
question when knocking down myosin, would an individual knockdown be sufficient in cancer? Or 
require an associate protein for co-knockdown? Chapter 1 and 2 also cited the vital role RNAi played 
in an individual knockdown of NM1 that was sufficient to investigate the link between NM1 role in 
rapid chromosome spatial organisation (in young proliferating HDF) by Mehta et al., 2010.  
The elevation of NM has also been studied for its tumorigenic value in many cancers through RNAi. 
siRNA knockdown of NM1 reduced the migratory and invasive potential of prostate cancer cells (PC-
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3) and for NM6 led to a 3-fold reduction in NM6 activity in breast cancer cells (MCF-7) (Maly et al., 
2017; Fili et al., 2017). NM6 showed cancer-specific expression in prostate cancer cells (LNCaP), 
and upon siRNA knockdown, cells had significantly reduced migration potential (Dunn et al., 2006). 
Wang et al., 2015 even performed a lentivirus-mediated RNA interference knockdown of NM6 in 
breast cancer cells (ZR-75-30 and MDA-MB-231) and found reduced viability and proliferation, in 
addition to cell cycle suppression. 
A role for NM6 in chromosome behaviour and dynamics has not been studied by RNAi; it has been 
studied for its role in whole chromosome movement by Zorca et al., 2015 who found that 
chromosome 17 was not able to move when transcription was stimulated in NM6 deficient T-helper 
cells. Zorca et al., 2015 concluded a possible dual role for NM6 in genome organisation upon gene 
activation and transition modulator for RNA Pol II from pause to elongation for a rapid transcriptional 
response. The constant cell activation cycles of cancerous cells may be the reason NMs are elevated; 
however, while it may be favourable for some chromosomes, it may be causing unstimulated re-
locations of other chromosomes. 
  




In retrospect, while related research into the deadliest of gynaecological cancers is deficient, some 
have focused on knocking down NM1 and NM6 to learn about its mechanism regarding migratory 
and proliferation potential of cancers (Dunn et al., 2006; Ouderkirk and Krendek, 2014; Maly et al., 
2017;). Chapter 2 showed discrepancies in NM1 and NM6 levels and distribution, which may be 
linked to their function in the altered spatial genome organisation in OC cells. The identification of 
chromosomes that improve their spatial positions with a protein knockdown is valuable for finding 
new drug targets. However, not one size fits all; therefore, this chapter aims to target the 
hypothetical nuclear complex through its NMs end and assess the restorative value that temporarily 
reducing the level of NM1 and NM6 through siRNA may have on spatial chromosome organisation 
(of chromosome 1, 13, 17 and X) in OC cells (SKOV-3, PEO-4, MDH-2774, PEO-1).   




3.2.1 RNA interference 
3.2.1.1 Making the siRNA Transfection media (1mL):  
100µL of 15nM siRNA solution (0.75µL of 20uM siRNA* stock, 4.25µL siRNA Buffer 1X and 95µL 
serum-free media) and 100µL of transfection reagent (3µL of dharmaFECT1 (Dharmacon) and 97µL 
serum-free media) was made. They were both incubated at room temperature for 5 mins separately 
and then for another 20 mins combined (200µL). 800µL of supplemented complete media was added 
to the 200µL to make 1mL.   
*Control (ON-TARGETplus Non-targeting Control Pool) (Dharmacon) 
*NM1 (ON-TARGETplus Human MYO1b siRNA – SMARTpool) (Dharmacon) 
*NM6 (ON-TARGETplus Human MYO6 siRNA – SMARTpool) (Dharmacon) 
3.2.1.2 Transfection  
The freshly trypsinised cells were re-suspended in the transfection medium (scaled accordingly) and 
plated. After 48 hours, the media was replaced with freshly made siRNA transfection medium. This 
was performed on all cell lines (SKOV-3, PEO-1, PEO-4 and MDAH-2774) in 24-well plates three 
times and then scaled up (x5 for T25 and x3 for 6-well plates) to collect material for WB (T25), 
FISH (T25) and IF (coverslips in 6-well plates) after 96 hrs.  
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3.2.2 Cell Culture – refer to section 2.2.1 
Plating densities were 7.5x103, 2.5x105 and 5.0x105 for 96-well, 6-well and T25 respectively. 96-
well plates were used initially for trials and optimization, 6-well dishes were used to grows cells on 
glass coverslips for IF and T25 to scale up for WBs and 2D-FISH.  
3.2.3 FISH – refer to section 2.2.2  
Post knockdown cells were left in the hypotonic solution were left for 15-20 mins instead of 10 mins 
as the cytoplasm became challenging to remove. This was discovered by Venit et al., 2016 in NM1 
knockdown cells showed 50% more elasticity with 25% higher resistance to swelling.   
3.2.4 Indirect IF – refer to section 2.2.3 
3.2.5 WB – refer to section 2.2.4  




3.3.1 Knockdown of NM1 and NM6 in 4 OC Cell Lines: 
Chromosomes 1, 13 and 17 displayed significant differences in their spatial organisation in the OC 
cells to that of the control cell line and in addition, also have a significant increase in the protein 
levels of NM1 and NM6. To investigate whether there is any relationship between the spatial 
occupancy of interphase chromosomes and NM1 and NM6 levels in OC, the proteins were individually 
reduced by RNAi in the cancer cells then nuclear positions for chromosomes 1, 13 and 17 nuclear 
positions were examined post-knockdown. The siRNA constructs were obtained from Dharmacon 
who also outlined a protocol involving plating the cells and replacing the media after 24 hrs with 
the transfection media. This method was not allowing a sufficient knockdown without affecting the 
control, as it required high concentrations of the siRNA reagents (50-100nM). To improve the 
efficiency, the ‘reverse transfection method’ outlined by ThermoFisher was used that involved 
plating the cells at 0 hrs with the transfection media (15nM siRNA) and replacing the media with 
freshly made transfection media (15nM siRNA) after 48 hrs. This economised and reduced the 




































Figure 3. 1 NM1 and NM6 Levels Pre- and Post-knockdown of NM1 and NM6 in Cell Lines SKOV-3, 
PEO-1 and MDAH-2774:  
Cytoplasmic and Nuclear extracts of 3 OC cell lines SKOV-3 (lane 1,2 and 3), PEO-1 (lane 4, 5 and 6) and 
MDAH-2774 (lane 7, 8 and 9) post siRNA of NM1 and NM6 were analysed by WB on the Li-Cor Odyssey for 
band intensity quantification via the ImageJ software (Version 1.53a). The quantities were normalised against 
the loading control GAPDH (top band) in their corresponding cytoplasmic extracts (n=1). 
 
The band intensities were calculated using the ImageJ application and normalised against their 
control to estimate their knockdown level. The aim was a 50% knockdown to combat the elevation 










Figure 3. 2 NM1 Band Intensities:  
Showing the reduction of NM1 following siRNA knockdown of NM1 (ON-TARGETplus Human MYO1b siRNA – 
SMARTpool) in cell lines SKOV-3, PEO-1 and MDAH-2774 quantified by band intensities (NM1 / GAPDH) 
calculated using the ImageJ software (Version 1.53a) and normalised with the loading control GAPDH. SKOV-
3, PEO-1 and MDAH-2774 were reduced to 38%, 43% and 26% of the original NM1 amount respectively that 
was estimated against the control (ON-TARGETplus Non-targeting Control Pool).  
 
 
Figure 3. 3 NM6 Band Intensities:  
Showing the reduction of NM1 following siRNA knockdown of NM6 (ON-TARGETplus Human MYO6 siRNA – 
SMARTpool) in cell lines SKOV-3, PEO-1 and MDAH-2774 quantified by band intensities (NM6 / GAPDH) 
calculated using the ImageJ software (Version 1.53a) and normalised with the loading control GAPDH. SKOV-
3, PEO-1 and MDAH-2774 were reduced to 33%, 35% and 27% of the original NM6 amount respectively that 
was estimated against the control (ON-TARGETplus Non-targeting Control Pool).  
 
The knockdown effect was also evident by microscopy, which afforded the scoring of the positively 
and negatively stained nuclei, thus providing a subjective estimation for the knockdown. This was 
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2). The protein levels of the IF proportionally reflected the protein levels of the other cell lines on 
the WB; therefore, the FISH of PEO-4 cell line has been assumed to have had a knockdown efficiency 
of 47% and 32% in NM1 and NM6 respectively.  
 
 
NM1    NM6 
 
 
   
 
Figure 3. 4 NM1 and NM6 Positively and Negatively Stained Nuclei:   
Representative images of the positively and negatively stained nucleus in OC cells to score the level of 
knockdown in the 4 OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774. DNA was stained using DAPI (blue), 
and the NM1 and NM6 protein were revealed by Indirect IF with a Cy3 conjugated secondary antibody. The 
arrows point to negative nuclei—magnification x400. Scale bars represent 25µm. 
 
  




Figure 3. 5 NM1 Levels Pre- and Post-Knockdown of NM1 in Cell Lines SKOV-3, PEO-1, PEO-4 and 
MDAH-2774 as Estimated by Indirect-IF:  
The bars and error bars for each cell line (X-axis) represents means and standard error of the mean for a total 
of 200 nuclei as a percentage (% / Y-axis) of positive and negative stained cells before and after NM1 
knockdown NM1 (ON-TARGETplus Human MYO1b siRNA – SMARTpool). SKOV-3, PEO-1, PEO-4 and MDAH-
2774 were reduced to 43%, 52%, 53% and 30% of the original NM1 amount respectively that was normalised 
against the control (ON-TARGETplus Non-targeting Control Pool) (n=2). 
 
 
Figure 3. 6 NM1 Levels Pre and Post Knockdown of NM1 in Cell Lines SKOV-3, PEO-1, PEO-4 and 
MDAH-2774 as Estimated by Indirect-IF:  
The bars and error bars for each cell line (X-axis) represents means and standard error of the mean for a total 
of 200 nuclei as a percentage (% / Y-axis) of positive and negative stained cells before and after NM6 
knockdown NM6 (ON-TARGETplus Human MYO6 siRNA – SMARTpool). SKOV-3, PEO-1, PEO-4 and MDAH-2774 
were reduced to 54%, 55%, 68% and 29% of the original NM6 amount respectively that was normalised 
against the control (ON-TARGETplus Non-targeting Control Pool) (n=2). 
 
Once satisfactory knockdown was obtained by assessing both the WB and immunofluorescence, the 
spatial positioning of chromosomes 1, 13, 17 were analysed as outlined in chapter 2 with re-
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3.3.2 Spatial Chromosome Organisation Post-NM1 and -NM6 Knockdown: 
  
NM1 -knockdown  
Chromosome SKOV-3 PEO-1 PEO-4 MDAH-2774 
1 
    
13 
    
17 
    
X 
    
Figure 3. 7 Post-NM1 Knockdown Chromosome Spatial Positioning Images:  
Fluorescence images for the nuclear localisations of chromosomes 1, 13, 17 and X in OC cell lines SKOV-3, 
PEO-1, PEO-4 and MDAH-2774 positioned using 2D-FISH post NM1 knockdown. Nuclear genetic material 
stained blue with DAPI and whole chromosome signals were stained red with Cy3 and converted to green for 
software recognition. Magnification x400 / x1000. Scale bars represent 25µm. 
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Figure 3. 8 Post-NM6 Knockdown Chromosome Spatial Positioning Images:  
Fluorescence images for the nuclear localisations of chromosomes 1, 13, 17 and X in OC cell lines SKOV-3, 
PEO-1, PEO-4 and MDAH-2774 positioned using 2D-FISH post NM6 knockdown. Nuclear genetic material 
stained blue with DAPI and whole chromosome signals were stained red with Cy3 and converted to green for 
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Figure 3. 9 Graphical Representation: Image Analysis Chromosome Spatial Positioning Post-NM1 
Knockdown:  
Histograms show the nuclear localisations of chromosomes 1, 13, 17 and X in OC cell lines SKOV-3, PEO-1, 
PEO-4 and MDAH-2774  before (light blue) and after (dark green) siRNA knockdown of NM1, positioned using 
2D-FISH and analysed by erosion analysis software [section 2.2.2]. The bars and error bars signify means and 
standard error of the mean of 50-100 nuclei, respectively. Y-Axis represents % Cy3 whole chromosome probe 
signal / % DAPI nuclear signal, and the X-axis represents periphery to the central position (1 to 5). Student’s 
t-test of all cancer cells performed against their origin cell and to the wild-type (healthy HOSEpi) [p0.5 
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Figure 3. 10 Graphical Representation: Image Analysis Chromosome Spatial Positioning Post-NM6 
Knockdown:  
Histograms show the nuclear localisations of chromosomes 1, 13, 17 and X in OC cell lines SKOV-3, PEO-1, 
PEO-4 and MDAH-2774  before (light blue) and after (dark green) siRNA knockdown of NM6, positioned using 
2D-FISH and analysed by erosion analysis software [section 2.2.2]. The bars and error bars signify means and 
standard error of the mean of 50-100 nuclei, respectively. Y-Axis represents % Cy3 whole chromosome probe 
signal / % DAPI nuclear signal, and the X-axis represents periphery to the central position (1 to 5). Student’s 
t-test of all cancer cells performed against their origin cell and to the wild-type (healthy HOSEpi) [p0.5 
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Each shell of each OC cell line was statistically compared to the corresponding shell of the control 
cell and then categorised by no significant difference (p0.5), a significant difference (p0.5) and a 
significant difference (p0.05) (table 3.1).  
 
Table 3. 1 p-values Post-NM1 and NM6 Knockdown Against HOSEpi:  
Each shell was calculated in MS Excel and the below. Shells that showed no significant differences with p0.5 
are highlighted in red, the shells that showed statistical differences with p0.5 are unhighlighted, and the shells 
that showed statistical differences with p0.05 are highlighted in green. The average values listed below; the 
red value represents no significant differences [p0.5]; the black values are significantly different [p0.5] and 
the green values significantly different [p0.05]. 
NM1 KNOCKDOWN 
 SKOV-3 PEO-1 PEO-4 MDAH-2774 
Chromosome 1 
Shell 1 0.626 0.754 0.214 0.789 
Shell 2 0.922 0.103 0.603 0.621 
Shell 3 0.486 0.890 0.198 0.854 
Shell 4 0.417 0.064 0.000 0.351 
Shell 5 0.630 0.790 0.978 0.633 
AVG ➔ 0.616 0.520 0.399 0.650 
Chromosome 13 
Shell 1 0.336 0.022 0.012 0.210 
Shell 2 0.329 0.106 0.142 0.242 
Shell 3 0.107 0.018 0.000 0.119 
Shell 4 0.021 0.761 0.000 0.015 
Shell 5 0.004 0.299 0.000 0.595 
AVG ➔ 0.160 0.241 0.031 0.236 
Chromosome 17 
Shell 1 0.047 0.287 0.669 0.968 
Shell 2 0.012 0.331 0.838 0.210 
Shell 3 0.376 0.325 0.600 0.000 
Shell 4 0.089 0.261 0.108 0.195 
Shell 5 0.048 0.811 0.106 0.007 
AVG ➔ 0.114 0.403 0.464 0.276 
Chromosome X 
Shell 1 0.361 0.095 0.415 0.052 
Shell 2 0.392 0.000 0.001 0.016 
Shell 3 0.091 0.047 0.008 0.002 
Shell 4 0.900 0.106 0.004 0.059 
Shell 5 0.500 0.022 0.009 0.415 
AVG ➔ 0.449 0.054 0.087 0.109 
 
NM6 KNOCKDOWN 
 SKOV-3 PEO-1 PEO-4 MDAH-2774 
Chromosome 1 
Shell 1 0.142 0.482 0.162 0.771 
Shell 2 0.285 0.785 0.028 0.980 
Shell 3 0.924 0.044 0.660 0.122 
Shell 4 0.000 0.495 0.285 0.174 
Shell 5 0.602 0.014 0.005 0.187 
AVG ➔ 0.391 0.364 0.228 0.447 
Chromosome 13 
Shell 1 0.200 0.040 0.146 0.125 
Shell 2 0.001 0.269 0.901 0.436 
Shell 3 0.000 0.000 0.013 0.003 
Shell 4 0.015 0.199 0.952 0.490 
Shell 5 0.000 0.720 0.336 0.422 
AVG ➔ 0.043 0.245 0.470 0.295 
Chromosome 17 
Shell 1 0.049 0.778 0.074 0.047 
Shell 2 0.001 0.266 0.001 0.001 
Shell 3 0.203 0.755 0.383 0.000 
Shell 4 0.112 0.481 0.033 0.562 
Shell 5 0.002 0.660 0.059 0.003 
AVG ➔ 0.073 0.588 0.110 0.122 
Chromosome X 
Shell 1 0.752 0.088 0.888 0.873 
Shell 2 0.035 0.004 0.108 0.003 
Shell 3 0.210 0.387 0.973 0.011 
Shell 4 0.140 0.044 0.067 0.011 
Shell 5 0.120 0.339 0.031 0.003 
AVG ➔ 0.251 0.172 0.413 0.180 
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These data were summarised and compared to their pre-knockdown state on a heat-map (figure 
3.4) and a statistical table with entire nuclear averages (table 3.2).  
 
Figure 3. 11 Heat-Map of Post-Knockdowns Effect Using p-values Against HOSEpi:  
Blocks highlighted in red are shells that showed no significant differences (p0.5), highlighted in green are shells 
that showed statistical differences with p0.05), and the yellow shells showed statistical differences (p0.5). The 
higher similarity to the control cells is reflected by more red blocks and the lowest similarities reflected by 
more green blocks. 
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Table 3. 2 Summary of p-values Post-Knockdown Cancer Cells vs Control Cell:  
After the siRNA knockdown of NM1 and NM6 for cell lines SKOV-3, PEO-1, PEO-4, and MDAH-2774 their 
chromosome positions analysed for improvements statistically. Red bold – denotes higher p-value than pre-
knockdown implicative of CTs re-positioning in locations closer to those adopted by the control cell. Means of 
50-100 nuclei. 
Chromosome  
Cell Line  Pre-Knockdown  NM1 knockdown NM6 knockdown 
1 SKOV-3  0.842 0.616 0.391 
 
PEO-1 0.133 0.520 0.364 
 
PEO-4 0.091 0.399 0.228 
 
MDAH-2774  0.103 0.650 0.447 
13 SKOV-3  0.138 0.160 0.043 
 
PEO-1 0.132 0.241 0.245 
 
PEO-4 0.119 0.031 0.470 
 
MDAH-2774  0.207 0.236 0.295 
17 SKOV-3  0.095 0.114 0.073 
 
PEO-1* 0.306 0.403 0.588 
 
PEO-4 0.318 0.464 0.110 
 
MDAH-2774  0.268 0.276 0.122 
X SKOV-3  0.037 0.449 0.251 
 
PEO-1* 0.326 0.037 0.172 
 
PEO-4 0.002 0.087 0.413 
 
MDAH-2774  0.101 0.109 0.180 
Post-knockdown showed 13/16 chromosome positions of NM1 knockdown and 10/16 chromosome 
positions NM6 had CTs re-positioning in locations closer to that adopted by the control cell when 
compared to the pre-knockdown position (table 3.2). Chromosome 17 of the NM6 knockdowns 
showed the least restored shifts overall (1/4) and chromosome 1 of SKOV-3 stood no chance of 
restoration as its pre-knockdown state was already close to ideal with no significant difference to 
the control cell line. However, the heat map showed that each shell had an overall improvement 
(increase in red), more so in NM1 knockdown (figure 3.4). This led to questioning the extent of re-
location causing these improvements. Table 3.3 shows a summary of p-value averages from the 
chromosome position of the same cell line after the knockdown against its own position pre-
knockdown or ‘knockdown gap’.  
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Table 3. 3 Knockdown Gap: Magnitude of Change from Original Territory to Post Knockdown in OC 
cells 
After the siRNA knockdown of NM1 and NM6 for cell lines SKOV-3, PEO-1, PEO-4, and MDAH-2774, their new 
chromosome positions were compared to the previous positions statistically [p0.5]. The higher the p-value, 
the smaller the ‘knockdown gap’ and vice versa. P>0.250 was considered a small gap, and p<0.250 was 
considered a large gap—means of 50-100 nuclei. 
*- small gap with positive change   **- large gap with positive change 
***- small gap with negative change   ****- large gap with negative change 
Chromosome 




1 SKOV-3  0.676*** 0.368*** 
 
PEO-1 0.496* 0.152** 
 
PEO-4 0.348* 0.127** 
 
MDAH-2774  0.265* 0.408* 
13 SKOV-3  0.271* 0.116**** 
 
PEO-1 0.334* 0.489* 
 
PEO-4 0.129**** 0.734* 
 
MDAH-2774  0.060** 0.294* 
17 SKOV-3  0.240** 0.600*** 
 
PEO-1* 0.748* 0.528* 
 
PEO-4 0.422* 0.484*** 
 
MDAH-2774  0.190** 0.149**** 
X SKOV-3  0.601* 0.099** 
 
PEO-1 0.038**** 0.108**** 
 
PEO-4 0.131** 0.225** 
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Figure 3. 12 Knockdown Gap Influence:  
The knockdown gap (small or large) influence on the outcome of CTs re-positioning in locations closer to that 
adopted by the control cell, i.e., positive or negative. A. the overall influence of small and large gaps on positive 
and negative outcomes that were then B. categorised into NM and further C. divided into NM and chromosomes. 
D. categorised the influence according to overall chromosomes and E. showed the influence in individual 
chromosomes.  
 
Overall, more positive relocalisations came from smaller gaps compared to larger gaps (figure 
3.11A) which was also the same between NM1 and NM6 (figure 3.11B/C). The same trend was also 
observed was also observe amongst the chromosomes, except for chromosome X that had more 
large changes resulting in positive relocalisations (figure 3.11D/E). Chromosome 17 showed 
exhibited the four variations of influence, but the trend of positive relocalisations from smaller gaps 
remained the highest. In table 3.2, the p-values >0.5 that showed no significant difference to the 
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Spatial territories of chromosomes and genes have altered positions in many cancers (breast, 
cervical, colon, lymphocytes, and melanoma) that are orchestrated by many proteins, including a 
family of nuclear motor myosins and together with chapter 2 findings, warranted further 
investigation (Cremer et al., 2003; Meaburn, 2016). Chapter 2 showed that key chromosomes of 
OC had altered spatial positioning in nuclei when compared to their healthy counterpart. Moreover, 
nuclear motor proteins NM1 and NM6 were elevated in all of 4 cancer cell lines investigated. This 
presents NM1 and NM6 as favourable targets to investigate changes in chromosome positions (1, 
13, 17 and X) post knockdown. To determine if these motor proteins influence disease-associated 
spatial alterations, NM1 and NM6 were knocked down in the 4 OC cell lines, and their positions were 
mapped.  
Both NM1 and NM6 are detected in the cytoplasm and appeared to be constitutive due to the 
plethora of roles they encompass (Vreugde et al., 2006; Venit et al., 2016). For this reason, it was 
not favourable to completely rid the cells of proteins that otherwise have crucial roles at normal 
levels. It was also impossible to completely knock down NM1 and NM6 without harming the cells. A 
high concentration of reagents and high knockdown efficiency led to nuclear and cellular membranes 
with serrated edges. By changing the method to ‘reverse transfection’ where the cells are treated 
at the time of seeding and post -48 hrs, instead of just post-24 and -48 hrs, the reagent 
concentration was lowered from 50-100nM to 10-15nM for an aim of 50% knockdown efficiency. 
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3.4.1 Disruption of the tumorigenic superfamily stoichiometry of NM1/NM6  
The WBs of SKOV-3, PEO-1 and MDAH-2774 showed knockdowns of efficiency of 62%, 57% and 
74% for NM1 and 67%, 65% and 73% for NM6, respectively. [was not able to perform the WB for 
PEO-4 due to SARS-CoV-2]. The IF of SKOV-3, PEO-1, PEO-4 and MDAH-2774 estimated 
knockdowns efficiency of 57%, 48%, 47% and 70% for NM1 and 46%, 55%, 32% and 71% for 
NM6 respectively. Through the correlation of the WB quantification and the Indirect IF scoring, an 
estimation (subjective) of PEO-4 knockdown was made.  
The average knockdown effect of NM1 (64%) was relatively similar to that of NM6 (68%); and while 
the CTs did not show large re-positionings in some cases, NM1 knockdown led to a higher number 
of CTs adopting positions closer to that of the control cells, when compared to NM6 knockdown 
(table 3.2). In chapter 2, NM6 was higher than NM1 in the control cell and chemoresistant tumour 
cell, however the opposite way around for all other tumour cell lines. Perhaps knocking down NM1 
shifted to a healthy NM1/NM6 stoichiometry, and NM6 knockdown resulted in chaotic of the 
stoichiometry, also hinting that stoichiometry is just as or maybe more critical than having elevated 
levels; not only did it combatted high levels of the protein but also restored some balance between 












Figure 3. 13 NM1 and NM6 Levels Before and After Knockdown:  
The before figure (extracted from figure 2.9) was amended using the per cent knockdown (extracted from 
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3.4.2 One size does not fit all 
In the tumour cells, both knockdowns resulted in CTs re-positioning in locations closer to that 
adopted by the control cells as the new chromosome positions had lower statistical differences 
to the control cell in 13/16 and 10/16 instances for NM1 and NM6 respectively (table 3.2).  
Even though more positive adoption of CT location came from smaller gaps post-knockdown, 
compared to larger gaps (figure 3.11A), one must consider the severity of the initial mispositioning 
and question the repositioning on large gaps, is it too much? For instance, chromosome 13 and 17 
that was grossly altered initially would require a larger knockdown gap to reach a healthy position, 
and chromosome 1 would not require as much. The data shows that different chromosomes require 
different degrees of re-location to be beneficial as one size does not fit all, however, while some 
chromosomes require large-scale re-location, others revealed that too much might not be beneficial. 
Intriguingly, chromosome X showed re-location from the periphery to intermediate or interior 
positions (figure 3.9 and 3.10) leading to the hypothesis that NM knockdowns may have altered the 
stoichiometry, in turn, dysregulating the mechanotransduction signals amongst other associated 
structural proteins such as lamins. Together with LADs, this may result in the attachment of gene-
poor areas of the essential chromosomes, thus displacing chromosome X. This type of chromosome 
X misplacement was also observed in atypical HGPS (expresses Lamin A, not progerin) cell line upon 
telomere elongation (immortalisation) by human telomerase reverse transcriptase (hTERT) (Bikkul 
et al., 2019).  
Assessing the therapeutic value of chromosome re-location via NM1/6 knockdown could possibly 
mean that patients with chromosome 1 and 13-associated TSGs and oncogenes will benefit from 
NM1 knockdown therapy and patients with chromosome 17-associated TSGs and oncogenes will 
benefit from either NM1 or NM6 knockdown therapy. A broad-range attempt that affects all myosins 
by blocking its ATP/GTP-derived energy source using enzymes ouabain (ATP inhibitor) and AG10 
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(GTP inhibitor) can be considered, as it also found overexpressed in the cytoplasm (Mehta et al., 
2010). However, ATP/GTP of healthy tissue becomes vulnerable and despite the overexpression of 
numerous NMs including NM2, NM5α/β, NM9, NM10 in ovarian and other cancers, some NMs such 
as NM18β is found under-expressed in OC, and due to the relative specificity of RNAi, a siRNA pool 
of only overexpressed NMs for the requirement of particular cancers would be a more favourable 
clinical approach (Yanaihara et al., 2004).  
3.4.3 Conclusion  
The complex nature of the myosin superfamily provides a multifaceted target in drug discovery. 
Complementary and compensatory associations have been proposed as they both interact with RNA 
Pol II, and both possess motor functions. The forward moving NM1 has its own unique association 
with RNA Pol I while NM6 that moves backwards with anchorage properties gives no lesser 
superiority to either. However, it appears that NM1 levels are problematic in cancer cells as it may 
offset its stoichiometry with NM6, and considering the plethora of NM6 roles, more work needs to 
be done. Interestingly, the platinum-resistant cell retained the healthy stoichiometry of NM1/NM6 
while also both being elevated. This warrants further investigation to assess its inclusivity to NM1 
and NM6 therapy. Would a perturbation of this balance re-sensitise resistant cells, providing a 
rationale for NM1/NM6 knockdown in combating drug resistance?
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CHAPTER 4  
UNDERSTANDING CHEMORESISTANCE AND RE-
SENSITISATION IN OC  
4.1 INTRODUCTION 
OC can be effectively treated with chemotherapy where taxols (e.g. paclitaxel) and platinols (e.g. 
cisplatin) are the chosen first-line drugs; however, due to the high toxicity and allergenic nature of 
taxols, patients are started and often limited to platinum-based drugs (Lheureux, Braunstein and 
Oza, 2019). Platinum-based drugs are highly effective in the first cycle, but with an intricate disease 
like OC with platinum resistance relapses, the patient is further rendered unsuitable for 
chemotherapy (Lheureux, Braunstein and Oza, 2019). Even though a patient might be able to 
tolerate taxols (with or without steroids), reoccurrence and resistance still occur as 75% of Taxol 
recipients eventually relapse after 18 months (Sherman-Baust et al., 2011; Siegal et al., 2011). 
Patients continue to go through the list of drugs until they are halted by multi-drug resistance 
(MDR). Wiech et al., 2009 stated that transcription levels are altered with chromosome positioning, 
in which Meaburn and Misteli, 2008, added that it does not affect transcription levels in early disease 
states and therefore, it may be of more benefit to start from the advance states such as 
chemoresistance and work backwards.  
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4.1.1 Modelling a Lab-Grade Platinum-Resistant Cell Line  
Development of drug-resistant cell lines in-vitro has always been of interest to scientists to study 
this poorly understood phenomenon. The first resistant cell line to be produced was in 1970 on 
Chinese hamster cells; before that, in-vivo models were used in the 1950s and 1960s (Biedler and 
Riehm, 1970). Developing such cell lines usually takes 3 to 18 months, and the method can vary 
between continuous and pulse treatments or a mixture of drugs (Penner-Goeke et al., 2017). Pulse 
treatment of drugs (low doses below IC50 with recovery time) best mimics the clinical cycles a 
patient receives, however, the cell lines derived have low and unstable resistance with changes too 
subtle to detect and analyse (reviewed in Penner-Goeke et al., 2017). Despite having lower clinical 
relevance, continuous treatments (high doses at IC50 or above then escalated with time) produces 
stable high-level resistant lines that are easier to maintain and molecular changes are more 
significant making them easier to study. This study will use a hybrid of both methods by treating 
the cells with its long-term IC50 once a week for 24 hrs, then 144 hrs recovery time, increasing the 
dose when doubling time returns, all within a duration of 3 months, in which Penner-Goeke et al., 
2017 also found as sufficient time for resistance acquisition in eOC cell lines from patients. This 
ensured a robust, resistant line in the shortest time possible.  
Cell line groups such as PEO-1 (platinum-sensitive) / PEO-4 (platinum-resistant) are widely used 
for platinum-resistant research as they were derived from the same patient displaying common 
marker chromosomes (table 2.2). However, PEO-4 shows a re-appearance of chromosome 8 and 
17 that were missing in PEO-1 that instead suggests a clonal origin and then a divergence into a 
heterogeneous population (Langdon et al., 1988; Wolf et al., 1987). The best cell lines for 
comparative studies start with parental cell lines with no previous treatment or low IC50 values 
(Beaufort et al., 2014). For this study, we employed the naïve cell line MDAH-2774 and created a 
new cisplatin-resistant line, MDAH-2774CR. 
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4.1.2 Understanding Drug Resistance by Spatial Chromosome Organisation   
A disease with multiple re-occurrences, each accompanied by increasing resistance to 
chemotherapy, needs just as much attention as the sensitive form of the disease, as it cannot be 
treated the same. Drug metabolism, membrane transporters, modification in drug targets, cell cycle 
pathways, RNA transcription, epigenetics, oxidative stress, and oncogenes have all been linked to 
platinum drug resistance of OC (reviewed in Norouzi-Barough et al., 2017; section 1.1.7). All these 
factors are associated with either overexpression or mutations in genes, both poorly understood in 
OC and, due to the complexity of interactions, pinpointing one pathway may be unsuccessful. 
However, by broadening the scope and studying spatial genome organisation in drug-resistant cell 
lines, more can be understood while new targets or therapy could be discovered. To date, no prior 
literature addressing spatial genome organisation in chemoresistance, far less in OC can be found; 
however, Penner-Goeke et al., 2017 found that well-studied carcinogenesis-associated chromosome 
instability (CIN) continues onto the chemoresistant and re-occurrent disease stages in OC cells.      
4.1.3 Re-sensitisation using siRNA 
Sun et al., 2011 outlined the benefits of lower toxic doses as siRNA of polo-like kinase 1 (Plk1), and 
paclitaxel resulted in a synergistic tumour suppression in MDA-MB-435s inoculate in murine models 
resulting in requiring 1000-fold less paclitaxel compared to its monotherapy. In sensitive OC, Xue 
et al., 2019 showed synergistic outcomes in SKOV-3 inoculated into nude mice with siRNA of 
ribonucleotide reductase M2 (RRM2), resulting in reduced tumour volume, as well as an increased 
growth inhibition rate, from 36% in siRNA only and 41% in cisplatin only, to 64% in siRNA combined 
with cisplatin group. Also seen in drug-resistant OC, Yang et al., 2015 reported synergistic effects 
in OVCAR8TR (paclitaxel-resistant) and mice with siRNA of Multi-Drug Resistance Gene 1 (MDR1).   
siRNA has been invaluable in discovering new drug targets, and in addition to its stand-alone effects, 
its synergistic effects have benefited disease response to drugs. siRNA treatment strategies fall into 
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two categories; discrimination against tumour growth (and angiogenesis) and drug-resistance (and 
cell survival) (van den Brand et al., 2018). Chapter 2 and 3 used FISH and siRNA to understand 
tumour growth from the perspective of spatial chromosomal organisation, where this chapter builds 
on that to investigate drug-resistance. 
4.1.4 Outlook 
Dismantling the stability of chemoresistance cells through siRNA re-sensitisation provides a suitable 
and potential target in drug treatment and resistance, leading to lower drug doses and delayed drug 
resistance. This chapter aims to investigate the spatial territories of chromosomes 1, 13, 17 and X 
in addition to the protein level ratio of NM1/NM6 in a lab-created platinum-resistant cell line. This 
attempts to challenge the findings of chapter 2; where all the cancer cells had both NM1 and NM6 
elevated levels, NM1 being higher; and on the other hand, the platinum-resistant cell line PEO-4 
had NM6 higher a ratio also reflected by the control cell line (figure 2.9). Chapter 3 demonstrated 
spatial chromosome re-positionings post-NM1 and -NM6 knockdown in PEO-4, that was ideal in 
some cases; however, this chapter explores combination treatments of siRNA and cisplatin through 
survival assays since NM1/NM6 knockdowns may be a better candidate in re-sensitisation over 
therapy.  
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4.2 METHODS  
4.2.1 Sulforhodamine B (SRB) Calibration for use in Cytotoxicity Assays 
In 96-well plates, 50% serial dilutions of 1x104 cells (SKOV-3, PEO-4, PEO-1 and MDAH-2774) were 
grown. After 48 hrs, in one plate, the cells were fixed by adding 25µL of cold 50% TCA directly to 
the media (100µL) and incubated for an hour on ice. The TCA was gently removed, and the plates 
were gently washed by submersion into water 4 times then air-dried at room temperature. Once 
dried, 50µL of 0.04% SRB solution was added to each well and incubated for 1hr. This was then 
gently tapped out and rinsed by submersion in 1% acetic acid 4 times then air-dried at room 
temperature. Once ready to be analysed 100µL of 10mM TRIS base (pH10.5) was added to each 
well, and the plate was shaken on an orbital shaker for at least 10 mins, then analysed at 510nm 
using the CLARIOStar plate reader. The cells in the second plate were used to count cell numbers 
using the Countess (ThermoFisher); trypsinised cell suspension (50µL) was neutralised with 2% 
Trypan Blue media (50µL). The results of both methods were combined to create a calibration curve 
so that cell proliferation could be determined by the SRB assay onwards. Its linearity exceeds the 
likes of the Lowry and Bradford assays, and with the MTT assay, it is also faster, simpler and more 
sensitive, which provides several advantages for large-scale screening (NCI; Skehan et al. 1990).  
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4.2.2 50% Growth Inhibitory Concentration (IC50) Assay  
PEO-1, PEO-4 and MDAH-2774 (1.0 x 103 to 1.0 x 104) were seeded in 96-well plates and assayed 
120 hrs later to choose an appropriate cell density (near confluency) for drug treatment as shown 
in figure 4.2.  From this, the ideal seeding density for 96-well plates was determined to be 1.0 x 
104 cells for PEO-4 and MDAH-2774CR and 8.0 x 103 cells for PEO-1 and MDAH-2774. 5mM stocks 
of Cisplatin (Abcam/ab141398) were made using 0.09% NaCl and working concentrations were 
made before use by dissolving in complete RPMI media. The 50% Growth Inhibitory Concentration 
(IC50) values for MDAH-2774 and PEO-1 were determined. The cells were plated, and after 24 hrs, 
plates were treated with varying drug concentrations (20µM, 15µM, 10µM, 5µM, 2µM and 1µM). The 
media was refreshed with drug-free media, and after another 24 hrs and 72 hrs, they were fixed 
for the SRB assay.  
4.2.3 Chemoresistance induction  
The naïve cell line MDAH-2774 was treated once a week for 24 hrs with the 96hr IC50 cisplatin dose 
(1µM) for seven weeks and the last six weeks treated with 2µM, for a total of 3 months (Penner-
Goeke et al., 2017). Thus, cells for FISH, IF and WB were harvested on week 12.   
4.2.4 Cytotoxic Assay  
Cells were plated in 96-well plates using the ideal cell density and treated with siRNA via the reverse 
transfection method (as described in section 3.2.1). After 48 hrs they were re-treated with siRNA.  
After another 24 hrs, the media was refreshed and selected wells treated with 1µM cisplatin 
(determined from the IC50 assay). The media was refreshed in all wells after a further 24 hrs. After 
the final 24 hrs (120 hrs in total), the cells were fixed for the SRB assay.  
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4.2.5 Cell Culture – refer to section 2.2.1 
4.2.6 FISH – refer to section 2.2.2  
Combinations containing post knockdown cells were left in the hypotonic solution for 15-20 mins 
instead of 10 mins since the cytoplasm became challenging to remove (refer to section 3.2.3).  
4.2.7 Indirect IF – refer to section 2.2.3 
4.2.8 WB – refer to section 2.2.4 
4.2.9 RNAi – refer to section 3.2.1 
 
  




Data presented in chapter 2 demonstrated both NM1 and NM6 protein elevation in all the cancer 
cells where NM1 was higher than NM6, however, the platinum-resistant cell-line PEO-4 and the 
control cell line had higher NM6 levels instead than NM1. This delicate balance prompted the 
investigation into OC chemoresistance. Due to the divergence in using PEO-1/PEO-4 for chemo-
sensitive studies, the chemo-naïve cell line MDAH-2774 was used to create a novel chemoresistance 
cell line for an absolute baseline of, before and after, within the same lineage.  
4.3.1 Creation of a Platinum-Resistant MDAH-2774, MDAH-2774CR: 
Firstly, a long-term IC50 had to be determined so that the naïve cell-line could be treated with 
cisplatin in 12 weeks while remaining sufficiently viable. Several assays had to be done to determine 
the cell survival in large cohorts, and so SRB assays were performed. Basically, at the time of 
analysis, the floating (dead) cells were removed, the live adherent cells were fixed, dyed and washed 
to exclude excess dye and the protein-bound dye was re-solubilised in 100µL of 10mM TRIS base, 










Figure 4. 1 SRB Calibration:  
The linear correlation with SRB dye and cell density for cell line MDAH2774, MDAH-2774CR, PEO-4, PEO-1 and 
SKOV-3. After 48 hrs of growth, varying plate densities were subjected to spectrophotometric analysis post-
SRB staining and correlated with duplicates quantified by the countess. The absorbencies were normalised, 
and the intercept was set at zero, the gradient (MDAH-2774 = 1.45 x 106, MDAH-2774CR = 2.49 x 106, PEO-
4 = 1.71 x 106, PEO-1 = 1.72 x 106 and SKOV-3 = 1.24 x 106) can be used to convert absorbencies to cell 
numbers. This index also illustrates the relative protein content of the cell, where SKOV-3 contains the least, 
PEO-1 and PEO-4 are similar and MDAH-2774 has an increase as it gains resistance. The data represent 
normalised means (n=3). 
The survival assays and combination treatment experiments were set-up to take place within a 6-
day (120 hrs) block, and un-treated control cells had to be able to grow to that time frame healthily. 
The cell lines to be experimented on were plated at different densities, and the seeding density that 
resulted in maximum growth before the curve plateaued at day 6 was selected as the density to 
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and slower-growing PEO-4 and MDAH-2774CR were plated at 1x104 in 96-well plates. MDAH-2774CR 
data was included from work post-IC50 experiments.  
 
Figure 4. 2 Seeding Density Determination for Cytotoxic Assay:  
Cell growth after 120 hrs to determine near confluence for cell lines MDAH2774, MDAH-2774CR, PEO-4, and 
PEO-1. Varying cell densities between 1 x 103 to 1 x 104 were plated, and after 120 hrs of growth, the cells 
were subjected to spectrophotometric analysis post-SRB staining to determine the lowest plating density near 
full confluence (before plateau). The arrows indicate MDAH-2774 and PEO-1 at 8.0x103 and MDAH-2774CR and 
PEO-4 at 1.0x104. The data represent normalised means (n=4) 
From this, 8x103 MDAH-2774 and PEO-1 cells were seeded (0 hrs) and after 24 hrs treated with 
different concentrations of cisplatin for another 24 hrs at which point the media was refreshed with 
drug-free media. The absorbance was taken at 72 hrs and 120 hrs (6 days). The absorbance that 
reflected 50% survival was used as the IC50. At 48 hrs the IC50 of MDAH-2774 and PEO-1 was 5µM 
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Figure 4. 3 IC50 for MDAH-2774 and PEO-1:  
Spectral analysis post-SRB staining for cell line MDAH2774 and PEO-1 after treating with varying cisplatin 
concentrations (1µM, 2µM, 5µM, 10µM, 15µM and 20µM), incubated for 24 hrs, refreshed and after 24 hrs and 
72 hrs, then subjected to spectral analysis post-SRB staining to determine the IC50 (concentration at 
approximately 50% survival). The yellow bar represents the approximate IC50 which decreases (MDAH-2774: 
5µM to 1µM and PEO-1 5µM to 2µM) the longer the culture it is treated (48 hrs vs 96 hrs respectively). The 
data represents normalised means (n=3). 
 
Using the long-term IC50, for seven weeks, once a week, MDAH-2774 was treated with 1µM cisplatin 
for 24 hrs. In the last six weeks, this was increased to 2µM. They were passaged twice a week as 
usual, and in the last month, they were passaged once a week. At the end of 12 weeks, they were 
now recognised as MDAH-2774CR. MDAH-2774CR was subjected to SRB calibration and plating 
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4.3.2 NMI and NM6 Distribution and Quantity of newly created Platinum-Resistant 
MDAH-2774CR: 
Before starting combination treatments with cisplatin and siRNA, NM1 and NM6 distribution 
(dispersed foci, aggregate foci, dispersed and aggregate foci and negative; see figure 2.5 for 
representative images) and protein levels of MDAH-2774CR were analysed using IF and WB 
respectively (figure 4.4/4.5 and 4.6/4.7).  
  
Figure 4. 4 NM1 and NM6 Distribution Patterns Score:  
Bar graphs show the score of 4 NM1 patterns (dispersed foci, aggregate foci, dispersed and aggregate foci and 
negative) in cell lines MDAH-2774 and MDAH-2774CR. The bars and error bars for each cell line (X-axis) 
represents means of 3 replicate slides and SEM for a total of 200 nuclei as a percentage (% / Y-axis). Student’s 
t-test of the cancer cells NM1 and NM6 patterns was performed against the wild-type (control HOSEpi) p-
values: 0.026** and 0.010** for MDAH-2774 and 0.125* and 0.032** MDAH-277CR respectively.  
* - denotes statistically different by one confidence interval (0.5) and ** - denotes statistically different by two confidence 
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Figure 4. 5 NM1 and NM6 Distribution Patterns Images:  
Representative images of the nuclear most prevalent distribution pattern captured in cell lines MDAH-2774 and 
MDAH-2774CR. DNA was stained using DAPI (blue), and the NM1/NM6 protein was revealed by Indirect IF with 
a Cy3 conjugated secondary antibody. Magnification x400 / x1000. Scale bars represent 25µm. 
 
IF revealed the platinum-resistant cell MDAH-2774CR had a unique distribution that displayed 
features of both its sensitive counterpart MDAH-2774 and the control cell line. Figure 4.4 shows the 
re-emergence of NM1 and NM6 (both large-aggregate foci) patterns in the resistant cell that was 
absent in the tumour cell and present in the control cell. Additionally, the modal pattern of NM1 
(dispersed and aggregate) and NM6 (dispersed) in the control cell elevated in the tumour cell but 
then declined as it acquired resistance to the point where dispersed and aggregate patterns of NM1 
were absent in the platinum-resistant cell. Lastly, NM1 (dispersed) and NM6 (dispersed and 
aggregate) patterns that were absent in the control cells, were present in the tumour cell and 
amplified further in the platinum-resistant cell. Interestingly, the increase in negative cells was not 
expected as there were protein elevations in the platinum-resistant line as the tumour line (figure 
4.6 and 4.7). 
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Figure 4. 6 NM1 and NM6 Levels:  
Cytoplasmic and Nuclear extracts of cell line MDAH-2774 (lane 4) and MDAH-2774CR (lane 8) were quantified 
by WB on the Li-Cor Odyssey for NM1 and NM6 using ImageJ software (Version 1.53a), the band intensities 
were calculated. The quantities were normalised against GAPDH levels (first band) in the corresponding 
cytoplasmic extracts. Lane 5, 6 and 7 are the control HOSEpi. 
 
 
Figure 4. 7 NM1 and NM6 Band Intensities:  
The fluorescence Li-Cor image of the membrane was uploaded to ImageJ software (Version 1.53a) to calculate 
the band intensities. The bars represent protein signal intensity / corresponding GAPDH signal intensity = X-
axis. Above each cancer cell bar is the % increase; SKOV-3 (174%,114%), PEO-1 (286%,158%), PEO-4 
(149%,264%), MDAH-2774 (199%,57%) and MDAH-2774CR (279%, 284%) when compared to the healthy 
levels of the HOSEpi cell.  
 
NM1/NM6 protein levels for MDAH-2774CR conformed to the findings of chapter 2 as it not only 






















HOSEpi SKOV-3 PEO-1 PEO-4 MDAH-2774 MDAH-2774CR
NM1 3.04 8.31 11.71 10.59 9.08 11.50
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MDAH-2774, but also that NM6 was higher than NM1 in HOSEpi, PEO-4 and MDAH-2774CR.  
4.3.3 Investigating Re-Sensitisation of MDAH-2774CR through Combination 
Treatments of siRNA and Cisplatin:  
To investigate the potential synergy of siRNA and traditional chemotherapy combined to combat 
unresponsiveness to drugs by resistant forms of diseases, siRNA of NM1 and NM6 was used to 
reduce their levels in the resistant cell lines followed by treatment with cisplatin and then they were 
assayed for cell survival. The knockdown efficiency was 39% and 38% for NM1 and NM6 respectively 
by estimating by scoring the positive and negative cells from IF (see figure 3.7 for positive and 
negatively stained representative images). [Figure 4.10/4.11 could not be completed due to SARS-
CoV-2] 
 
Figure 4. 8 MDAH-2774CR NM1 and NM6 levels:  
Pre- and post-siRNA knockdown if NM1 and NM6 as estimated by Indirect IF. The bars and error bars for each 
cell line (X-axis) represents means and standard error of the mean for a total of 200 nuclei as a percentage 
(% / Y-axis) of positive and negative stained cells before and after NM1/NM6 knockdown (ON-TARGETplus 
Human MYO1b and MYO6 siRNA – SMARTpool). MDAH-2774CR NM1 and NM6 were reduced to 61% and 62% 
of the original amount, respectively, that was normalised against the control (ON-TARGETplus Non-targeting 








































Figure 4. 9 Cisplatin Cytotoxic Assay:  
Cell survival following different combination of cisplatin treatments and NM1/NM6 siRNA. Sensitive and 
resistant paired cell line (MDAH-2774/MDAH-2774CR) were subjected to a series of treatments. At the end of 
120 hrs, they were assessed by spectral analysis post-SRB staining. The bars for each condition (X-axis) 
represent means and standard error of the mean (Y-axis; Absorbance @510nm) of triplicates wells.  
 
When the cells were treated with IC50 MDAH-2774 (1µM) cisplatin, there was *49% survival (desired 
outcome) in the sensitive cell line and **94% survival (unwanted outcome) in the resistant cell line. 
The knockdown of NM1 and NM6 reduced the survival to 77% and 93% respectively (with the control 
knockdown consideration). However, when the knockdown of NM1 and NM6 was combined with 1µM 
of cisplatin, survival was reduced to ***47% (exceeding the desired outcome) and ****67% 
respectively (with the control knockdown consideration). Exceeding the desired outcome is valuable 
as the effect is reduced when phased into clinics, and this result also highlights the role of NM in 
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4.3.4 The Role of Spatial Chromosomal Organisation in Platinum-Resistance and 
Re-Sensitisation: 
To understand how MDAH-2774CR became resistant and re-sensitized to cisplatin treatments 
through NM1 knockdown, the spatial territories of chromosomes 1, 13, 17 and X were investigated 
in MDAH-2774CR pre- and post-NM1 knockdown.  
 
Chromosome 









Figure 4. 100 Chromosome Spatial Positioning Images: MDAH-2774CR Pre- and Post-NM1 
Knockdown: 
Fluorescence images for the nuclear localisations of chromosomes 1, 13, 17 and X in cell lines MDAH-2774CR 
positioned using 2D-FISH pre/post NM1 knockdown. Nuclear genetic material blue-stained using DAPI and 
whole chromosome signals were red-stained with Cy3 and converted to green for software recognition. 
Magnification x400 / x1000. Scale bars represent 25µm.Images from fluorescent microscopy following 2D-
FISH of MDAH-2774CR and MDAH-2774CR-NM1 were then analysed by erosion analysis and compared against 
their originator MDAH-2774 and the control cell line using p-values from the students’ t-test (figure 4.13 and 
table 4.1). 
 

































































Figure 4. 11 Graphical Representation: MDAH-2774CR Image Analysis Chromosome Spatial 
Positioning Pre- and Post-NM1 Knockdown:  
Histograms show the nuclear localisations of chromosomes 1, 13, 17 and X in cell line MDAH-2774CR  before 
(light green) and after (dark green) siRNA knockdown of NM1, positioned using 2D-FISH and analysed by 
erosion analysis software [section 2.2.2]. The bars and error bars signify means and standard error of the 
mean of 50-75 nuclei, respectively. Y-Axis represents % Cy3 whole chromosome probe signal / % DAPI nuclear 
signal, and the X-axis represents periphery to the interior position (1 to 5). Student’s t-test of all cancer cells 
performed against their origin cell and to the wild-type (healthy HOSEpi) [p0.5 considered as significant]. 
 
Upon chemoresistance acquisition, Chromosome 1 in MDAH-2774 altered from internal to bi-modal 
(internal and periphery population), chromosome 13 stayed central, chromosome 17 moved further 
central and chromosome X from periphery to central. However, when NM1 was knocked down in 
MDAH-2774CR, only chromosome 1 and X showed reversion to intermediate and periphery 
respectively as the control cell while Chromosome 13 became bi-modal and chromosome 17 
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Table 4. 1 p-values for MDAH-2774CR and Post-NM1 Knockdown Against HOSEpi:  
Each shell was calculated in MS Excel and the below. Shells that showed no significant differences with p>0.5 
are highlighted in red, the shells that showed statistical differences with p<0.5 are unhighlighted, and the 
shells that showed statistical differences with p<0.05 are highlighted in green. The average values listed below; 
the red value represents no significant differences [p>0.5]; the black values are significantly different [p<0.5] 
and the green values significantly different [p<0.05]. 




Shell 1 0.925 0.482 
Shell 2 0.001 0.594 
Shell 3 0.046 0.262 
Shell 4 0.315 0.499 
Shell 5 0.023 0.990 
AVG ➔ 0.262 0.565 
Chromosome 13 
Shell 1 0.057 0.421 
Shell 2 0.004 0.654 
Shell 3 0.007 0.000 
Shell 4 0.467 0.278 
Shell 5 0.070 0.325 
AVG ➔ 0.121 0.336 
Chromosome 17 
Shell 1 0.279 0.069 
Shell 2 0.028 0.002 
Shell 3 0.352 0.001 
Shell 4 0.015 0.812 
Shell 5 0.315 0.001 
AVG ➔ 0.198 0.177 
Chromosome X 
Shell 1 0.138 0.009 
Shell 2 0.062 0.243 
Shell 3 0.001 0.161 
Shell 4 0.215 0.997 
Shell 5 0.317 0.500 
AVG ➔ 0.147 0.382 
 
Table 4. 2 p-values of MDAH-2774CR Pre- and 
Post-NM1 Knockdown Against HOSEpi:  
Summarised from table 4.1 - MDAH-2774CR had a 
higher significant difference to the control cell line 
before the knockdown and a lower significant 











1 0.262 0.565 
13 0.121 0.336 
17 0.198 0.177 
X 0.147 0.382 
AVG 0.182  0.365 
 
The p-values of spatial chromosomal 
organisation showed that the created resistant 
MDAH-2774CR had an unexpected decrease in its 
statistical similarities to the control cell line. 
However, when NM1 was knocked down, its 
statistical similarity increases with large 
contributions from chromosome 1 and X.   













Figure 4. 12 Post-Knockdown Effect by p-values Against HOSEpi:  
Heat-maps represent the level of shifts from the control cell that MDAH-2774 experiences when NM1 and NM6 
are knocked down, when it acquires chemoresistance and when its resistant progeny undergoes NM1 
knockdown. Blocks highlighted in red are shells that showed no significant differences with p>0.5, highlighted 
in green are shells that showed statistical differences with p<0.05 and the yellow shells showed statistical 
differences with p<0.5. The higher similarity to the control cells 
 
The heat maps showed that post NM1 knockdown resulted in both MDAH-2774CR and MDAH-2774 
having increased statistical similarities to the control cell line.  
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A major problem in treating a disease commonly diagnosed at a late stage is reoccurrence and 
cumulative chemoresistance. At this point, the disease is still cancerous, but its response is not the 
same as it has a new collection of properties allowing it to evade treatment despite a change in 
drug and dosage. Chemoresistant cancers cannot be treated as sensitive cancers; thus, greater 
understanding and therapy is required. This chapter aims to investigate the spatial arrangement 
and myosin level alterations that an OC cell undergoes upon the acquisition of chemoresistance and 
explore the synergistic effects of combining chemotherapy with siRNA.  
4.4.1 NM1/NM6 Role in Acquiring Chemoresistance.  
Chapter 2 presented altered CT positionings and NM distributions in the cancer cell lines. However, 
although elevated as in the other cell lines, PEO-4 NM1/NM6 stoichiometry stood out as it was 
similar to the control cell stoichiometry (NM6 higher than NM1; figure 2.9). In chapter 3, when NM1 
was knocked down, NM6 then also became higher in the cancer cells, which was accompanied by a 
slightly more significant improvement in the localisation of chromosomal territories when compared 
to the control cells. This led to the production of a lab-grade cisplatin-resistant cell line (MDAH-
2774CR), in which a similar characteristic stoichiometry was found (NM6 higher than NM1; figure 
4.7). In the family of NMs, NM2 was also found overexpressed in drug-resistant OC, increasing the 
migratory potential of the disease and has been proposed as a potential suppression target (Kapoor 
et al., 2018). This research also presents an exciting role for NM6 in chemoresistance.  
Data presented in chapter 2 also found that PEO-4 NM1 and NM6 distribution was inconsistent with 
the distribution in the control cells (figure 2.7). MDAH-2774CR on the other hand, while it had 
inconsistent distribution in both NM1 and NM6 when compared to both its originator cell line and 
control cell line, a decline of the modal tumour-specific patterns, an emergence of patterns 
associated with normal control cells and an amplification of sporadic tumour-cell associated 
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patterns (figure 4.4). The selective pressure in-vitro may have been intense compared to in-vivo, 
which may have resulted in extreme perturbations in NM1 and NM6 distribution patterns in MDAH-
2774CR versus the in-vivo line PEO-4.  
4.4.2 Synergy 
Nuclear myosins were also targeted to investigate its role in resistance-related chromosomal 
reorganisation. This required over-expressed NM1 and NM6 to be knocked down in the platinum-
resistant line and then treated as the sensitive line would be. Figure 4.11 showed that sensitive 
MDAH-2774 had 49% survival while the resistant MDAH-2774CR had 94% survival when treated 
with cisplatin alone, however when combined with NM1 or NM6 knockdown, MDAH-2774CR survival 
reduced to had 47% and 67% survival respectively, where the NM1 knockdown combination 
surpassed the expected outcome of the sensitive line highlighting exceptional synergy of combining 
chemotherapy with the reduction of NM.  
The knockdown effect observed in NM1 (39%) was similar to NM6 (38%), and as the resistant cell 
line does have higher levels of both proteins compared when to the control cell and its tumour 
originator, NM6 is also higher than NM1 before the knockdown, therefore the magnitude of RNA 
interference would have to be greater for NM6.  
4.4.3 Chemoresistance and Spatial Chromosomal Organisation 
Chromosomes may move to advantageous locations favouring drug efflux/metabolism-related 
transcription, but are they staying there permanently or more likely the elevated levels of motor 
proteins causing them to move rapidly? Upon the acquisition of chemoresistance and the successful 
re-sensitisation by NM1 knockdown, chromosomes 1, 13, 17 and X territories were mapped to 
deduce correlations with the spatial organisation. When MDAH-2774 acquired resistance, it 
surprisingly had a small increase in its p-value when compare to the control cell, and interestingly 
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when NM1 was knocked down, its p-value unexpectedly increased, both circumstances going against 
the ‘resistance principle’ (figure 4.14 and table 4.2). Under the ‘resistance principle’, resistant cells 
evade drugs by adopting features resembling control cells while also accumulating tumorigenic 
traits; therefore, it was expected that MDAH-2774CR would have shown larger similarities to HOSEpi 
(see resistance principle section 1.1.8). The lack of templates of control cells may be the reason in-
vitro experiments have been unsuccessfully translated into therapy, and future studies should 
consider spiking chemo-induction treatments with control cells.  It was also expected that for re-
sensitisation, MDAH-2774CR-NM1 would have shown similarities to MDAH-2774 rather than HOSEpi. 
Intriguingly, the only chromosome that had this expected repositioning was chromosome X. The 
consensus is that the re-sensitisation should push the resistant cell to such vulnerability to be 
destroyed by the drug, and this may have been achieved by the chaos of chromosomes adopting 
abnormal and normal positions.  
4.4.4 Conclusion 
Co-delivery to treat and combat resistance using a multifunctional nanoparticle-based delivery 
system that delivers drugs and siRNA targets has been used to investigate many multi-drug 
resistant cancers and has been found to inhibit growth drastically (Saad et al., 2008). However, 
after first discovered in 2004, the wave of optimism died as delivery techniques faced challenges to 
translate into clinics in addition to innate immune responses and off-target effects (Wang et al., 
2017). This caused suspension of numerous RNAi clinical trials, including the first RNAi drug 
Bevasiranib (Garba and Mousa, 2010). Introducing RNAi in clinical therapies heavily relies on 
nanoparticle biology, and as research design and standards improve, RNAi-based anticancer 
therapies will soon become available. In August 2018, the first RNAi drug, Onpattro (patisiran), that 
knocks down transthyretin (TTR) was approved for polyneuropathy in hATTR amyloidosis, then in 
November 2019, Givlaari (givosiran), that knocks down aminolevulinate synthase 1 (ALAS1) for 
acute hepatic porphyria (AHP), both by Alnylam Pharmaceuticals. 
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Additionally, when combating drug resistance through RNAi, a technique that rarely provides 100% 
knockdown needs to be directed to a protein that is required at reduced levels coupled with a 
synergistic treatment. This study reduced the protein, whereas other studies approach targets by 
complete eradication of a gene/protein (perhaps CRISPR might be required instead). This chapter 
also showed that the spatial organisation of just four chromosomes was able to reveal information 
about resistance in OC, while its role in re-sensitisation warrants further studies. NM1/NM6 
knockdowns may also be a better candidate in re-sensitisation over therapy but can potentially 
reduce toxic drug doses and delay resistance. More work needs to be done to include more 





GENERAL DISCUSSION   
This project aimed to bridge the gap in research by investigating the nuclear organisation of four 
chromosomes and two NMs in four OC cell lines, as well as highlight their relevance of 
chemoresistance in hopes of improving the prognosis of OC. Widening the gap by possibly delaying 
chemoresistance through improved therapy or a prognostic prediction may allow a patient extended 
time and/or better quality of life. While the management of OC has improved over the decades, it 
remains the deadliest female gynaecological cancer as it continues to be shadowed by other cancers 
in terms of funding and research. 
1. Chromosome X 
This research began by reserving the use of chromosome X as a control for chromosome 1, 13 and 
17 in FISH as it is known to occupy the periphery, however, with recent findings of the paternal X 
chromosome being linked to OC, we continued investigations in the knockdown where instability 
emerged as chromosome X moved internally in 7/8 instances (Belmont et al., 1986; Boyle et al., 
2001; Eng et al., 2018). Though some of these were positive relocations, it was not expected based 
on Mehta’s study where chromosome X showed no change in position regardless of the presence of 
serum or not (Mehta et al., 2010). Moreover, chromosome X did not occupy the absolute periphery 
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in the control cells and may imply a yet to be elucidated correlations with its position and roles in 
OC.  
Throughout this project, the knockdown by NM showed favourable outcomes when the knockdown 
gap (the spatial difference in CT pre- and post-knockdown) was small, and despite having relatively 
similar knockdown efficiencies, a more significant number of CTs adopted new positions post-NM1 
knockdown that were similar to the control cells, even in the cisplatin-resistant cells when compared 
to NM6 knockdown. Interestingly, chromosome X is the only chromosome of the four to show higher 
favourable outcomes with larger knockdown gaps (Figure 3.11E). The re-location of CTs varied 
widely with knockdowns, where one chromosome that seemed to respond in a rehabilitative way 
(figure 3.11) was chromosome 1 (more significant in NM1). However, in the cisplatin-resistant line, 
chromosome 1 was not alone as chromosome X also showed the same rehabilitative response 
(figure 4.13).  
Chromosome X may no longer be a suitable reference when investigating CT, at least in OC as it 
may have a role in the development and progression of the disease. This unsuitability stems from 
the observation of the escape of X chromosome inactivation (XCI) by inactive chromosome X 
(Xinactive) due to interaction with the active form of chromosome X (Xactive) (Laskowski et al., 2019). 
Xinactive is more peripherally positioned in a distinct, condensed and spherical structure known as a 
Barr body and perhaps the Xactive may also influence the position of the Xinactive making it less 
peripheral further explaining the loss of Barr bodies in cancer cells (Pageau et al., 2007; Jowhar et 
al., 2018; Etter et al., 2020).  
X chromosome interactions and influence have been found to exacerbate disease response in 
autoimmune diseases coherent with the supernumerary of X, thus the higher prevalence of X-linked 
diseases (i.e. 10% of diseases with a mendelian inheritance pattern) in women than in men (Ross 
et al., 2005; Jowhar et al., 2018; Laskowski et al., 2019). X chromosome interactions and escaping 
CHAPTER 5: General Discussion 
 
173 
XCI is problematic for oncogenic X-linked genes, for example, the "cancer-testis" genes that are 
typically expressed in adult testes tissue, are also expressed by many tumours, including the ovary 
(Dezhong et al., 2003; Etter et al., 2020). Even XCI has been observed in high-grade serous 
tumours, patterns of OC-related XCI remains largely unknown (Winham et al., 2019).  
2. Characterisation of whole chromosome spatial organisation  
Chromosome 1, particularly interesting as the ARID1A it possesses roles in chromosome 
partitioning, so while its position may show partial agreement to the size-based theory of 
chromosome organisation rather than the gene-density based, this is beginning to be disputed as 
more information on individual chromosomes with various specificities (tissue and cell state) is 
emerging, thus, may also be considered on an individual basis. However, with the emergence 
‘chromosome stretching’ or CT extension as possibly displayed by chromosome 13 and 17 and the 
element of the lack of complete repression of at the periphery, this large gene-rich chromosome 1 
can still be active while near or tethered to the periphery and stretched into the centre. Also 
interesting is that spatial position of chromosome 1 and NM6 distribution in SKOV-3 showed no 
significant difference to the control cells. However, this was followed with aberrance its other 
chromosomes 13, 17 and X presenting larger p-values than the other cell lines and both its NM1 
and NM6 also having >100% elevations as the other tumour lines (figure 2.9 and 3.11). Amongst 
the OC tumour lines and the lab-created cisplatin-resistant line MDAH-2774CR, there was a frequent 
re-location of the chromosome to the centre, especially in the case of chromosome 17 (Figure 2.4 
and 4.13). Chromosome 17 contains the oncogene HER2, which may be problematic in the 
transcriptionally active centre.   
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3. Tethering versus Anchorage Stoichiometry  
This then shifts focus on a dysregulation at the nuclear periphery in which we found irregularities in 
lamin staining, particularly lamin B2 was deficient or mis-localised internally, and lamin C was also 
deficient, that may have disrupted LAD tethering. Also, the possible chromosome stretching that 
peripheral chromosome experience requires an internal opposite force in which we attributed to the 
force-generating and anchorage properties of NM1 and NM6, both of which were found elevated and 
irregularly distributed. Therefore, while lamin tethering was deficient chromosome stretching was 
overpowered by the elevated pull by NM towards the active centre likely cargoing oncogenes with 
it. Just as stoichiometry within the lamin and myosin superfamily is important, stoichiometry with 
the hypothetical nuclear motor complex is as well (Swift et al., 2013).  
4. Superfamily/Supercomplex stoichiometry  
Swift et al. 2013 mentioned the cell-type-specific stoichiometry of A/B-type lamins determines the 
mechanical properties of nuclei and disruption of this ratio can have downstream effects to other 
protein and lead to diseases. Lamin B2 and C showed irregular characteristic lamin staining that 
may have disrupted the ratio within A-type and B-type lamins and the superfamily, with probable 
downstream effects on the proteins of the hypothetical nuclear motor complex such as NM1 and 
NM6 that was found elevated and irregularly distributed. The tumour cells showed a different 
stoichiometry to the control cell where NM1 was higher opposed to NM6 being higher in the control 
cell, which may also be accompanied by downstream effects. Additionally, there is compensation 
within the superfamily where A-type lamins step in during B-type lamin deficiency; which is also 
observed between nucleoplasmic and cytoplasmic isoforms of NM1, and also between NM1 and NM6 
when NM6 was perturbed (Yang et al., 2011a/b; Venit et al., 2013; Chen et al., 2019; Cook, Gough 
and Toseland, 2020). Whether disruption in the lamin stoichiometry affected NM stoichiometry or 
vice versa would require further investigation that perturbs the one protein and assess the other. 
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5. Other Nuclear Myosins 
My work also included other NMs that uncovered some interesting patterns that paves the way for 
future research (figure 5.1). While NM16 and NM18b showed patterns similar to the "dispersed" and 
"aggregates" as for NM1 and NM6 staining, a further pattern was apparent whereby NM was located 
at the nuclear rim, thus, making an exciting future co-study. NM18b showed a high number of 
negative stains consistent with its reduced expression report in OC justifying restorative 
investigations and its levels in the resistant disease (Yanaihara et al., 2004; Ajima et al., 2007). 
Though NM5b showed a uniform splicing speckles pattern (due to proposed roles in transcription 
splicing) throughout all the cell lines, it is understudied, and its emerging in transcription is 
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Figure 5. 1 NM16, NM18β and NM5β:  
Representative images of the nuclear distribution pattern (dispersed, dispersed and aggregate, rim deposits 
and splicing speckles) were captured in 4 OC cell lines SKOV-3, PEO-1, PEO-4 and MDAH-2774. DNA was 
stained using DAPI (blue), and the NM1 protein was revealed by Indirect IF with a Cy3 conjugated secondary 
antibody. Magnification x400 / x1000. 
 




The NM1/NM6 stoichiometry stood out in the platinum-resistant PEO-4 that showed similarities of 
control cells, which may have given it the resistant advantage. The lab-created cisplatin-resistant 
also showed the same stoichiometry, which was expected. We anticipated the platinum-resistant 
line, according to ‘the resistant principle’ to encompass mesh of healthy and tumorigenic properties; 
however, the principle lies on the fact that in-vivo a healthy template is available that enables this 
to take place, so it was not astonishing when the following expectations were not met during 
chemoresistant acquisition and re-sensitisation. Following the acquisition of chemoresistance 
MDAH-2774CR showed very little shift in CT that was similar to the control cell; instead, the CTs 
become more central. Moreover, when MDAH-2774CR re-sensitised through NM1 knockdown, an 
expectation is that it would resemble the sensitive tumour line; however, it showed higher 
similarities to the control cell. These outcomes may have been due to the lack of template during 
resistance acquisition and creation of such chaos instead through re-sensitisation that it did not 
matter which CT was at a healthy territory or not.  
Furthermore, even though no healthy template was available, the cisplatin-resistant MDAH-2774CR 
showed a re-emergence of NM patterns that were not seen its tumour originator cell MDAH-2774 
but observed in the control cell. Interestingly, this was also accompanied by a decline of the modal 
tumour-specific patterns and an increase in sporadic tumour-cell associated patterns (figure 4.4), 
highlighting the lineage advantage of the naïve cell and in-vitro chemoresistant line (Penner-Goeke 
et al., 2017). This novel investigation opens the avenues for research into chemoresistance 
concerning CTs and protein stoichiometry within the nucleus. However, the field of studying 
chemoresistance in-vitro requires control experiments to address the validity of the resistance 
principle by spiking resistance induction with control cells.  
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7. Conclusion  
While the irregularities of lamins and NM may have resulted in the detachment of some CTs from 
the periphery and to repositioning to the centre, this may have led to the displacement of 
chromosome X territory to the periphery. Following the NM knockdown, the anchorage effect was 
relaxed, resulting in the return of chromosome 17 to the periphery and pushing chromosome X back 
to its intermediate position. Perhaps restoring lamin with its tethering property and reducing NM 
with their anchorage would be ideal. However, the individual reduction of NM provided a remarkable 
response providing clinical possibilities with co-manipulations.  
 
Figure 5. 2 Summary of the CT Re-Positionings from Healthy to Cancer to NM Knockdown and 
Chemoresistance:  
In the control cell, Chromosome 17 (green) and 13 (pink) exhibited chromosome stretching, chromosome 1 
(lilac) and X (blue) occupied with intermediate spaces. In the cancer cell chromosome, X occupied the periphery 
while chromosomes 1, 13 and 17 had a relatively more internal occupancy. In the NM knockdown, chromosome 
17 reverted towards the periphery reverted internally with little knockdown gaps in between the states, 
chromosome 1 also reverted towards the periphery. Chromosome 13 varied with its occupancy; thus, a trend 
could not be summarised; however, there were some instances where it moves back outwards. The platinum-
resistant line exhibited bi-modalism in its chromosome 1 population, but all four chromosomes predominated 
in the centre.  
The re-locations of these CTs may have displaced each other, however in the platinum-resistant 
line, they all showed central occupancy and thus begged the question of what CTs have they 
displaced? The vast amount of information extracted from 4 chromosomes indicates that there is a 
vast potential for expansion in this field to investigate other chromosomes including genes to 
understand the tumour biology of OC and with a clinical role in prognosis. It also would be interesting 
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to investigate the speed at which chromosomes move with differing myosin quantities at each stage 
of the disease, and under cisplatin, during and upon resistance acquisition and knockdown treatment 
conditions via real-time FISH. This research was also able to combine pulse and continuous methods 
in chemoresistant induction to create a robust and stable resistant line, thus saving months of 
resources; however, this may not be applicable to every cell line. It must also be considered that 
investigations need to go beyond in-vitro, which reduces the time producing research material and 
provides a comprehensive portrait of nuclear and sub-nuclear organization, however, this will 
require novel high-throughput assays that preserves the spatial information.  
In terms of diagnosis, acquiring cells to diagnose OC efficiently is a challenge due to the location of 
the disease and organ; however, just as non-invasive (clinically) blood samples employed in CA-
125 tests, samples can be enriched for circulating tumour cells (CTCs). CTCs can reveal valuable 
in-vivo insights into CTs and NM levels, distribution, and roles at every stage of the disease, 
including resistance. Simultaneously, research is required for clinical transitioning relating to drug 
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Eickelberg, O., Stoeger, T., Wolf, E., Yildirim, A. Ö., Gailus-Durner, V., Fuchs, H., de Angelis, M. H., & Hozák, P. 
(2013). Mouse Nuclear Myosin I Knock-Out Shows Interchangeability and Redundancy of Myosin Isoforms in the 
Cell Nucleus. PLOS ONE, 8(4), e61406. https://doi.org/10.1371/journal.pone.0061406 
Venit, T., Kalendová, A., Petr, M., Dzijak, R., Pastorek, L., Rohožková, J., Malohlava, J., & Hozák, P. (2016). Nuclear myosin 
I regulates cell membrane tension. Scientific Reports, 6(1), 30864. https://doi.org/10.1038/srep30864 
Volpi, E. V, Chevret, E., Jones, T., Vatcheva, R., Williamson, J., Beck, S., Campbell, R. D., Goldsworthy, M., Powis, S. H., & 
Ragoussis, J. (2000). Large-scale chromatin organization of the major histocompatibility complex and other 
regions of human chromosome 6 and its response to interferon in interphase nuclei. Journal of Cell Science, 
113(9), 1565–1576. 
Vreugde, S., Ferrai, C., Miluzio, A., Hauben, E., Marchisio, P. C., Crippa, M. P., Bussi, M., & Biffo, S. (2006). Nuclear Myosin 
VI Enhances RNA Polymerase II-Dependent Transcription. Molecular Cell, 23(5), 749–755. 
https://doi.org/https://doi.org/10.1016/j.molcel.2006.07.005 
Wang, H., Wang, B., Zhu, W., & Yang, Z. (2015). Lentivirus-Mediated Knockdown of Myosin VI Inhibits Cell Proliferation of 
Breast Cancer Cell. Cancer Biotherapy and Radiopharmaceuticals, 30(8), 330–335. 
https://doi.org/10.1089/cbr.2014.1759 
Wang, T., Shigdar, S., Shamaileh, H. Al, Gantier, M. P., Yin, W., Xiang, D., Wang, L., Zhou, S. F., Hou, Y., Wang, P., Zhang, 
W., Pu, C., & Duan, W. (2017). Challenges and opportunities for siRNA-based cancer treatment. In Cancer Letters 
(Vol. 387, pp. 77–83). Elsevier Ireland Ltd. https://doi.org/10.1016/j.canlet.2016.03.045 
Wang, Y., Wu, R., Cho, K. R., Thomas, D. G., Gossner, G., Liu, J. R., Giordano, T. J., Shedden, K. A., Misek, D. E., & Lubman, 




for distinct tumor stage. Journal of Proteome Research, 8(3), 1452–1463. https://doi.org/10.1021/pr800820z 
Weaver, B. A. (2014). How Taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell, 25(18), 2677–2681. 
Weil, M. K., & Chen, A. P. (2011). PARP Inhibitor Treatment in Ovarian and Breast Cancer. Current Problems in Cancer, 
35(1), 7–50. https://doi.org/10.1016/j.currproblcancer.2010.12.002 
Welch, H. G., & Black, W. C. (2010). Overdiagnosis in Cancer. JNCI: Journal of the National Cancer Institute, 102(9), 605–
613. https://doi.org/10.1093/jnci/djq099 
Wells, A. L., Lin, A. W., Chen, L.-Q., Safer, D., Cain, S. M., Hasson, T., Carragher, B. O., Milligan, R. A., & Sweeney, H. L. 
(1999). Myosin VI is an actin-based motor that moves backwards. Nature, 401(6752), 505–508. 
https://doi.org/10.1038/46835 
Wiech, T., Stein, S., Lachenmaier, V., Schmitt, E., Schwarz-Finsterle, J., Wiech, E., Hildenbrand, G., Werner, M., & 
Hausmann, M. (2009). Spatial allelic imbalance of BCL2 genes and chromosome 18 territories in nonneoplastic 
and neoplastic cervical squamous epithelium. European Biophysics Journal, 38(6), 793–806. 
https://doi.org/10.1007/s00249-009-0474-5 
Williams, R. R. E., Broad, S., Sheer, D., & Ragoussis, J. (2002). Subchromosomal Positioning of the Epidermal Differentiation 
Complex (EDC) in Keratinocyte and Lymphoblast Interphase Nuclei. Experimental Cell Research, 272(2), 163–
175. https://doi.org/https://doi.org/10.1006/excr.2001.5400 
Winham, S. J., Larson, N. B., Armasu, S. M., Fogarty, Z. C., Larson, M. C., McCauley, B. M., Wang, C., Lawrenson, K., 
Gayther, S., Cunningham, J. M., Fridley, B. L., & Goode, E. L. (2018). Molecular signatures of X chromosome 
inactivation and associations with clinical outcomes in epithelial ovarian cancer. Human Molecular Genetics, 28(8), 
1331–1342. https://doi.org/10.1093/hmg/ddy444 
Wolf, C. R., Hayward, I. P., Lawrie, S. S., Buckton, K., McIntyre, M. A., Adams, D. J., Lewis, A. D., Scott, A. R. R., & Smyth, 
J. F. (1987). Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a 
single patient. International Journal of Cancer, 39(6), 695–702. https://doi.org/10.1002/ijc.2910390607 
Wu, S., Fatkhutdinov, N., Rosin, L., Luppino, J. M., Iwasaki, O., Tanizawa, H., Tang, H.-Y., Kossenkov, A. V, Gardini, A., 
Noma, K.-I., Speicher, D. W., Joyce, E. F., & Zhang, R. (2019). ARID1A spatially partitions interphase 
chromosomes. Science Advances, 5(5), eaaw5294–eaaw5294. https://doi.org/10.1126/sciadv.aaw5294 
Xue, T., Wang, L., Li, Y., Song, H., Chu, H., Yang, H., Guo, A., & Jiao, J. (2019). SiRNA-Mediated RRM2 Gene Silencing 
Combined with Cisplatin in the Treatment of Epithelial Ovarian Cancer In Vivo: An Experimental Study of Nude 
Mice. International Journal of Medical Sciences, 16(11), 1510–1516. https://doi.org/10.7150/ijms.33979 
Yanaihara, N., Nishioka, M., Kohno, T., Otsuka, A., Okamoto, A., Ochiai, K., Tanaka, T., & Yokota, J. (2004). Reduced 
expression of MYO18B, a candidate tumor-suppressor gene on chromosome ARM 22Q, in ovarian cancer. 
International Journal of Cancer, 112(1), 150–154. https://doi.org/10.1002/ijc.20339 
Yang-Hartwich, Y., Soteras, M. G., Lin, Z. P., Holmberg, J., Sumi, N., Craveiro, V., Liang, M., Romanoff, E., Bingham, J., 
Garofalo, F., Alvero, A., & Mor, G. (2015). p53 protein aggregation promotes platinum resistance in ovarian cancer. 
Oncogene, 34(27), 3605–3616. https://doi.org/10.1038/onc.2014.296 
Yang, S. H., Chang, S. Y., Yin, L., Tu, Y., Hu, Y., Yoshinaga, Y., de Jong, P. J., Fong, L. G., & Young, S. G. (2011). An absence 
of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and 
hair. Human Molecular Genetics, 20(18), 3537–3544. https://doi.org/10.1093/hmg/ddr266 
Yang, S. H., Jung, H.-J., Coffinier, C., Fong, L. G., & Young, S. G. (2011). Are B-type lamins essential in all mammalian 
cells? Nucleus (Austin, Tex.), 2(6), 562–569. https://doi.org/10.4161/nucl.2.6.18085 
Yang, X., Iyer, A. K., Singh, A., Milane, L., Choy, E., Hornicek, F. J., Amiji, M. M., & Duan, Z. (2015). Cluster of Differentiation 
44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian 
Cancer. Pharmaceutical Research, 32(6), 2097–2109. https://doi.org/10.1007/s11095-014-1602-1 
Yoshida, H., Cheng, W., Hung, J., Montell, D., Geisbrecht, E., Rosen, D., Liu, J., & Naora, H. (2004). Lessons from border 
cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proceedings 
of the National Academy of Sciences of the United States of America, 101(21), 8144–8149. 
https://doi.org/10.1073/pnas.0400400101 
Yusufzai, T. M., Tagami, H., Nakatani, Y., & Felsenfeld, G. (2004). CTCF Tethers an Insulator to Subnuclear Sites, Suggesting 
Shared Insulator Mechanisms across Species. Molecular Cell, 13(2), 291–298. 
https://doi.org/https://doi.org/10.1016/S1097-2765(04)00029-2 
Zeitz, M. J., Ay, F., Heidmann, J. D., Lerner, P. L., Noble, W. S., Steelman, B. N., & Hoffman, A. R. (2013). Genomic 
Interaction Profiles in Breast Cancer Reveal Altered Chromatin Architecture. PLoS ONE, 8(9), 73974. 
https://doi.org/10.1371/journal.pone.0073974 





Zorca, C. E., Kim, L. K., Kim, Y. J., Krause, M. R., Zenklusen, D., Spilianakis, C. G., & Flavell, R. A. (2015). Myosin VI 
regulates gene pairing and transcriptional pause release in T cells. Proceedings of the National Academy of 





Figure 7.1 Overview of OC cell lines characteristics (Next Page): Morphology: E-Epithelial, R-Round, S-
Spindle. Histology: S-serous, HGS-high-grade serous, LGS-low-grade serous, E-endometrioid, C-clear cell, Mx-
mixed, M-mucinous. Origin: A-ascites, T-tumour tissue, TM-tissue from metastasis, TO-ovarian tumour tissue, 
P-pleural effusion. Time: P-primary disease, R-relapsed disease, CR-clinical resistance. Platinum treated: U-
untreated, P-platinum-based treatment, O-other chemotherapy, R-radiotherapy. Protein markers: bright red-
no expression, light red-low expression, light green-expression, bright green-high expression, grey-not 
determined. Therapy response: green to red - sensitive to resistant. Doubling time: green-less than one day, 
yellow-1-2days, orange >2days. Mutations: dark blue-identified by at least two methods, light blue-identified 
by one method, light red-identified with one method BUT not with second method. Amplification: orange-
amplified, red-highly amplified. The homologous recombination repair (HRR) and WNT/bCatenin pathway 
(WNT/bCAT) columns show the number of mutated genes in these pathways. MSI-microsatellite instability 
(Beaufort et al., 2014).  
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